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I ABSTRACT 
 
Aldehydes and ketones are widely distributed in nature and can be very reactive, causing damage to 
DNA, proteins and lipids within the cell. A number of antioxidant molecules are able to react with 
reactive molecules to minimize their damaging effects. The human body also has a series of enzyme 
systems for protecting itself against reactive aldehydes and ketones including alcohol dehydrogenases 
(ADH), aldehyde reductases (AKR) and aldehyde dehydrogenases (ALDH). Some antioxidants are also 
able to increase the expression of these protective enzymes thereby leading to enhanced protection. In 
this thesis, intrinsic and extrinsic mechanisms of protection against the toxicity of aldehydes were 
investigated.  
 
In the first part of this thesis, the toxicity of acetaldehyde to HepG2 human hepatoma and 1321N1 
astrocytoma cells was investigated as a model for liver and brain cells. Acetaldehyde is a toxic 
metabolite of ethanol, and is thought to be a major determinant in alcohol toxicity. Acetaldehyde did 
not cause significant toxicity to 1321N1 or HepG2 at concentrations below 1 mM, but was toxic to 
1321N1 cells at higher concentrations. However, acetaldehyde was able to cause an increase in 
activated caspase-ca3 and DNA fragmentation at concentrations between 5 and 25 µM in HepG2 cells, 
indicating an induction of apoptosis. 
 
Three antioxidants (vanillin, gallic acid and resveratrol) were investigated for their capacity to protect 
cells against the toxicity of reactive aldehydes. Methylglyoxal and acrolein are products of the 
peroxidation of lipids and arise during exposure of cells to oxidants. The antioxidants vanillin and 
gallic acid are found in whisky in the non-volatile fraction and resveratrol is found in red wine. The 
antioxidants were not able to protect the cells against the aldehydes at the concentrations tested, but 
did increase cell viability. It appears that vanillin can  inhibit ADH as well as ALDH activity by binding 
to the enzymes without altering their expression levels. 
 
To investigate whether the AKR enzymes are involved in protection against aldehyde toxicity, human 
AKR7A2 and the mouse AKR7A5 were purified and characterized with different substrates including 
muconaldehyde, crotonaldehyde, acetaldehyde and methylglyoxal. Both AKR7A2 and AKR7A5 
enzymes showed a high Km and low turnover number for all three of the aldehydes tested, indicating 
relatively low specificity.  
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To better understand the role of AKR7A2, the gene encoding the enzyme was transiently transfected 
into 1321N1 and HepG2 cell lines and exposed to crotonaldehyde, muconaldehyde and methylglyoxal. 
However, AKR7A2 was not able to protect cells against aldehyde toxicity, and, in some cases, its 
overexpression increased toxicity. Only when crotonaldehyde was tested at a relatively high 
concentration the transfected cells did show increased viability compared to the control, suggesting 
that the enzyme AKR7A2 could be involved in crotonaldehyde detoxification.  Transfected HepG2 cells 
showed an  increase in viability compared to the non-transfected control cells, at almost all the tested 
concentrations.  Taken together these results show that AKR7A2 is able to protect HepG2 liver cells 
against the aldehydes, but is not able to protect 1321N1 brain cells.  
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II INTRODUCTION  
 
ETHANOL OXIDATION 
 
The consumption of alcohol (ethanol) is common in many countries around the world and in some 
places overconsumption has become a social problem. The potential dangerous effects caused by 
alcohol are influenced by the time and quantity present in the blood stream. Initially the alcohol, after 
ingestion, starts diffuse throughout the body. This is the first stage of alcohol metabolism. Only a small 
part of ethanol is able to leave the body by evaporation or during breathing. In the second stage, a low 
amount of ethanol estimated between 2 and 10% is metabolized by kidney and lung, but the highest 
amount is metabolized by the liver  (1).  It is difficult to establish a proper and exact rate for alcohol 
metabolism; different characteristics such as age, ethnicity and habits such as smoking and diet can 
interact with the metabolism rate. In a recent study it was established that an average rate for ethanol 
metabolism is between 50-80 mg/h/kg (2). However a major influence is made by the amount and 
efficiency of the enzymes involve in metabolism (3).  
The metabolism of alcohol has been studied extensively and appears to be predominantly a series of 
oxidation reactions. The conversion of molecules through oxidation reactions is classified as Phase I 
metabolism (functionalization), and several different enzymes are involved in these reactions 
including alcohol dehydrogenases (ADH), cytochromes P450 and catalase. Hepatocytes have all three 
pathways for metabolizing ethanol. The three pathways are located in three different places inside the 
cell. The catalase enzymes are located inside the peroxisomes, the cytochrome P450 system in the 
endoplasmic reticulum (microsomes) and the ADH in the cell’s cytosol.  
Each metabolic pathway generates different products, but they share the same main metabolite, that is 
acetaldehyde. This metabolic product is reputed to be very dangerous and responsible for the main 
damage caused by alcohol abuse..  Figure 1 shows the main oxidative pathways involved in alcohol 
metabolism. Each of these enzyme families are described in detail below. Further metabolism is then 
carried out by aldehyde dehydrogenase (ALDH) enzymes, described in the next section. 
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Figure 1:  Main ethanol oxidation pathways in humans. 
 
ALCOHOL DEHYDROGENASE 
 
The enzymes of the alcohol dehydrogenase (ADH) family are responsible for alcohol oxidation and 
consequently they modify the time and the concentration of the alcohol in the human body. The 
alcohol dehydrogenases (ADH), are a group of enzymes and Class I is the most important class of ADH 
in ethanol oxidation. The ADHs are a group of enzymes composed of two subunits. Each subunit has a 
molecular weight around 40kDa, and each enzyme is made by two identical subunits. The ADH 
enzymes are classified in five different classes compared by sequence homology and the catalytic 
properties. All five classes are present in human (4). Each enzyme has two independent catalytic active 
sites, one for each subunit. In the core of the enzyme, there is a zinc atom. In Table 1, a summary of the 
different classes of ADH present in the human body and the different subunits made from different 
genes as well the distribution of the different enzymes in human body is given. 
Table 1: Alcohol dehydrogenase classes and subunits differentiation and distribution in human body. 
Class Gene Subunit Distribution Km (mM) 
I ADH1A α Liver 4 
 ADH1B*1 β1 Liver, lung, kidney 0.05-34 
 ADH1B*2 β2  0.6-1 
 ADH1B*3 β3   
 ADH1C*1 ɣ1 Liver, stomach  
 ADH1C*2 ɣ2   
II ADH2 π liver 34 
III ADH3 χ Everywhere 1000 
IV ADH4 µ Stomach, esophagus, liver, skin  20 
V ADH5 ? stomach 30 
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The first class of ADH (Class I) shows a very low Km value for ethanol, indicating high affinity. These 
enzymes are very easily saturated but the high levels present in the liver indicate that they play a 
central role in ethanol detoxification. The first class of enzymes can be easily inhibited by pyrozilic 
derivatives (4). 
The Class II ADH enzymes show a relatively high Km and hence low affinity for ethanol, and in contrast 
to the Class I enzymes these can’t be blocked by pyrozilic derivative as reported from  (5). 
The Class III ADH enzymes have a very high Km and very low affinity for ethanol, and for this reason it 
is believed that they do not play an important role in the ethanol oxidation. Also experimental data has 
shown that the Class III prefers alcohols with a long chain or fatty acid, especially the ω (4). More 
recent studies have shown that this class of enzymes may be involved during the acute intoxication, 
because the expression of this class looks to be dependent on the amount of alcohol ingested (6). 
The Class IV ADH are enzymes widely distributed in the body: stomach, esophagus, cornea are just 
some example of distribution. They have a high Km for ethanol of around 1M and it is difficult to 
saturate them with the physiological alcohol concentrations found normally in the human body and 
also in hard drinkers.  
The Class V ADH is identified with the name ADH6. This enzyme has not been purified yet, but its 
mRNA has been found in the stomach and liver. In vivo studies show it to have an apparent Km around 
30 mM. (7). 
The Class VI ADH has been discovered only in rat and mouse.  
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CYTOCHROME P450 OR MEOS 
 
Other than the ADH enzymes, other metabolic pathways are believed to play an important role in 
ethanol oxidation (6). This pathway, independent from ADH has been identified and it became 
relevant in acute intoxications and in subjects that are chronically addicted to alcohol. This pathway is 
also known as the Microsomal Ethanol Oxidizing System (MEOS), (8) because the oxidation process 
happens inside the endoplasmic reticulum (ER) (microsomal) lumen.  
 
The enzymes responsible are members of the cytochrome 450 (CYP) super family, and the isoenzymes 
CYP2E1, 1A2 and 3A4 are mainly responsible for ethanol oxidation and are localized in the liver in the 
internal lumen of the ER. The enzymes utilize NADPH and O2 for their metabolizing system (1). The 
isoform CYP2E1 is inducible by chronic alcohol consumption (9) for this reason this metabolic 
pathway is believed to play a major role in alcoholism, more so than in the occasional drinker. This 
pathway in the brain is very important because the ADH enzymes present there, show a very low 
affinity for alcohol metabolism, leaving brain cells more exposed to damaging effects of ethanol. The 
cytochromes P450 have a Km for ethanol between 2-8 mM (2).  
The MEOS is not only an exclusive ethanol metabolism system but can also interact with other 
hepatotoxins. This metabolic pathway however can produce some dangerous molecules known as 
Reactive Oxygen Species (ROS).  
These molecules are derived from oxygen and can react with different molecules present in cells such 
as DNA, RNA, protein and lipids and cause significant damage. In particular, the end products of the 
reaction between lipids and ROS are very dangerous, and normally are aldehydes and ketones with a 
high reactivity against the macromolecules cited above (10). Hence, although the MEOS can potentially 
reduce the levels of ethanol in a system, the unwanted side effects can cause more extensive molecular 
damage than the ethanol itself. 
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CATALASE  
 
Catalase enzymes are also involved in alcohol oxidation although their role is less clear (6). Catalase is 
an enzyme that is located inside the peroxisomes.  This enzyme has the capacity to oxidize ethanol and 
has been proposed to act in two different ways. In one route, during catalysis, catalase forms a 
complex with oxygen and peroxide, and this complex can react with a molecule of ethanol to give two 
molecules of water and acetaldehyde and the free enzyme. The second route involves the cofactor 
NADPH and a molecule of oxygen, which by the action of the NADPH oxidase gives oxygen, peroxide 
and NADP+. In a second step the ethanol is oxidized and the molecule of peroxide is reduced by the 
action of catalase  (9).  
This metabolic pathway seems have an important role especially during the first phase of alcohol 
metabolism. Other studies carried out using rats shows an increase in hydrogen peroxide when the 
rats are driving to an chronic alcohol abuse. Other than catalase, the MEOS systems seem to increase 
its activity (11). Other mechanisms involving catalase are present in the human body, but they play a 
minor role.  
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ALDEHYDE METABOLISM 
ALDEHYDE DEHYDROGENASE  
 
The aldehyde dehydrogenase enzymes (ALDH) are a super family of enzymes that were discovered in 
the early 1940s. These enzymes serve to oxidize aldehydes and are involved in the second step of 
ethanol metabolism because they are able to oxidize the acetaldehyde derived from the first step of 
ethanol oxidation. The acetaldehyde is oxidized to acetate, which can be used by other metabolic 
pathways.  
 
ALDH enzymes use the cofactor NAD+ and have a huge range of substrate in addition to acetaldehyde. 
They can accommodate in their active site different molecules with different chemical structures: 
aliphatic and aromatic aldehydes that can be derived from different sources, both exogenous and 
endogenous. Many aldehydes and ketones are directly involved in the aroma of some fruits such as 
apples (12). The aldehydes made inside the body are normally derived from the metabolism of amino 
acid, lipids, steroids and during the metabolism of some drugs, including alcohol.  Exogenous sources 
of aldehydes are cigarette smoke, pollution, and food.  
 
Reactive aldehydes can be detoxified by both Phase I reactions (oxidation by ALDH or reduction by 
ADH and aldo-keto reductases) and Phase II reactions (conjugation to eg glutathione by glutathione S-
transferases) (13).  
 
The substrate needs to be very specific for some ALDH enzymes, but other enzymes can accept a wide 
range of different substrates. Some ALDH have an important role tissue development or to keep them 
perfectly operational. An example of this physiological role is the conversion of the aldehyde retinal 
(retinaldehyde) into retinoic acid which is essential for the brain development.  
 
The ALDH enzymes are subdivided in different subclasses, as in the case for the ADH on the basis of 
the amino acid sequence similarity, which can be related to chemical, physical characterize, catalytic 
propriety and distribution in the different tissue (14). In the human genome, nineteen different 
aldehyde dehydrogenases have been identified (15). The most studied aldehyde dehydrogenases are 
the class I ALDH1 and the class II ALDH2. The ALDH1 and ALDH2 share 68% of sequence identity and 
they have a chain of 499-500 amino acid. These two enzymes are composed of four identical subunits 
(16). By multiple sequence alignment system and crystallography it was possible identify the 
conserved region of the catalytic site and the cofactor binding site. Four amino acids are essential for 
the catalysis Cys-302, Glu-268, Gly-299 and Asn-169. 
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 Other amino acids are involved in the binding of the cofactor:  Gly-245 and Gly-250. These amino acids 
are important for the Rossmann fold. (The amino acid numeration is based on the ALDH2 sequence 
present in the human species). Briefly the Cys-302 changes its position when the cofactor binds the 
subunit and this result in activation of the enzyme. The role of the Cys-302 is to be the nucleophile. The 
reaction between the nucleophile and the aldehyde results in an oxyanion thiohemiacetal 
intermediate. The intermediate is stabilized by Asn-169. The negative charge on the oxygen drives the 
next step, where the hydride is lost from the tetramer atom of carbon to bind the cofactor to change its 
redox state to NAD(P)H.  A molecule of water hydrolyzes the thioacylenzyme intermediate helped by 
the Glu-268 that works as a base. This second nucleophilic attack gives the free enzyme and the 
production of the reaction the carboxylic acid. In this mechanism the cofactor is very important 
because it is the first to bind the enzyme, and the last to leave the enzyme. The interaction of the 
cofactor with the enzyme is important for the Vmax of the enzyme.  In Figure 2 is the mechanism of 
action proposed by (15). 
 
 
Figure 2: ALDH catalytic mechanism. 1, Cofactor binding results in a conformation change of the enzyme and 
activation of the catalytic thiol (Cys-S−); 2, Nucleophilic attack of the aldehyde substrate; 3, Oxyanion intermediate is 
stabilized by two NH groups of the ALDH peptide chain; 4, Hydride transfer to cofactor. 5; Glutamate residue acts as a 
base catalyst in the hydrolysis of the thioacylenzyme intermediate; 6, Release of carboxylic acid product followed by 
cofactor. 
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ALDH I FAMILY  
ALDH1A1 
 
The gene production ALDH1A1 is a tetramer protein ALDH1A1 made by identically subunit. The 
subunits have a molecular weight around 55kDa. This enzyme is widely distributed in different tissue 
such as brain, kidney, liver and gut. It is present at a very high concentration (3%) in the cytosol of the 
retina (17). More specifically, this protein provides a protective role against ultra violet radiation 
(UVR).  This protein is also called RALDH1 because show a very low value of Km 0.1µM for 
retinaldehyde and catalyzes the irreversible oxidation of retinaldehyde to retinoic acid and acetate 
(18). The active site of this enzyme is also able to accommodate acetaldehyde but the enzymatic rate of 
this reaction is slow compared to retinaldehyde, and the affinity of the enzyme for acetaldehyde is 
relatively high, between 50-100 µM(19).   
ALDH1A1 also plays a role in the detoxification of various reactive aldehydes generated during lipid 
peroxidation. These aldehydes are very reactive with almost all the macromolecules present in cells. 
ALDH1A1 is able to metabolize 4-hydroxy-2-nonenal (4-HNE) with a Km of 17.9 µM, hexanal with a Km 
of 14.3 µM, and malondialdehyde (MDA) with a Km of 114.4 µM (15). Other than reactive aldehydes, 
this enzyme is also able to oxidize the aldehydes present in some anti cancer drugs. This results in 
reduced efficiency of the drugs. A rat variant of this enzyme known as ALDH1A2 can metabolize 
retinoids in vitro with a lower Km (0.2µM) compared to the human ALDH1A1. However this variant has 
lower efficiency for acetaldehyde with a Km of 0.65 mM (20). 
 
ALDH1B1 
 
In contrast to other enzymes of the ALDH1 family, ALDH1B1 has acetaldehyde as a favorite substrate, 
with a Km of 30 µM. This enzyme is localized in the cytosol of many types of cells, including liver, 
kidney and brain (15). UV light has shown the capacity to up regulate this enzyme in vivo (21).  
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ALDH II FAMILY 
 
ALDH2 is localized in the mitochondria, and has four subunits each with a mass of around 56 kDa. 
Based on sequence similarity this enzyme could be called ALDH1B and should be in the class I, but it is 
commonly reported in the scientific papers as ALDH2. Sequence similarity with the Class I enzymes is 
around 70%.  
ALDH2 enzymes have a key role in the metabolism of the ethanol, and their best substrates are 
acetaldehyde. ALDH2 is present in the liver where the first step of the ethanol metabolism occurs, and 
can metabolize the acetaldehyde in acetate. Its Km for acetaldehyde is 1 µM (15).  ALDH2 enzyme is 
also expressed in kidney, heart, lung and brain. Of relevance, is the allele variant that is high diverse in 
the Asiatic population, the variant ALDH2*2. This variant is briefly discussed in section 0 THE 
ALDH2*2 IN ASIAN POPULATION. Other than acetaldehyde other molecules can be metabolize by 
ALDH2 including chloroacetaldehyde (13). Of importance is the capacity of this enzyme to metabolize 
4-hydroxy-2-nonenal (4-HNE), and it is also able to metabolize some inorganic acids such as nitrate 
reductase in inorganic molecular as nitroglycerin (22).  
 
ALDH III FAMILY 
ALDH3B1 
 
This enzyme plays a central role in the detoxification of long chain aldehydes such as octanal, but is not 
so efficient with short chain aldehydes such as acetaldehyde or malondialdehyde (MDA). The 
efficiency of this enzyme with different toxic substrates has been evaluated by transfecting human 
cells with the gene encoding the enzyme (23). This protein is able to use both the cofactor NAD+ and 
NADP+. This protein is also highly expressed in kidney and liver. 
 
ALDH7A1 
 
The aldehyde dehydrogenase found in black seabream fish (sbALDH7A1) was investigated to try and 
establish the putative role of the human enzyme because it shares 83% of identity. The fish enzyme is 
able to metabolize different aldehyde including acetaldehyde (Km 3.6 mM), propionaldehyde (Km 1.2 
mM), and benzaldehyde (Km 0.45 mM) (15). Later the gene encoding the human enzyme was cloned 
(24) and is role was investigated.  
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It was supposed to play a defensive role against aldehydes made during cell metabolism based on its 
sequence similarity with analogues in plants. This protein was tested with different products normally 
made during lipid peroxidation inside the cell. This protein is able to metabolize aliphatic molecules 
such as octanal and trans-2-nonenal, which appear to be the best substrate for this enzyme; but also 
with a Km one thousand times higher with molecules such as glyceraldehyde. The human and the fish 
enzyme show a close Km to each other for the substrate benzaldehyde, respectively 0.53mM and 
0.45mM.  
THE ALDH2*2 IN ASIAN POPULATIONS 
 
A single amino acid substitution from lysine to glutamate in position 487 makes the variant ALDH2*2. 
The mutation does not involve the catalytic sites directly, but is able to change the conformation of the 
protein. The change in conformation reduces the nucleophilic power of the Cys and reduces the 
cofactor affinity.  Compared to ALDH2, the ALDH2*2 has a very slow turnover (Kcat) for acetaldehyde. 
This low turnover value means this variant enzyme is not so efficient in removing acetaldehyde 
present in the blood stream (25). This natural variant is not generally widely distributed in the human 
population but is very common in the Asian population. It is estimated that around the 50% of this 
population express this slow variant of ALDH2 (16). The slow variant results in abnormal 
accumulation of acetaldehyde in blood after the ingestion of ethanol compared to the people with the 
normal ALDH2. The high and long permanence of the acetaldehyde in the blood stream induces some 
adverse effect to these people such as: red flushing in the face, warm face, nausea, dizziness and 
tachycardia. These adverse affect in half of the Asian people are proposed to be the reason for the low 
incidence of alcoholism in this country (26),(27). 
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ALDO-KETO REDUCTASE SUPERFAMILY 
 
The aldo keto reductases (AKR) are a broad group of enzymes that form a superfamily. These enzymes 
are also widely distributed in nature, being present in human, invertebrate, protozoa, plants, yeast and 
in the bacteria (28). These enzymes are involved in different reactions from the biosynthesis of new 
molecules to reaction intermediate and detoxification of various aldehydes and ketones from 
endogenous and exogenous source.  The AKR enzymes catalyze the reduction of aldehydes and 
ketones to their corresponding primary and secondary alcohol. NADH and NADPH are both cofactors 
for this family of enzymes.  
More than one hundred proteins are believed belong to the AKR superfamily. This protein superfamily 
includes aldose reductases, aldehyde reductases, hydroxysteroid dehydrogenases and dihydrodiol 
dehydrogenases. All these proteins seem to have arisen from a single multi-functional gene; this gene 
has disappeared during the evolutionary process. These enzymes went on to develop different 
affinities for different substrates.  
Based on sequence identity an official nomenclature has been accepted for these enzymes. The sign 
AKR is for aldo keto reductase enzyme; the first Arabic number is used for identify the subfamily and 
the following letter for the subclass, the last Arabic number is for identify a unique protein sequence. 
Each AKR subfamily differs from other AKR subfamilies by its members having less than 40% amino 
acid identity to other subfamilies. Inside the same subfamily, the identity is higher, and enzymes are in 
the same subclass when they have over 60% identity. A web page (29) is periodically updated with the 
new AKR discovered, and now it is possible count fifteen families (AKR1 to AKR15).  
Different substrates can interact with the active site of these enzymes including steroids, glucose, 
many glycosilate molecules and many molecules derived from the lipid peroxidation. Other than 
protecting cells from aldehydes and ketones, this class of enzymes is responsible for the Phase I 
metabolism of a broad range of drugs and xenobiotics. In some cases this can be a problem, because 
interaction with some therapy drugs can reduce their efficacy before they react with their molecular 
target.  
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 STRUCTURE AND KINETICS 
 
The average size of the AKR enzymes is 350 amino acids. This chain forms a conserved (β/α)8 barrel 
structure in all the aldo keto reductase family, but some loops differ from enzyme to enzyme in order 
to determinate substrate specificity. Four amino acids are involved in the catalytic action mechanism: 
tyrosine, lysine, aspartate and histidine (30). The structure is usually monomeric and that is true for 
all most the family; however the families AKR2, AKR6 and AKR7 can all form multi subunit enzymes as 
dimers or tetramers (31).  
The three-dimensional structure in Figure 3 shows the typical barrel structure for the AKRs. Eight β-
sheets are responsible of the structure of the barrel. Every sheet is linked to the other with an α-helix 
anti parallel to the barrel. In total eight α-helices are used to link all eight β-sheets.  Another two loops 
are present in this structure but they are not involved in the junction with the β-sheet. They seem to be 
involved in keeping the right three dimensional structure of the molecule (32).  A multiple sequence 
alignment of many AKRs has shown that the least conserved regions are in the last three carboxy 
terminal loops. As proposed (28) the loops near the C-terminal are involved in determining substrate 
specificity, but it is not totally clear the mechanism by which these enzymes are able to distinguish 
between different substrates.  The numeration of the following amino acid residues is based on the rat 
3α-hydroxysteroid dehydrogenase (3α-HSD). The Asp-50, Tyr-55, Lys-84 and His-117 are the amino 
acids involved in the catalytic system in both the oxidation and reduction direction. Another five 
amino acids are conserved in the same family and are involved in cofactor binding (either NADH or 
NADPH). The AKR proteins do not show the typical Rossmann fold present in other kinds of proteins. 
(32). However, different studies have shown that the amino acids involved in the cofactor binding are 
much conserved. The position of the cofactor inside the AKR proteins is conserved and the 
nicotinamide ring is positioned in the core of the barrel. Many hydrogen interactions stabilize this 
interaction.  These amino acids are much conserved also between different proteins with sequence 
identities of less than 30% (28).  
Within the same family the AKR enzymes hold the same structure in space. Even a single amino acid 
changed in the catalytic site is able to switch the enzyme catalytic system from carbon oxidation to a 
double carbon bond oxidation (28).  
21 
 
 
Figure 3: structure of the main AKRs. In pink the β- sheet structure that involve in the barrel. In black α-helix involve 
in the barrel structure. With H1 and H2 the two α-helix not involved in the barrel structure. From (28). 
 
The catalytic reaction itself is divided into many steps. What has been shown for many AKRs is that the 
cofactor is the first molecule to bind to the enzyme (before the substrate) and is the last one to leave 
the enzyme (33).  After this first step, the protein will be able to bind the right substrate. The oxygen of 
the aldehyde or ketone group involved in the reaction acquires a proton group from one of the amino 
acids involve in the catalytic process. Now the atom of carbon can be reduced by the hydride group 
donated by the cofactor. It is not clear which is the first hydrogen to be added to start the reduction 
process (28). The process that drives the carbon reduction that will accept the negative hydrogen is an 
amino acid in the catalytic system. This amino acid has an acid residue that is able to polarize the 
oxygen so that the carbon is active for the nucleophilic attack by negative hydrogen. For reduction the 
pKa and to make easier the polarization of the oxygen by the amino acid with an acidic residue from 
another amino acid, normally a tyrosine is very close to the acidic residue. This tyrosine has the role to 
make the surroundings around the acidic residue more favorable for donating a proton to carbon 
oxygen. This mechanism has been shown for many AKR.  
After the reduction or oxidation, the substrate is let free and its dissociated to the enzyme. In the last 
step the oxidized cofactor is separated from the enzyme (34). The interaction between the enzyme and 
the cofactor seem to be the limited factor in the turnover of the substrate (35). This reaction 
mechanism has been identified in AKR1C2.  
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THE AKR7A FAMILY 
 
THE RAT ENZYME AKR7A1 
 
Aflatoxin B1 (AFB1) is one of the most diffuse oxidative agents in the world. This dangerous toxin is 
made by Aspergillus flavus toxin and was found in many foods. The main target of this toxin is the liver 
(36). In the 1993 a research group from Scotland discovered that rat fed with a diet rich in ethoxiquin 
were more resistant to the AFB1 (37). Ethoxyquin is able to increase one protein, an aldehyde 
reductase. This protein is able to interact with the aldehyde group present in the AFB1 and change 
them into alcohols generating the AFB1-dihydrodiol. This AFB1-dihydrodiol is not able to react with 
proteins and DNA and for this reason is less dangerous that the dialdehyde form. Sequence analysis 
shows that this protein is a member of the aldo-keto-reductase family (38). In the same paper the 
authors suggest that this enzyme could have others physiological roles and they suggest the possibility 
to an analogous enzyme in human.  
In a study carried out to characterize the enzyme, it was cloned and expressed in bacteria with a His-
tag, and it was shown that it is able to work at a broad range of pH from 5 to 9 with the optimum 
around pH 6.6 estimated using as substrate the 4-nitro benzaldehyde (4-NBA) (39).  4-NBA is 
recognized is a model substrate for AKR, and AKR7A1 was also able to reduce a broad range of 
aldehydes and diketones. 
The crystal structure of AKR7A1 has been determined and this enzyme was shown to be a dimer. It is 
one of the few AKR enzymes that are dimeric. 
 
HUMAN AKR7A2 
 
With a blast analysis based on the nucleotide sequence of the rat aldo-keto reductase AKR7A1, a 
human library was screened and a related protein identified. This protein shares with the rat a 78% 
identity and 87% similarity (40). Based on this data it was assumed that AKR7A2 is the corresponding 
protein to the rat AFB1 aldehyde reductase (AKR7A1). A year later Schaller et al. cloned a succinic 
semialdehyde reductase (SSA) from human brain (41). The enzyme showed the same SDS-PAGE 
mobility as the SSA reductase.  
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They showed that their enzyme gave a very poor match with the AKR superfamily, showing less than 
the 20% identity with the AKR1 family and a bit higher with the AKR6 family known also as the K+ 
channel. Despite this, the enzyme was identified as part of the aldo-keto reductase family, being 
identical to the AKR7A2 cloned by Ireland et al., 1998 (40).  
The AKR family are characterized by their ability to transfer the 4 H- R donate by the cofactor, whereas 
the SSA reductases were originally thought to transfer the 4 H- S (42). The enzyme characterized by 
(41) showed a very low Km for SSA indicating that this enzyme plays a key role in the metabolism of 
the SSA in vivo. This enzyme shows a low Km for aflatoxin B1, one of the original substrates identified 
for the rat enzyme AKR7A1.  
In the paper by (40), they discovered that AKR7A2 is the principal enzyme responsible for 
metabolizing 2-carboxybenzaldehyde (2-CBA) to its alcohol in the liver. 2-CBA is an important drug 
and is metabolized to its corresponding alcohol by AKR7A2 (40). Studying different substrates to 
understand the physiological role of this enzyme showed that AFB1 is not the best substrate and that 
the then enzyme has a Km for SSA that is lower than for the toxin, and more importantly SSA is a 
normal chemical present in the body. GABA-transaminase, the precursor of SSA for the SSA-reductase 
is widely spread throughout the body. The AKR7A2 enzyme is also widely distributed in many tissue 
and organs like liver kidney, pancreas, skeletal muscle and in more moderate amount in the liver, 
heart, testis and ovary. Lower amounts of mRNA were found in the brain and colon. These data, the 
low Km for SSA and the wide distribution led to the proposal (40) that AKR7A2 has a specific role in 
SSA metabolism not just in the brain. Often the gene encoding the AKR7A2 in the chromosome I is 
missing in many kinds of cancer (43). This evidence suggests that this enzyme is able to protect cells 
against the cancer. Other evidence shows a high level of expression of this enzyme in the brain and its 
role is in GHB biosynthesis in response to a degenerative stress such as Alzheimer’s disease. More 
works need to be done to discover the real role of this enzyme that is widely expressed in the human 
body.  
Another point that needs to be clarified is the relationship between the antioxidant and the expression 
of this human enzyme, especially after it was discovered is that the rat AKR7A1 is inducible by  the 
antioxidant ethoxyquin (37).   
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MOUSE AKR7A5 
 
The enzyme known as AKR7A5 was cloned from mouse, and shares 78% identity with the rat AKR7A1, 
but is more closely related to the human AKR7A2 with 89% of identity.  A multiple sequence alignment 
of this new class of enzymes revealed they show a very high identity to each other placing them in a 
proper category the AKR7 family, that are quite distant to most other mammalian AKR enzymes (44). 
To study the role of this enzyme, it was cloned and a his tag purification, dynamic light scattering 
showed this enzyme is also dimer (45).  
This enzyme also is versatile for the cofactor and is able to use NADPH and NADH, but with a strong 
preference for NADPH (45).  AKR7A5 showed a very high affinity for the aromatic aldehydes, but a 
very low activity for the benzaldehyde. The aliphatic aldehyde SSA gave a very high rate that is almost 
double the rate of the 4 nitrobenzaldehyde. In contrast, the specific activity with aldose sugars is very 
low.  
More analysis is needed to discover the physiological role of this enzyme in the mouse. This enzyme is 
also able to metabolize some powerful and reactive aldehydes such as trans-trans muconaldehyde that 
is derived from benzene detoxification in the liver. Trans-trans muconaldehyde is considered an 
exogenous aldehyde, whereas acrolein is a powerful toxic aldehyde made endogenously during the 
oxidative stress. For both these aldehydes this enzyme shows a very low activity (44). 
The structure of the AKR7A enzymes is the typical for the family of aldo keto reductases. It has a barrel 
made with eight β-sheets that are linked by many α-helices. Two α-helices H1 and H2 are involve in 
the three dimensional structure of the enzyme. A reported for other aldo keto reductases each subunit 
has a cofactor molecule bound that makes various interaction with amino acid chain. The nicotinamide 
ring is deeply inserted in the core of the barrel. The reaction site is conserved and is typical for the 
AKR.  Tyr 45 and His 109 (base on the human AKR7A1 numeration) are involve in the interaction with 
the substrate, Asp40 and Lys73 have the role to made a more favorable environment for the proton 
transfer give way from Tyr45 during the reduction reaction. As in other AKR the more important loops 
A-C play a crucial role in the substrate recognition (46).  
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The structure of the AKR7A5 enzyme is show in Figure 4 with the cofactor NADP+ and the citrate used 
in the crystallization process. 
 
Figure 4: structure of mouse  aldo keto reductase AKR7A5. Loops A, B and C are shown for their important in the 
substrate identification and interaction. The nicotinamide ring cofactor NADP+ is localize in the core of the barrel in 
violet. In light blue the α-helices. H1 and H2 α-helices involve in the right structure of the protein from (46). 
This crystal structure is very close to human AKR7A1, just some amino acid difference in the loops 
involved in the substrate recognition, these amino acids difference seem be the answer to the different 
activity of these enzymes for the same substrate (46).  
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ACETALDEHYDE TOXICITY 
 
Acetaldehyde CH3CHO, is the main metabolite of ethanol, generated during the first step of the ethanol 
oxidation. Acetaldehyde is also present in a wide range of food and beverages and pollution. Also 
cigarette smoke is able to produce this dangerous aldehyde that is breathed during the smoking. The 
bacteria present in the gut and in the mucosa is also a source of acetaldehyde. The bacteria in the gut 
make acetaldehyde during the metabolism of different molecules and expel it into the gut. The bacteria 
present in the teeth and mouth are also a source of acetaldehyde; an experiment showed that the 
acetaldehyde concentration in the mouth after the ingestion of ethanol is around 50 to 200 µM. This 
value is influenced by the oral hygiene of the mouth (47).  
The Environmental Protection Agency (EPA) had classified acetaldehyde as a class II component. This 
means that is probably able to generate cancer in the human. This is supported by some experiments 
carried out using rats - these animals develop cancer in the nose and throat after being exposed to air 
and acetaldehyde (48). The acetaldehyde in the human body is metabolized to acetate. Different 
enzymes are able to carry out this reduction but particularly the acetaldehyde reductase.  A study 
made by (49) using human cells and animals proved that this toxic aldehyde is mutagenic and is also 
carcinogenic.  
O6-methylguanosine transferase is an enzyme involve in the DNA repair when damage by alkylating 
agents.  Acetaldehyde in very low amounts (0.01 µM )is able to stop the activity of this enzyme (50). A 
study using plasma serum showed that acetaldehyde is also able to interact with membrane proteins. 
When the concentration of acetaldehyde is 100 µM a small amount of it (38 nM) had reacted with 
membrane proteins (51). Damage to DNA was much greater. Other than protein damage the 
acetaldehyde is able to interact directly with DNA and damage it. The TP53 gene is a tumor suppressor 
gene. After acetaldehyde exposure this gene showed a modification in the guanidine that is swapped 
with an adenine, leading to a common mutation found, which can have drastic effects on the proteins 
function and folding. Sometimes the mutation in the gene makes it not able to encode the protein. (52). 
The minimal amount of acetaldehyde able to induce this modification is 100 µM (53); however 100 µM 
is a value higher than normal acetaldehyde found in the blood stream in heavy drinkers (10 µM). 
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LIPID PEROXIDATION PRODUCTS 
 
Living cells are enclosed by a double layer of phospholipids. These lipids are esterified with a molecule 
of glycerol. The lipids can be saturated or not saturated. Indirectly different pathways such as protein 
turnover, sugar metabolism and respiratory chain in the mitochondria are able to affect the lipid 
membrane. These pathways produce some harmful oxidant. The oxidant are able to remove an 
hydrogen to the lipid for made itself more stable but they leaving the fats chains more reactive to the 
oxygen. This is the starter of a long chain of lipid oxidations, were every radical lipid try to stabilize 
itself stolen a hydrogen from a neighbor lipid more unsaturated than it. This oxidative process is able 
to made some very dangerous molecule in the body, some of them still remaining in the lipid 
membrane linked with the glycerol but others are able to move around the cells. The oxidizing process 
is able to break the lipid chain giving rise to two different molecules. The molecules generated during 
this long series of reactions are aldehydes and ketones. It has been reported that these molecules are 
able to form adducts with other macromolecules present in the human body such as DNA, proteins or 
lipids. The interaction with DNA leads to the generation of mutations during DNA replication. In Figure 
5 it is possible to see the main products derived from the oxidation of the linoleic acid. 4-hydroxy 2(E) 
nonenal (HNE), malondialdehyde (MDA) and 4-oxo 2(E) nonenal (ONE) are all α-β-unsaturated 
aldehydes derived from the homolytic breakdown of the polyunsaturated fatty acids.  Not only are the 
unsaturated fats able to give rise to reactive aldehydes and ketones, the homolytic breakdown of the 
polyunsaturated fatty acid (PUFA) are able to generate a large amount of other reactive molecules 
(54). These electrophiles are able to react readily with proteins and DNA. This process is continuous in 
human body and its metabolite generate during the DNA repair after the adduction with the reactive 
aldehydes can be monitored in the urine. Some factors such as smoking are able to increase the 
amount of metabolites that can be detected in the urine. It is also possible using this metabolite as 
cancer biomarker (55). 
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Figure 5: diffusible lipid electrophiles and membrane-bound lipid electrophiles made by membrane phpspholipids 
from (56). 
 
Cells have developed different ways for protect itself from these dangerous molecules. Glutathione 
(GSH) is an important defense inside the cells, and is able to supply reducing equivalents to these 
aldehydes. Helped by the glutathione S-transferase (GST) it is able to forms adducts between the active 
lipids and GSH. These adducts are easy transport out to the cells. Some molecules directly derived 
from the lipid peroxidation such as HNE are so reactive with GSH, they have the effect of lowering the 
amount of GSH inside the cells. Other enzymes such as the aldo-keto reductases and aldehyde 
dehydrogenases can reduce aldehydes to alcohols. The alcohols are less reactive than the aldehydes. 
The importance of these aldehydes and ketones generated during the peroxidation process is apparent 
as when their amount is to high inside the cells and the cell is not able to eliminate them, this leads to 
cellular damage and can contribute to the aging process (57). 
ACROLEIN 
 
Drinking a normal wine can expose the human body to a various toxic compounds. Other than 
acetaldehyde in the wine it is possible to find another more toxic aldehyde, acrolein (2-propenal). The 
precursor is the 3-hydroxypropinaldehyde formed during the glycerol fermentation by bacteria (58). 
Wine is not the only external source of acrolein, and many foods are a source of it as well as cigarette 
smoke. Fried food is a source of acrolein because of the reaction between the fatty acid (oil) at high 
temperature used during the process (59).  
 Acrolein is present in the air as a product of the fuel combustion.  This means that acrolein can enter 
the human body by ingestion or inhalation.  
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Acrolein is also present in the body naturally. Acrolein is derived from the oxidation of lipids, 
especially during stress condition; but this source is very low compared to that in tobacco smokers       
(60). The organ most targeted by volatile acrolein is the stomach mucosa. The body protects itself by 
conjugating acrolein with GSH and cysteine groups, and this seems to the decrease the toxicity of 
acrolein (60). Conjugation with the glutathione could result in a low availability in free glutathione 
reductase and consequently a major expose to the ROS for the cell. Liver cytosol or the mitochondria 
are able to oxidize this toxic aldehyde to acrylic acid or reduce to allyl alcohol. Acrylic acid can be 
incorporate into different metabolic pathways. Lung and liver are also able to metabolize the acrolein 
by oxidation, the molecule that result is the glycidaldehyde, which is also toxic (61). In the review 
paper (59) presents a good scheme about the source of acrolein made by human body and also 
proposes the metabolic pathways for its detoxification.  
 
METHYLGLYOXAL 
 
An imbalance between radicals (especially ROS) and antioxidants drives the cell to a state called 
oxidative stress. Oxidative stress is looks to play a major role in the aging process (62). The 
mitochondrial electron transport chain and oxidative metabolism are sources of ROS.  Methylglyoxal 
(MG) looks to play a central role in the aging process. This aldehyde is very reactive with protein and 
DNA causing damage, and when a cell is not able to neutralize the aldehydes and the ketones made, the 
aging process starts. This reactive aldehyde has origins in lipid oxidation that can occur in two 
different ways: the random lipid oxidation made by ROS or during the lipid cycle oxidation that occurs 
at the cell membrane. Another source of MG is from the oxidation of sugars. In subjects with diabetes, 
where the metabolic pathway is not properly regulated, MG is present in higher concentration than 
people not affected by this illness.   Lactic acid is the final product of MG, and two enzymes glyoxalase-I 
and glyoxalase-II (glyoxalase system), and the cofactor glutathione are responsible for its conversion 
(57). In a recent study (63) used a human histiocytic cell line and proposed a different pathway for the 
MG. They gave attention to formic acid (FA), a sub product of MG degradation by oxidative stress. They 
showed that FA could be involved in the detoxification of the MG interacting with H2O2. 
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Figure 6: the propose MG system of detoxification proposed (63) 
In Figure 6 the possible pathways for MG degradation are shown; in this scheme it is possible see that 
one of the products of the MG degradation is the acetaldehyde another aldehyde known as damaging 
to cells.  
 
MALONALDEHYDE (MALONDIALDEHYDE; MDA) 
 
In 1974 it was reported that malonaldehyde was formed in animal tissue from lipid oxidation and a 
low presence of antioxidant. In the same study, (61) showed that this aldehyde when administered to 
the rat is able to cause cancer. This dangerous di-aldehyde is the final product of the phospholipid 
oxidation. It is able to diffuse into the cell far from the lipids membrane (64). This electrophile like 
others is able to interact with DNA, RNA and as well with proteins where a classic example is the group 
SH, acting as a good nucleophile.  MDA adducts were found in humans showing that this di-aldehyde is 
potentially dangerous for humans and not only for rats (65), (66). Malonaldehyde present in the 
human serum is used as an oxidation marker (67). The level of malonaldehyde correlates with some 
disease processes such as atherosclerosis and cardiovascular (68). 
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MUCONALDEHYDE  
 
Muchonaldehyde (MUC) is a reactive aldehyde that is a metabolite of benzene whose degradation is 
initiated by cytochrome P450. Muconic acid is around 10-20% of the metabolite made by benzene. The 
benzene ring is oxidized and oxygen forms an epoxide. This instable ring after opening will give 
muconaldehyde (69). It is known that the human liver is able to open the aromatic ring of the benzene. 
Muconoaldehyde like other reactive aldehydes is able to react with DNA and proteins. Benzene is 
recognized as a tumor promoter in the development of cancer, but the way in which it promotes this 
mechanism remains unclear. MUC is associated with hematopoietic damage leading to leukaemia. In 
2008 (70) showed that z-z MUC is more potent than benzene and is responsible for protein damage. 
MUC can be metabolized by aldehyde dehydrogenase isolated from yeast. This enzyme looks have a 
biphasic manner with a apparent Km of 0.48 and 3.2 µM and Vmax of 604 and 1227 respectively 
nmol/minute/mg of enzyme (71). Also a reduction reaction can occur carried out by a purified ADH 
from yeast (72). In animal studies two enzymes in mouse liver are mainly responsible for the MUC 
detoxification: an NADH dependent ADH1 and an NADPH-dependent AKR1A4.  These enzymes show a 
very similar Km for MUC but the ADH1 shows a much greater rate. The AKR could have a major role 
under stress condition when the NADH is in low concentration and the rate between NADPH/NADH is 
increased (73).  
 
AFLATOXIN B1 
 
Aflatoxin B1 (AFB1) is a metabolite produce by Aspergillus in particular conditions such as high 
humidity and temperature. This fungus is able to colonize corn and grain stored and consequently 
food as well. This toxin is responsible for the high incidence of liver cancer in the Asian and African 
population, where the storage conditions are not so good. The toxin is not dangerous in itself but its 
metabolites are. The first of them is the AFB1 exo 8,9 oxide. This metabolite made by cytochrome P450 
is able to forms adducts with DNA and causing mutations. This component is made less dangerous by 
the action of glutathione S-transferase (GSTs) that are able to conjugate the epoxide. The epoxide 
could also hydrolyze to give the AFB1 dihydrodiol. This can then rearrange to give a double aldehyde 
that is very reactive especially with amino groups of the protein to give the Schiff base (74). The 
double aldehyde can be reduced to a dialcohol by members of the AKR7 family, AKR7A1, AKR7A2, 
AKR7A3 and AKR7A5. In the Figure 7 is schematic of AFB1 metabolism in the liver. 
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Figure 7: the metabolism by the liver of the toxic AFB1 . With the number they  show the succession of the passage 
catalyzed by enzyme. 1 the formation of the AFB1 catalyze by cytochrome P450. 2 the adduction between the 
glucation and AFB1 catalyze by Glucation S-Transferase. 3 the reduction of two aldehyde  present in the AFB1 
dialdehyde to two alcohol for give the AFB1 dialcohol, the reaction is catalyze by an Aldo-Keto reductase. In this 
figure is also possible see which molecule is able to reactive with the macromolecules present in the human body. 
There is also show the non enzymatic molecular transformation like the hydrolysis. 
 
Ɣ HYDROXYBUTYRATE AND SUCCINIC SEMIALDEHYDE 
METABOLISM 
 
Gamma hydroxybutyrate (Gamma hydroxybutanoic acid; GHB) is an illegal drug that has increased in 
prevalence in rave parties and so-called “date-rape” abuse. Analogues of this substance include 1-4 
butanediol (1,4BD) and the ɣ-butyrolactone (GBL). These substances are also classified as illegal 
because they are metabolized to ɣ-hydroxybutyrate, but they are easy to obtain in the black market 
(75). GHB is a metabolite physiologically present in the human body.  GHB is supposed to be a 
moderator and regulator of itself in the central nervous system. When is taken in high dosage it can 
interact with the gamma-aminobutyric receptor (76).  This could result in low response of the GABA 
receptor against the effect of neurotransmitters. The effect of these substance to the human brain are 
typical of the benzodiazepines and alcohol, and are able to cause dysregulation  to the central nervous 
system (77). The classic effects of GHB are sedation, euphoria, decreased inhibitions, enhanced sex 
drive, and amnesia (78). GHB is commonly reported as a date-rape drug, as the victims are not able to 
remember what happened to them after the ingestion of high amounts of GHB (79). In Figure 8 the 
metabolic pathway for GHB from different precursors such as 1,4 BD and ɣ-butyrolactone is shown. 
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Figure 8: metabolic pathway of GHB. 
The reaction can occur in both directions to and from GHB for both the substrates. The human body is 
able to make GHB from the GABA or SSA in a physiological equilibrium that involves the concentration 
of the precursor. Following the ingestion of GHB or derivatives as “fun drugs or different purposes” the 
concentration is much higher, and the human body is not able to convert all the GHB to its metabolites.  
In a physiological system this fatty acid GHB is mainly synthesized from GABA. GABA-transaminase a 
mitochondrial enzyme, converts the GABA into succinic semialdehyde (SSA). Two enzymes are able to 
convert the SSA to GHB. One is the aldehyde reductase AKR1A1 and the other is AKR7A2, both from 
the aldo keto reductase superfamily, both being NADPH-dependent. These enzymes have a different 
Km for SSA, AKR1A1 has a Km ten times higher than AKR7A2; the low Km for AKR7A2 and localization to 
the brain indicates that the key role of this enzyme is the reduction of the SSA to GHB (80). In the brain 
there is more than one AKR present, and it is clear that AKR7A2 is not the only enzyme that reduces 
SSA. In neuroblastoma cells SH-SY5Y silenced for the AKR7A2 gene, it was shown that this enzyme is 
responsible for the majority of SSA reduction at low concentrations of SSA (10 µM) . The same study 
shows that at high concentrations of SSA such as 1mM AKR1A1 plays a more important role in 
metabolizing SSA (80). The same paper tried to establish the role of this enzyme inside the cell, and it 
was shown that this enzyme is not responsible for the oxidation GHB to SSA, because the silenced cells 
show the same level of GHB dehydrogenase as the control.  
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After this evidence the focus for GHB oxidation is look for an alcohol dehydrogenase that is NADH 
dependent and localized in the mitochondria. After this controversial evidence, the physiological role 
of AKR7A2 in the human brain is still open.  
 
In the Table 2 are summarized some of the enzymes known to be able to detoxify the dangerous 
aldehydes described above. The enzymes are taken from different sources, but a particular focus is 
gave to the enzymes in the AKR family. 
Table 2: enzymes able to metabolize aldehydes. The enzymes present are from different source. 
Substrate Enzyme Source Km Vmax 
(nmol/min/mg) 
Vmax/Km Referemce  
Muconaldehyde ALDH yeast 0.48 / 
0.32 µM 
604 / 1227  (72) 
ADH1 
(NADH) 
Mouse 
liver 
11 µM 2141+/- 500  (73) 
AKR1A4 
(NADPH) 
Mouse 
liver 
15µM 115+/-16  
Acrolein AKR7A1 Rat 
liver 
 17.5 [1mM]  (39) 
SSA AKR7A1 Rat 
liver 
0.14mM 1.46 
µM/min/mg 
10.43 (39) 
4-
nitrobenzaldehyde 
AKR7A1 Rat 
liver 
0.72mM 2.58 
µM/min/mg 
3.58 (39) 
Methglyoxal AKR7A1 Rat 
liver 
7.22mM 1.13 
µM/min/mg 
0.16 (39) 
Menadione AKR7A1 Rat 
liver 
 < 1.3 [1mM]  (39) 
Crotonaldehyde AKR7A1 Rat 
liver 
 48.4 [1mM]  (39) 
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MENADIONE AND NAPHTHOQUINONE  
 
Muconaldehyde is not the only chemical derived from modification accord to benzene ring. Other 
modifications can occur created without breaking the aromatic ring, but breaking the double bond 
between the two carbon atoms, adding a double bound with oxygen to one of the carbon atoms 
involved in the double bond. This modification changes the aromatic structure of the ring.  The same 
modification can happen to other aromatic rings such as naphthalene. The names of these changed 
molecules are quinones. Several of these molecules are present in human body, where they play 
different physiological roles such as electron transport in the aerobic respiration for example 
ubiquinone. A well known quinone is vitamin K1. This large class of components have show a wide 
range of functions from anti microbial proprieties to protein synthesis, and some of them are also 
studied for their  anti-tumor activity. 
Menadione is a quinone and its IUPAC name is 2-Methylnaphthalene-1,4-dione. It is commonly called 
vitamin K3. This molecule is a precursor of vitamin K and is considered toxic (81). Using human cell 
lines it was establish that vitamin K3 has anticancer properties in carcinoma cell lines by generating 
free radicals (82). When K3 is associated with vitamin C in the ratio 1:100 it can generate a redox cycle 
to kill tumor cells and leave unchanged the other cells (83).  So this vitamin could be part of anticancer 
cocktail. 
5-hydroxy-1,4-naphthalenedione its generally called Juglone, this chemical is present in different trees 
and leaves in the Juglandacea family. Juglone is used for several different purposes as a herbicide and 
cosmetic, and also in the food industry for is brown color. When the 5-hydroxy in Juglone is exchanged 
for 2-hydroxy-1,4-naphthalenedione, the new chemical takes the name of Lawsone.  This molecule is 
particularly abundant in the henna herb. The color of the molecule is black and is used to dye hair, 
nails and skin (84).  Both these molecules have the capacity to reduce significantly the glutathione 
inside the cells, as well as start a redox cycle able to generate a large amount of ROS. Their toxicity was 
establish in isolated hepatocytes cells (85). 5-hydroxy-1,4-naphthalenedione is more toxic for 
hepatocytes. For cosmetic use especially for skin tattoos the 2-hydroxy-1,4-naphthalenedione is 
considered safe (86).  The mechanism that the human body use for reduce the toxicity of these two 
toxic compounds is not clear, especially in the liver, the organ most involved in their toxicity.  
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WHISKY AND ITS POLYPHENOLS 
 
Alcohol is consumed everywhere in the world and is metabolized as a food. The high ingestion of 
alcoholic beverages is associate with different kinds of illness; contrarily, a moderate consumption of 
alcoholic beverage is associated with the prevention of some illnesses. A low intake of alcohol every 
day has shown improve the cardiovascular system (4), (87). A recent study has shown that moderate 
drinkers are less affected to same pathology for degenerative diseases such as Alzheimer (88). A study 
conducted in the same year was able to connect the amount of ethanol ingested with the protection to 
cardiovascular diseases in the Asiatic population (89). Many of the drinks normally consumed during 
the day such as beer and wine are also rich in secondary metabolite derived from the original fruit or 
during the manufacturing process. These molecules derived from the plants are associated with 
different pharmacology properties, and it is also believed that some of these molecules are able to 
promote an improved state of health. This is one of the reason that led to the belief that a moderate 
alcohol consummation is healthy: it is not the ethanol that is able to promote a moderate state of 
wellness but all the secondary metabolites that are in many alcoholic beverages. Of these beneficial 
molecules great interest is given to the polyphenols. Polyphenols are a class of organic molecules that 
possess several phenol groups. They components are divided into different classes: catechins, pro-
anthocyanidins and phenolics. Many of these molecules can react with different species of reactive 
oxygen. The oxidation of polyphenols could be chemical or enzymatic. The oxidation of these 
molecules can happen inside the plant during the ripening process of some fruits where the oxidized 
polyphenols contributes to the smell of these fruit.  Sometimes the oxidization process starts in 
humans following ingestion. During the maceration process, the plant material is broken and some of 
the enzymes stored in different parts in the cell came in contact with the polyphenols and begin their 
oxidization process. The change in oxidation of the phenols is responsible for black tea (90). This high 
capacity to be oxidized leads to the concept that in the human body these molecules can prevent the 
oxidation of macromolecules by being oxidized first themselves. 
Scottish whisky is particularly rich in aromatic components. Many of these components don’t derive 
directly from the malt but from the wood barrels (usually oak) used for the “spirit maturation”. The 
maturation process could be as long as twenty years. During this time some of the components of the 
wood are dissolved by the spirit and move into it. These components are then subject to other 
chemical modification including oxidation. The barrel is also able to promote exchange of oxygen 
between the environmental and the inside of the barrel. The diversity and quantity of these modified 
components can be influenced by many factors such as the contact time between the wood and fresh 
spirit, the barrel treatment before the contact with the spirit, the age of the barrel and others. 
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 However of great importance is the time of contact between the spirit and the barrel, as this seems to 
influence directly the amount of polyphenol in the final product (91). This evidence is support by 
many authors (92),(93). The effect is to change the polyphenol profile of the whisky (94). It’s difficult 
to establish the total amount of polyphenol in whisky because of the different methods used and the 
type of maturation. However some groups have quantified the amount in a range between 25 and 75 
ppm (95).  
The main polyphenols present in whisky are ellagic acid (29-50)%, gallic acid (13-23)%, 5-hydroxy 
methyl 2 formaldehyde (HMF) (2-38)%, and syringaldehyde (6-15)%. In Table 3 are shown the 
amount of the principal polyphenols found in whisky (91). 
Table 3: polyphenol constituent the non volatile fraction of the whisky.  
Component  µg/ml µM/ml 
Eallic acid  263.1 1.54 
Syringaldehyde 1.01 5.54 
 Β-Pentil alcohol 145 1.11 
Gallic acid 0.66 3.87 
Vanillin 103.7 0.68 
 
Figure 9 shows some of the many polyphenols found in whisky. These component are found in the non 
volatile part of the whisky. 
 
Figure 9: many polyphenols found in the whisky. These polyphenol have shown antioxidant propriety. 
 
Inside cells these components seem to play an important role in the defense against reactive oxygen 
species (ROS). ROS can be generated during alcohol metabolism, especially in the pathway involving 
the MEOS. The polyphenols are readily able to cross the gut barrier and enter the circulation. They 
have been found in the blood stream of people after the ingestion of wine or whisky (92). 
An evaluation of the antioxidant properties of many polyphenols found in whisky has been made. 
Gallic acid and ellagic acid have shown the best capacity to neutralize some radical molecules. 
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Significant interest is given to ellagic acid because of its high availability in whisky. However, not much 
is known about the bioavailability of the components, and which is the predominant form detectable in 
the human body after ingestion. Some components can be modified by the bacteria present in the 
human gut, during the absorption process. Also some enzymes are able to change the chemical 
structure of the polyphenols, to make them easier to be eliminated from the human body. Hence its 
difficult to establish which are the predominant forms present in the human body and which are the 
main polyphenols responsible for their antioxidant property.   
Not only are these polyphenols able to act as radical scavengers, some are also able to alter the 
expression of some of the protective enzymes. It is well know that some xenobiotics are able to affect 
the levels of some proteins in the cell (38). The mechanism of action is not always known, but one 
antioxidant ethoxyquin is able to increase in rat the mRNA that encodes the aldo keto reductase 
AKR7A1 (37). This antioxidant can increase the expression of AKR7A1 20 fold, although the increase is 
lower with other antioxidants. 
Experiment conduced using rat had shown that these polyphenols are able to change the rate in which 
the alcohol is metabolized in the rat body.  In particular, these polyphenols and especially the vanillin 
seem to be able to influence the first step that is ethanol oxidation. In the same study has been shown 
that this effect is increases with the age of the whisky used in the experiment and correlates with 
increased levels of polyphenols. The researchers noticed that in rat blood after the administration of 
ethanol and polyphenol together, the ethanol has a longer half-life compared to the control group (no 
polyphenol). The ethanol levels remain high in the blood stream, but acetaldehyde remains low in rat 
treated with polyphenol. This evidence indicates that the polyphenol can inhibit the oxidation of 
alcohol by ADH. Experiments conducted with single polyphenol show that strong inhibition of ethanol 
oxidation was also made by vanillin (91), (96). However they did not evaluate the effect on the second 
metabolite made during the ethanol metabolism that is the acetaldehyde. Acetaldehyde is considerate 
more toxic and powerful than ethanol, so knowledge of its levels are important to understand ethanol 
toxicity.  
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RESVERATROL 
 
3,5,4' –hydroxystilbene is the chemical component known as resveratrol. This is a polyphenol present 
in a wide variety of vegetables and fruits, but a particularly rich source is the grape skin, in particular 
the red grape cultivar, and peanuts and cranberries.  In vegetables, the main role of this phenol is to 
protect them from UV radiation as well as bacteria and yeast (97). Many good qualities are attributed 
to resveratrol, especially its ability to prevent cardiovascular disease. Resveratrol is able to protect 
low density lipoprotein (LDL) from oxidation, and also able to increase the quantity of high density 
lipoprotein (HDL) in the blood. Vasodilatation is another attribute of this molecule (98). This 
antioxidant is normally introduced in the human body through the diet but is also available as 
supplement. A recent study (99) reported a very low bioavailability for this component, and less then 
1% of resveratrol was detected in the blood stream in subjects treated with a single oral dose of 25mg 
(around the average intake with red wine in a day). The maximum amount of resveratrol found in the 
blood stream is less then 10ng/ml after no more than two hours after the oral ingestion. Other studies 
were made to evaluate the tolerability of resveratrol when is integrated in the diet. The intake of 
5g/day of resveratrol was studied and some subjects were not able to tolerate such a high amount. 
They were affected by adverse reaction such as vomiting, dizziness, and headache. There is not 
however any advice on intake but it is reputed that 1 mg/day is the right amount (100). In terms of 
metabolism, resveratrol is simply glycosylated by the liver to make it more easily eliminated from the 
human body; this is probably an explanation for the low amount of free resveratrol found in the blood 
and its low bioavailability (101). 
In vitro studies using HepG2 have shown that resveratrol is able to stop cell proliferation in a 
concentration between the range of 12.5 and 25 µM. Increasing the amount of resveratrol in the cell’s 
media in a range between 50 and 100µM and exposing for more than 24 hours leads to a typical 
apoptotic phenotype such as DNA fragmentation   (102).  However it should be noted that the cells 
used in this experiment are carcinoma cells and they are not able to express all the enzymes normally 
found in liver cells. It also been reported that the capacity of some secondary metabolites to interact in 
a specific way is effective only against cancer cells and an example is gallic acid (103). 
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VANILLIN 
 
Vanillin is produced by the vanilla orchid pods from Mexico. Other plants are able to produce this 
interesting metabolite such as the tobacco plants. Vanillin is present in the whisky and it passes into 
the distilled product through contact with the wooden barrel during maturation. Vanillin is recognized 
as one of the most important aromas worldwide. It is now possible to obtain vanillin by chemical 
synthesis. Vanillin displays some interesting properties and is able to interact with bacteria and yeast. 
Vanillin can be used as an antimicrobial, however is use for this purpose is limited by the high amount 
of vanillin required, so high as to make its aroma very strong, but it is used in low amounts to prevent 
the bacteria growing in food (104).  
Many studies have been carried out using cell lines in order to better understand the general 
properties of this flavour molecule; part of these studies were made using cancer cells. A study made 
with hamster lung fibroblast V79 cells line (105) showed that vanillin can protect against DNA damage 
as well against uv-induced mutation (106). The ability of vanillin to prevent mutagenesis was studied 
in vivo using mouse in order to show its ability to block cancer breast metastasis (107). An important 
consideration needed to be made, that is, vanillic acid the main metabolite of the vanillin does not 
show the same properties as vanillin. For this reason great importance is given to the aldehyde group 
present in the vanillin (108).  
Vanillin has the ability to interact with ADH, one of the enzymes responsible for alcohol metabolism, 
by steric inhibition. This inhibition is proportional to the amount of vanillin present in the distilled 
whisky used in the experiment (96). Not only is vanillin able to inhibit enzymes but it is also able to 
change the gene expression profile, particularly for those genes that are involved in the cell cycle and 
apoptosis (109).  
Only the property to interact with ADH has been investigated but there has been no other study made 
to evaluate the possible interaction with other enzymes involved in alcohol metabolism, such as the 
acetaldehyde reductase or other enzymes involve in the Kreb’s cycle where the acetate made from the 
acetaldehyde is directed.  
 
 
 
 
41 
 
GALLIC ACID 
 
Gallic acid is a polyhydroxyphenolic. This natural component is present in different fruits as pineapple 
and apple skin, strawberry, bananas and lemon. Not only are fruits rich in this secondary metabolite 
but also cereals such as oat bark, tea leaves and consequently also the products derived from them 
such as red and white wine and tea. This molecule has a high bioavailability. The presence of free gallic 
acid can be detected systemically after the ingestion of foods rich in it (110). Many virtues are given to 
this molecule. It has been shown to have cytotoxic properties against cancer cells (103). This is 
mediated by increasing the amount of ROS inside the cell, an increase of Ca2+ inside the cell, and 
abnormal mitochondrial function. It is not totally clear how the gallic acid is able to kill the cells. Gallic 
acid seems to have a strong influence on the cancer cells to induce apoptosis. In some cell lines (human 
lung cancer NCIH460) it has been reported that caspase-3 is directly involved in mediating gallic acid 
induced apoptosis (111). However as caspase-3 is not involved in cell death of lung cancer cells Calu-6 
and A549, and also as caspase-9 is not involved in the death of these cells this suggests that another 
pathway is involved in cell death (112).  Over the years a wide range of papers have accumulated  in 
which is shown the anti-inflammatory effect of this molecule other than cancer prevention (113).   
In non cancer cells, gallic acid is able to protect cells against glucolipotoxicity (112). In a recent study it 
has been established that gallic acid is able to offer a good protection against the formation of protein 
adducts with aldehydes and ketones. This experiment shows the ability of gallic acid to reduce the 
amount of adduction between the BSA (Bovine Serum Albumin) used as reference protein and the 
methylglyoxal used as an aldehyde (114). In animal studies, when the rats were fed with a gallic acid 
supplements they showed an increase in the levels of antioxidant enzymes and more resistance to the 
lipid oxidation (115). Supplements with gallic acid were also able to prevent some cytotoxic effects on 
the liver. Based on single cell migration (Comet assay) it was possible to establish that gallic acid could 
prevent DNA fragmentation by gallic acid. This protective effect was shown when gallic acid was 
added to human lymphocytes in the range 0.015 and 0.15 µg/ml (115). So this molecule is able to 
increase ROS when present at high concentrations but in low concentration it prevents the damage 
made by the ROS. 
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HEPG2 CELL LINE 
 
During this thesis works the cell line HepG2 was used. This cell line is derived from human liver. This 
cell line expresses almost of the enzyme that are responsible for the detoxification of xenobiotic by 
activation or detoxification Phase I and Phase II (116), However the profile expression of cytochrome 
P450 enzymes is much lower in the cell lines than in primary culture (117). For this characteristic this 
cell line is ideal for study different toxic aldehydes especially the acetaldehyde that is made in the liver 
during the ethanol oxidation and aldehydes generated during the lipid peroxidation. This cell line is 
particularly useful in the studying the oxidant defense mechanism, because it expresses many of the 
enzyme involve in the protection against it, including different superoxide-dismutases (118). The 
HepG2 cells line has kept the capacity to metabolize acetaldehyde by acetaldehyde dehydrogenase 
(ALDH) (119). In one of the few papers published (120), it has been shown that acetaldehyde is able to 
decrease the viability of these cells by around 14% when exposed to 1mM of acetaldehyde for four 
hours. In the same study it was also demonstrated that acetaldehyde showed greater toxicity 
compared to ethanol. Increasing concentrations of acetaldehyde to 200 mM for the same exposure 
time is able to kill these cells  (121). 
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1321N1 CELL LINE 
 
Astrocytes are one of the main types of cells present in the human brain. They have a primary role 
during the development of the neuron, and they support them by providing nutrients. Astrocytes are 
also the primary place for the detoxification of many neurotoxins (122). What is not totally understood 
is the metabolism of ethanol in the brain and the localization of it. However astrocytes are able to 
metabolize ethanol through three pathways: catalase; cytochrome P450 2E1 and ADH. ADH does not 
seem to play a great role in this metabolize so the other two are more important, especially the 
catalase (123),(124). The metabolism of ethanol is the main source of acetaldehyde in the brain. The 
acetaldehyde produced in other part of the body (mainly in the liver) it does not cross the encephalic 
barrier because is metabolized before it reaches it. High amounts of acetaldehyde 10-40 mg/kg 
administered to rats are able to saturate the enzymes involved in the conversion of acetaldehyde to 
acetate. In this condition the acetaldehyde is able to reach the blood brain barrier and cross it (125).  
Several studies have used the astrocytes as a model for targeting different molecular toxicities and 
effects.  
A study with the purpose of evaluating the toxicity of ethanol exposed rat astrocytes to concentrations 
ranging from 20 to 50mM. The viability of the cells was unchanged even at the high concentrations; the 
DNA did not show any damage indicating that ethanol is not very toxic. The same study evaluated the 
toxicity of acetaldehyde in astrocytes, using an exposure of three hours with different concentrations 
0.25, 0.5 and 1 mM.  There was no difference in the cells’ viability but DNA damage was observed 
(126).  Using rat primary cultures the lowest concentration of acetaldehyde able to lower the viability 
of cells is just less than 50 mM. This value is very high compared to the amount of acetaldehyde found 
in the blood stream of drinkers (127).  
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III AIM OF THE WORK 
 
 
 
The aim of the work described in this thesis is to elucidate the role of the AKR7A enzymes in 
acetaldehyde metabolism. This will be achieved through the following objectives: 
 Characterization of the human AKR7A2 and AKR7A5 enzymes. 
 Evaluation of the role of the AKR7A2 enzyme in detoxication in human cell lines. 
 Evaluation of the effect of the main antioxidants found in whisky and wine in the protection 
against aldehydes generate by lipid peroxidation. 
 Evaluation of acetaldehyde toxicity in the cell line 1321N1 and HepG2. 
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IV RESULTS AND DISCUSSION  
EVALUATION OF ACETALDEHYDE TOXICITY 
 
The main metabolite made during the ethanol oxidation is acetaldehyde. This metabolite is believed to 
be responsible for diseases related to alcoholism. Acetaldehyde may interact with other component 
present in alcoholic beverages. Normally the amount of acetaldehyde in drinkers is around 4-10 µM in 
the blood stream. A second study showed a considerably higher amount of acetaldehyde in the blood 
stream in a drinker of 27 µM. This was the average value after the ingestion of 1g of ethanol for kg of 
body weight (128).  
Several descriptions of the toxicity of acetaldehyde can be found, particularly the interaction with DNA 
and proteins. Acetaldehyde can affect cells in different ways. It could exercise its toxic effects over a 
long period of time or initiate processes able to damage the cell or kill it.  This aldehyde is able to react 
with different macromolecules such as DNA, proteins and lipids. Also the metabolism of this 
compound at high concentrations may be able to unbalance the NAD+/NADH radio in the cell.  
However there are only a few papers that discuss acetaldehyde toxicity in cell lines. One of the 
purposes of this project is to evaluate acetaldehyde toxicity in the human cells line 1321N1 and liver 
HepG2, especially with respect to their viability. Other than the viability of the cells, the capacity to 
induce apoptosis inside the cells was also investigated, and in particular the role of the caspase-3, a 
protein commonly involved in apoptosis was investigated. Agarose gel electrophoresis was used to 
investigate another marker of apoptosis, DNA fragmentation.  
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ACETALDEHYDE TOXICITY 
 
The first step was to evaluate the total toxicity in  the cells line 1321N1 and HepG2.  These parameters 
could be simply determined using an MTT assay, to understand the viability of the cells after being 
exposed to different concentrations of aldehyde.  In the Figure 10 and Figure 11 it is possible follow 
the loss of viability caused by acetaldehyde over increasing concentrations and during different times 
of exposure. 
During these viability experiments, to prevent the high volatility of acetaldehyde a layer of plastic film 
was used between the 96 well plate and its lid. The results without using the plastic film were quite 
different to the results shown in this thesis. In particularly, the acetaldehyde looks less toxic. This 
reduction in toxicity was attributed to the reduction of toxic concentration over the time, especially at 
the normal incubator temperature 37oC where evaporation would take place. 
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Figure 10: viability of the two different cells line studied, in different range of toxic concentration, after a short 
exposition, three hours. Three samples  for every  measurement. N=4, p<0,05. 
For the brain cells 1321N1, there is no significant difference in viability between the control cells and 
the acetaldehyde-treated cells concentration up to a concentration of 10 mM for 3 hours. Increasing 
the concentration up to 100 mM gives a significant decrease in cell viability.  The HepG2 cells start 
showing a decrease in viability at 10mM of acetaldehyde, and this loss of viability becomes more 
pronounced at higher concentrations. It is possible to see from Figure 10 that the two curves are very 
close to each other. In this short time frame, HepG2 looks more resistant to acetaldehyde showing a 
reduction of viability of 8% at 10mM and 89% at 50mM.  
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1321N1 cells are more sensitive to acetaldehyde exposure, showing a reduction of viability of 29% at 
1mM and 30% at 50 mM. However at higher concentrations these cells are more resistant than the 
HepG2. 
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Figure 11:  viability of the two different cells line studied, in different range of toxic concentration, after a long 
exposition, 16 hours. Three samples  for every  measurement. N=4, p<0,05. 
In Figure 11  a longer acetaldehyde exposure time was used and the two cells lines show clearly 
different behavior. The HepG2 cells seem very resistant to acetaldehyde, the only concentration being 
able to reduce the cells viability is the highest used 25mM. This data are particularly hard to explain 
especially when the concentration of 10mM is able to cause a significant drop in viability in three 
hours exposure. It should be born in mind that the MTT assay is strictly related to mitochondrial 
activity as the mitochondria are the catalytic site for the colorimetric reaction. It seem that the effects 
of acetaldehyde on mitochondrial activity (viability) is particularly apparent at an early stage but that 
over time, the cells begin to recover as the cells metabolism is able to eliminate / metabolize the 
aldehyde and the mitochondria regains function to give a strong viability signal.  
A different situation is observed for 1321N1 cells. The lowest concentration of acetaldehyde that is 
able to cause a loss of viability is 250 µM. Increasing the exposure time to acetaldehyde reduces cell 
viability by 4 times compared to the shorter exposure, indicating that these cells are not able to 
metabolize the acetaldehyde over time and hence are not able to recover mitochondrial function. 
Overall, the data presented for acetaldehyde toxicity at both exposure times indicates that 
acetaldehyde does not play a great role in the death of HepG2 cells, but does have an effect on 1321N1 
cells. However the high concentrations required for significant cell death (250 µM) is greater than 
would be expected to occur following ethanol consumption. The brain cells may be more sensitive 
because they are not normally exposed to aldehydes, unlike the liver which plays a major role in drug 
metabolism. Liver possesses a wide range of enzymes that can metabolize acetaldehyde whereas brain 
may not have these enzymes. 
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The metabolism of ethanol in the brain is a controversial topic. This metabolism could  be a source of 
acetaldehyde (129), and for this reason the human brain cells need to have some resistance to this 
chemical. It is relevant to note that the concentration of acetaldehyde produced in the brain is likely to 
be much lower than the concentration found in the liver, and all the concentration tested are therefore 
much higher than would be encountered physiologically. 
A few other studies have looked at acetaldehyde toxicity in human cells as a model. In one paper the 
viability of cells HepG2 treated with 180 µM of acetaldehyde plus liposomes showed a reduction of 
only of 10% compared to the cells used as control (130). These data are different to the data presented 
here. A concentration of 100 µM was able to reduce the cells viability by only 4% and this value was 
not statistically different to the control. The next concentration tested was 250 µM and at this 
concentration there wasn’t any further decrease in viability.   One of the reasons could be the different 
time of contact between the aldehyde and the cells. In the experiment reported previously,  (130) cells 
were kept in contact with acetaldehyde for 24 hours, and the concentration kept constant by adding 
acetaldehyde several times. In the experiment reported in this thesis, a single dose was used. Another 
study made with rats, in particularly rat astrocytes show that these cells are more resistant that the 
human. In that study (127) acetaldehyde started to show some toxic effects at concentrations above 
the 50 mM. These values are incredibly high compare to the normal levels fo acetaldehyde found in the 
human body,  or in heavy drinkers. However these result are in agreement with a previous paper in 
which it was shown that only concentrations above 10 mM are able to affect the gluconeogenesis and 
concentrations above 20 mM are able to affect cell biosynthesis; this evidence was obtained from 
isolated rat samples (51). 
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ACETALDEHYDE EXPOSURE AND APOPTOSIS 
 
Acetaldehyde appears slightly toxic to cells directly, but is known to cause significant damage in whole 
organisms. One mechanism that could explain these effects is via apoptotic processes (131).  Apoptosis 
can be measured using several techniques but the main ones include looking at caspase-3 activation 
and also DNA fragmentation, both of which are well-characterized indicators of apoptosis. The 
purpose of this experiment was to see whether acetaldehyde was able to damage the cell by inducing 
apoptosis. 
 
LEVELS OF ACTIVATED CASPASE-3 
 
One of the proteins directly involved in apoptosis is caspase-3, which is activation during apoptosis 
and is often known as the executioner caspase (132). Caspase-3 is not the only caspase involve in the 
apoptosis and other caspases can be monitored, but caspase-3 tends to be the most commonly 
monitored. Hence this protein was used for evaluate the capacity of the acetaldehyde to induce 
apoptosis in the cells after an exposure to this acetaldehyde. 
Different concentrations of acetaldehyde were added to the cells from 5 µM to 50 µM.  The exposure 
time used was 24 hours. The highest concentration used was 50 µM because it is considered a 
concentration higher than that normally found in the human body. Cells were also treated with 
resveratrol as a control in the concentration range of 100µM. A concentration of 50 µM resveratrol is 
able to induce apoptosis in HepG2 cells lines (133). Following treatment of both the cell lines, extracts 
were prepared and the levels of activated caspase-3 were monitored using Western Blots and 
antibodies (Santa Cruz Biotechnology, caspase-3 H277) that are able to react with inactive pro-
caspase-3 (30kDa) and the cleaved part of the protein the active part of capase p20 around 21kDa. 
Figure 12 shows the results for the detection of the caspase-3 in HepG2 cells. 
 
 
Figure 12: Western Blotting with antibody against Caspase-3, cell line HepG2. C; control non treated cells 1; cells 
treated with 5µM acetaldehyde, 2; cells treated with 10 µM acetaldehyde, 3; cells treated with 25 µM acetaldehyde, 4; 
cells treated with 50 µM acetaldehyde, 5; resveratrol 100µM 
In the Western Blot shown in Figure 12, is possible detect only the main protein, the pro-caspase-3. 
Under the main band it is not possible see bands that suggest caspase p20 fragment is present.  
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The strongest band corresponded to the control sample. The bands related to the acetaldehyde 
treatment the look a little fainter but don’t show a real significant difference. The band relative to the 
resveratrol treatment looks really faint compared to the others. However, in this last band it is not 
possible see the activated form of the caspase-3 protein. In the paper previously quoted it was shown 
that the capacity to induce apoptosis utilized caspase-7 activity but the caspase-3 was not investigated. 
This Western Blot does not give too much information about the capacity of the acetaldehyde to 
induce apoptosis in the cells.  The only conclusion that is possible is that there is no difference in the 
amount of inactive caspase-3 protein between the control and the treated samples.  The same 
experiment was done carried out with the cell line 1321N1. As shown in the Figure 13 this cell line 
seems to be more influence by acetaldehyde treatment compared to the HepG2 in the long exposure 
time. The same caspase-3 antibodies were used for this experiment and the same amount of protein in 
each well. In Figure 13 is possible to see the result of the Western Blotting using the cells line 1321N1. 
 
Figure 13: Western Blotting with antibody against Caspase-3, cell line 1321N1. C; control non treated cells 1; cells 
treated with 5µM acetaldehyde, 2; cells treated with 10 µM acetaldehyde, 3; cells treated with 25 µM acetaldehyde, 4; 
cells treated with 50 µM acetaldehyde, 5; resveratrol 100µM. 
In  Figure 13 the intensity of the bands is weaker compared to the Western Blotting made for the cell 
line HepG2 in Figure 12. Also in this Western Blot the control band is more intense, and lane 4 appears 
stronger than other bands.  However this may reflect a slight variation in the amount of protein loaded 
on the Blot. In both samples, the pro-caspase-3 band corresponding to the sample treated with 
resveratrol looks weaker compared to control, but it is not possible detect the small fragment that 
should be generated during caspase-3 activation. 
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CASPASE-3 ACTIVITY 
 
It appears that the Western Blots for both the cell lanes were not able to give a clear picture of the 
activity of the caspase-3 inside the cells treated with the acetaldehyde and resveratrol. For these 
reasons, the caspase-3 enzyme system was used to give an alternative way of measuring caspase-3. 
Caspase-3 activity is able to give a quantitative response and not just a qualitative response compared 
to the Western Blotting. 
A Promega caspACE kit was used to measure caspase-3 activity. This is colorimetric enzyme assay, 
where the cell extract is the source of caspase-3 and the kit uses a special amino acid probe as a 
fluorophore substrate. The probe has an amino acid sequence recognized by caspase-3. When the 
probe is cleaved it releases a yellow dye (chromophore p-nitroaniline). The dye is quenched when 
linked to the probe, but is yellow after the cleavage. Monitoring the absorbance at 405 nm means it is 
possible to see how much dye is free at the end of the reaction. For this experiment, the cell line HepG2 
was chosen because they are exposed to higher levels of acetaldehyde derived from ethanol 
metabolism. HepG2 cells were exposed to acetaldehyde at 5, 10, 25, 50 µM in the growth media for 
three hours. Resveratrol was also used as a control to induce apoptosis at a concentration of 100 µM 
(134).  
Using the free dye (chromophore p-nitroaniline) it was possible to make a calibration curve, to 
determine the activity of the active caspase-3 activated. The first stock of dye was quantify by 
spectrophotometry using a extinction coefficient  ε =10500 M-1 cm-1.  
 
 
Figure 14: calibration curve of the dye (chromophore p-nitroaniline). N=3. 
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The good quality of the standard curve is expressed by the R2 value. All the value were determined in 
triplicate.  
In the Figure 15 is possible to see the response of the HepG2 cells treated with different concentration 
of acetaldehyde. 
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Figure 15:  caspase-3 activity in cells HepG2 treated with difference concentration of acetaldehyde 5, 10, 25, 50µM 
and resveratrol as positive control. n=3. 
In the data shown in Figure 15 the negative control value was subtracted and the graph shows the 
difference between the control value and the value recorded in different extracts. Between the control 
and the acetaldehyde-treated cells there are no statistically significant differences. 
Cells treated with resveratrol shown a statistically significant difference compared to all the other 
samples (p<0.05). The results also show that caspase-3 activity is significantly increased by 
acetaldehyde at concentrations of 5, 10 and 25 µM. Treatment with 50 µM acetaldehyde shows less 
caspase-3 activity. This indicates that caspase-3 is activated by acetaldehyde treatment but not to the 
same extent as resveratrol. 
 
 
 
 
55 
 
With the formula expressed below it was possible calculate the amount of free dye generated.  
         
                                 
                        
 
             
                              
  
A= Absorbance 405nm (mean induced apoptosis sample)- (mean negative control sample) 
         
       
  
 
     
     
 
Free Dye: 9.19x10-3 pmol/h 
The calculated specific activity (SA) of the caspase-3 in HepG2 cells line activated during the 
resveratrol exposure. 
   
                           
          
 
   
         
  
  
Specific activity calculated (SA): 3.063X10-4 pmol/h/µg 
The specific activity of the caspase-3 activated from the exposure to resveratrol is 3.063 X 10-4 
pmol/h/µg. 
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EFFECT OF ACETALDEHYDE ON DNA FRAGMENTATION 
 
Kitazumi and Tsukahara, (135) proposed that the specific role of the caspase-3 is the generation of 
DNA fragments by activating a nuclease. Genomic DNA fragmentation is a marker of the apoptosis 
(136), and this fragmentation can be easily detect by agarose electrophoresis (137). This method is 
independent of caspase-3 used to generate the DNA fragmentation. It gives less information than the 
Western Blotting with specific antibody but is still a good method for identifying apoptosis inside the 
cells. 
This technique was used to investigate HepG2 cells after exposure to acetaldehyde at the same  
concentrations used previously. DNA is extracted and then split into Genomic DNA and Apoptotic DNA. 
In Figure 16 it is possible to see the result of the agarose gel for the detection of the fragmented DNA. 
 
Figure 16: Apoptosis induced by acetaldehyde in cells line HepG2. A: the solution with the small fragment of DNA 
generated during apoptosis. G: the solution containing the genomic DNA as control of the DNA extraction. 1: control 
cells (un-treated). 2: cells exposed to 5µM of acetaldehyde. 3: cells exposed to 10µM of acetaldehyde. 4: cells exposed 
to 25µM of acetaldehyde. 5: cells exposed to 50µM of acetaldehyde. 6: cells exposed to 50µM of resveratrol. 7: cells 
exposed to 100µM of resveratrol. M: Marker. 
The method chosen to detect DNA fragmentation appears to work well.  In all the Genomic lanes it is 
possible see a strong band with a very high molecular weight. This band does not move too far from 
the loading well. The band is the intact genomic DNA. A small amount of contamination of genomic 
DNA is also present in the lanes that should contain only the fragmented (Apoptotic) DNA.  
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The control untreated sample (1) shows only genomic DNA in both lanes. No fragmented DNA is 
presented. The presence of the genomic DNA is a good indicator that the extraction procedure has 
worked.  The situation is different for the samples treated with the acetaldehyde. Concentrations of 5, 
10 and 25 µM are able to induce DNA fragmentation and presumably apoptosis in this cell line. In all 
the lanes corresponding to apoptotic DNA it is possible see the typical fragmentation with a molecular 
weight below 1kb.  In samples 2 and 3 is possible see a little contamination in the genomic lanes. In 
these lanes it is possible to see a weak fragmented DNA that is clearer in the corresponding A lane. 
This data suggest that acetaldehyde is able to induce fragmentation at concentrations found in the 
human body after the ingestion of moderate consumption of alcohol. It is not clear why the higher 
concentration of acetaldehyde 50µM is not able to induce fragmentation, but it is possible that this 
high concentration reacts with the cell macromolecular and tissue causing direct damage and necrosis, 
which is an alternative cell death endpoint.  
The sample treated with resveratrol does not shows the typical fragmentation or the minimum 
amount of fragmented DNA despite showing caspase-3 activation.  
The same analysis was also carried out using the brain cells 1321N1. This cell line looks less resistant 
to the toxic aldehyde as confirmed by the MTT assay made with different concentrations of aldehydes 
for the different cells line studied.  
 
 
Figure 17: Apoptosis induced by acetaldehyde in cells line 1321N1. A: the solution with the small fragment of DNA 
generated during apoptosis. G: the solution containing the genomic DNA as control of the DNA extraction. 1: control 
cells (un-treated). 2: cells exposed to 5µM of acetaldehyde. 3: cells exposed to 10µM of acetaldehyde. 4: cells exposed 
to 25µM of acetaldehyde. 5: cells exposed to 50µM of acetaldehyde. 6: cells exposed to 100µM of resveratrol. M: 
Marker. 
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The agarose gel corresponding to the 1321N1 cells line is more easy to interpret. In every lane it is 
possible to see the bands corresponding to genomic DNA and consequently the quality of the 
extraction protocol. All the samples with the exclusion of the 3A, the lanes are totally clear with the 
minimal presence of fragmented DNA.  Lane 3A looks degraded but it does not present the typical 
pattern of apoptosis. The sample 6 treated with resveratrol also did not show any fragmentation but 
this was not expected at this concentration. In conclusion the agarose gels had shown that 
acetaldehyde at low concentrations is not able to induce apoptosis in 1321N1 cells but it is in HepG2 
cells.  
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CONCLUSION 
 
With the data obtained in this thesis is possible to say that the acetaldehyde does not cause a 
significant reduction in cell viability in samples exposed to a high concentration of acetaldehyde higher 
than the physiological level found in the blood stream from 5 to 50µM.  A 16 hours exposure does not 
generate a significant reduction of viability in HepG2 cells, but does show some decrease in viability in 
1321N1 cells. A 3 hours exposure time did not show a difference in viability. The capacity of the 
acetaldehyde to induce apoptosis was also investigated. Apoptosis process was follow using the 
caspase-3 activity, which indicated that some apoptosis was occurring at medium doses of 
acetaldehyde. This was supported by the DNA fragmentation assay in HepG2 cells.  
The next step will be to investigate the role of acetaldehyde in direct interactions with 
macromolecules. In particularly, it would be interesting to investigate the activity of different enzymes 
after cells were exposed to different concentrations of acetaldehyde. The main goal is to investigate 
whether there will a change in the substrate specificity or efficiency in the catalysis of different 
substrate. In this way it could be possible monitored the real interference made by the adduction 
between protein and acetaldehyde. Another analysis that will suggest is determining the expression  of 
different genes after the exposure of the cells to acetaldehyde and evaluate the effect on the cell cycle. 
With this method it is possible to evaluate in the long term the effect on DNA adducts in a first 
exposure to acetaldehyde. 
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EVALUATING THE PROTECTIVE EFFECT OF PHENOLICS 
FOUND IN WHISKY AND WINE 
 
In this Chapter, different concentrations of vanillin, gallic acid and resveratrol are investigated in order 
to evaluate the cells tolerability and response to these compounds. To investigate their role as 
chemoprotectants, 1321N1 and HepG2 cells are exposed to different concentrations of each compound 
follow by exposure to toxic aldehydes. The purpose is to evaluate the possible toxic effects of each 
compound, and then to determine the best concentrations that could give possible protective effects 
against different aldehydes such as acetaldehyde, acrolein and methylglyoxal . Acetaldehyde is directly 
related to alcohol consumption by its metabolism; acrolein is a marker of pollution; and methylglyoxal 
is an indicator of oxidative stress inside the cell.    
 
TOXICITY OF VANILLIN, RESVERATROL AND GALLIC ACID 
 
Initially an evaluation of the tolerability of the selected antioxidant by the two cell lines was carried 
out.  In this part of the work, the normal amount of antioxidant ingested with the food was not 
considered for two main reasons. First it would be possible to supplement the diet using higher 
amounts of the antioxidant. The second and more important reason is that other studies would need to 
be carried out to evaluate to concentration present in the blood stream after the ingestion of the 
component. It was reported previously that even when the intake of resveratrol is quiet high, the 
resveratrol present inside the blood stream is very low, caused by the detoxification processes in the 
human body. The average intake of resveratrol with the ingestion of red wine is 25mg, and only 10 ng 
is the maximum amount found in the blood stream. This is equivalent to 2 µM in the blood stream (99). 
Resveratrol is mainly metabolized by conjugation to glucuronides and sulfates of resveratrol. The main 
organ responsible for this transformation is the liver and the bacteria present in the gut. Gallic acid 
seems to be well absorbed by the human body, and it is possible to obtain a concentration around 4 
µM of gallic acid and its glucuronidated forms included the main metabolite 4-O-methylgallic acid after 
ingestion of a pure dose of 50 mg of this compound (138). Red wine is rich in gallic acid from 10 to 
50mg/l (139). 
1321 NI cells and the HepG2 cells used in this experiment were treated with a range of concentrations 
of antioxidants from 10 nM to 100 µM for 16 hours. The exact amount of compound entering the cells 
was not known but was assumed to be proportional to the amount added to the cells. 
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The first antioxidant tested was vanillin. In Figure 18 the viability of HepG2 and 1321N1 cells treated 
with different concentration of vanillin in the cell media is shown. 
 Vanillin curve
100 101 102 103 104 105 106
60
80
100
120
1321
Hepg2
  [Vanillin] nM
V
ia
ta
li
ty
 %
 
Figure 18: effect on the vitality of different concentration of Vanillin in cell 1321N1 and HepG2, n=4 for every sample. 
 
Both curves looks very similar to each other. The 1321N1 cells show an increase in viability at the 
lower concentrations of vanillin from 10 nM to 10 µM. This increased is not statistically significant as 
judged by the ANOVA test with a confidence p <0,05. The higher concentration of vanillin 100µM is 
able to significantly to reduce the cell’s viability by 33% compared to untreated cells. The situation for 
HepG2 cells is different and the range of vanillin tested from 10nM to 100µM is not able to significantly 
change the viability of HepG2 cells. With these data it is possible say that the brain cells 1321N1 are 
more sensitive to vanillin at high dosage.  
A similar viability curve was determined for resveratrol using the same range of concentrations in the 
media for16 hours. In this case, the curves made for the two different cells line are not similar. 
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Figure 19: effect on the vitality of different concentration of Resveratrol in cell 1321N1 and HepG2, n=4 for every 
sample. 
In particular, the 1321N1 seem to increase in viability up to 10µM resveratrol. This effect is not 
statistically significant. However there is a significant decrease in viability above 50 µM. A 
concentration of 75 µM of resveratrol is not able to reduce the viability of the cells compared to 50 µM 
of resveratrol. The highest concentration tested was able to reduce cell proliferation by around 50% 
compared to control.  
In comparison, HepG2 cells are more sensitive to the amount of resveratrol present in the media than 
1321N1 cells and 100 nM resveratrol is able to significantly reduce the viability of the cells (p<0.05). 
Higher concentrations of resveratrol are not able to significantly reduce the viability of the cells.  The 
most noticeable difference was at 100 µM which reduced the cell’s viability by around 40%. This value 
is not far from the 33% reduction in viability seen at a concentration of 1 µM. The two values between 
1µM and 100µM are very close to each other and they are not able to generate a statistical difference. 
Statistically there is no difference between the reductions of viability obtained with 100µM of 
resveratrol in both cells line.  
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Figure 20: effect on the vitality of different concentration of gallic acid in cell 1321N1 and HepG2 n=3 for every 
sample. P <0.05. 
Similarly, the two cells line 1321N1 and HepG2 were tested to evaluate their response after exposure 
to different concentration of gallic acid (Figure 20). HepG2 showed a minimal reduction in viability 
compared to the control cells which is not statistically significant. In the range tested from 1 nM to 
25µM gallic acid is not able to reduce or increase cell viability. The cell line 1321N1 differed from 
HepG2 cells showing a slight increase in proliferation compared to the control, but this increase in 
viability isn’t statistically significant. 1321N1 cells were not able to change the viability cells compared 
to the control.  
To summarize, none of the antioxidants altered cell viability significantly at low concentrations. Only 
the high concentration 100 µM was able to cause a significant reduction in viability with exception of 
gallic acid which showed no effect.  
As some loss of viability was observed at the highest concentration, each antioxidant was tested for its 
capacity to induce apoptosis in the cell. The capacity of 100 M resveratrol to induce apoptosis in 
HepG2 cell lines after an exposure time of 24 hours has been reported previously (134).  
The ability of 100 M of the three antioxidants to induce apoptosis was investigated using a DNA 
fragmentation assay based on agarose gel electrophoresis. In addition to the antioxidants, 150 µM 
acrolein was used as a control. Cells were treated with compound for 24 hours and DNA extracted for 
analysis. DNA was separated into Genomic and Apoptotic DNA. In Figure 21 it is possible to see the 
agarose gel used to determine the DNA fragmentation. In all the samples, the DNA extraction was 
successful. All the Genomic (G) DNA samples show two different bands with a high molecular weight 
not able to migrate in the agarose gel, remaining close to the sample well.  
For the Apoptotic (A) DNA, it is possible to see the same two bands but these much weaker compared 
to the G lane of each sample. The A lanes do not show any fragmented DNA with the notable exception 
of Sample 5 (100 µM resveratrol-treated cells) and to some extent Sample 4 (50 µM resveratrol).  
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Figure 21: Agarose DNA  gel 1% of human HepG2 cells treated with different antioxidants and toxic compounds.  G: 
genomic DNA. A: apoptotic DNA.  1:sample treated with acrolein 150µM. 2: sample treated with 100µM gallic acid. 3: 
sample treated with vanillin 100µM. 4: sample treated with 50µM of resveratrol. 5: sample treated with 100µM of 
resveratrol. M: marker. 
With this test is possible say that the high amount of vanillin (100 µM) is able to induce a reduction of 
viability but does not cause apoptosis. A similar situation is seen for gallic acid even though the high 
concentration used in the apoptotic test was not tested in the viability test. Resveratrol on the other 
hand leads to a reduction in viability and can cause apoptosis in HepG2 cells.  
Analyzing the data present in this chapter indicates it is possible to say that the human cells are able to 
manage a different amount of antioxidant in the culture media and this could reflect the same 
tendency in the body. Only resveratrol was found able to induce DNA fragmentation supporting data 
reported by other authors (134).  
With this result is possible to say that antioxidants in the diet at high concentrations may not always 
healthy.  This data supports data presented in the paper (100) where it was reported that high doses 
of resveratrol causes nausea in individuals. This is not the first report that shows the toxicity  of some 
antioxidants. β-carotene at a concentration of 1.5 µM able to reduce the vitality of the cells to around 
30%(130). To make this data more significant, the amount of free resveratrol and its metabolite inside 
the cells needs to be calculated, and also the experiment needs to be repeated with different kind of 
cells.  
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EFFECT OF PHENOLICS IN PROTECTING AGAINST TOXIC 
ALDEHYDES 
 
The phenolics vanillin, resveratrol and gallic acid were tested for their ability to protect cells against 
different aldehydes. Vanillin and gallic acid are present in whisky and resveratrol is present in red 
wine. Some phenolics found in the whisky have shown the capacity to interact and slow down with 
alcohol metabolism, resulting in a low amount of acetaldehyde in the blood stream (96). This study 
supports the idea that these phenolics and especially the vanillin are able to interact with ADH 
enzymes. That study does not investigate the role of these phenolics in the protection against 
acetaldehyde, and different aldehydes generated during the metabolism, especially ethanol.  
The aim of this part of thesis is to evaluate the protection offer from these different phenolics (vanillin, 
resveratrol, and gallic acid) against the acetaldehyde, the direct product of  the alcohol metabolism and 
some of the reactive aldehydes generate by the ROS such as methylglyoxyal and acrolein. A range of 
concentrations of antioxidant were used to treat the cells before being exposed to different 
concentrations of toxic aldehydes. The concentrations selected were based on the previous section, 
being those that did not cause significant toxicity to the cells. Toxicity was monitored using the MTT 
assay.   
The first toxic aldehyde tested was acrolein. A range of concentrations of acrolein was used and a 
killing curve determined for both cell lines. In the Figure 22 is possible to see the reduction of viability 
caused in both the cells line by acrolein. 
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Figure 22: vitality of 1321NI and HepG2 cells line after acroelin exposure for 16 hours. N=3 p<0.05. exposure time 16 
hours. 
66 
 
In both lines, treatment with acrolein led to a significant difference in viability compared to control 
cells. 200 µM acrolein is able to reduce cell viability around the 60%. In the 1321N1 cells line 25µM 
acrolein is able to cause a significant decrease in cell viability. Compared with control cells, the lowest 
concentration of acrolein able to generate a significant reduction of viability is 100µM for HepG2 cell 
line. Concentration of 150µM  and 50µM of acrolein respectively for the HepG2 cells and 1321N1 were 
used. Other toxic aldehydes were also used – methyglyoxal and acetaldehyde.  
 
The two cells line were pre-treated with different concentration of vanillin, resveratrol and gallic acid 
10nM to 45µM as described in the previous section for 24 hours, and afterwards exposed to the toxic 
aldehyde. Cell viability was measured using the MTT assay. 
Vanillin was the first antioxidant investigated in the protection against methylglyoxal, acetaldehyde 
and acrolein in the cells line 1321N1. In the Figure 23 below is possible to see the result of the MTT 
assays. 
Vanillin against 
methylglyoxal 
Vanillin against acrolein Vanillin against 
acetaldehyde 
  
 
 
Figure 23: protection offer to cell line 1321N1 by vanillin. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Vanillin in different concentration let in contact with the cells for 24 
hours. The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the 
antioxidant. 
The results show that there is no statistical difference between the control cells and those pre-treated 
with the vanillin only. However there is a significant difference between control cells and cells treated 
with methylglyoxal. The aldehyde causes a significant decrease in viability in 1321N1. However, none 
of the vanillin concentrations tested was able to significantly protect the cells against methylglyoxal 
toxicity. A similar result was observed with acrolein where pre-treatement with vanillin does not 
protect 1321N1 cells from acrolein toxicity. However with acetaldehyde, the cells pre-treated with 
vanillin show a significant reduction in viability compared to the control. The last plate treated with 
acetaldehyde showed the sample treated with the antioxidant very close to the sample treated with 
acetaldehyde and pre treated with antioxidant or with the acetaldehyde control.  
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Analyzing the effect of the pre-treated samples with different concentration of vanillin against the 
samples used as reference (treated only with the toxic) it is apparent that vanillin is not able to offer 
protection against the toxic aldehydes tested in this cell line. 
The same analysis was made for the cell line HepG2. The result are shown in the Figure 24. 
Vanillin against 
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Figure 24: protection offer to cell line HepG2 by vanillin. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Vanillin in different concentration let in contact with the cells for 24 
hours. The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the 
antioxidant. 
Treatment with 2 mM methylglyoxal led to a significant decrease in cell viability compared to control.  
Pre-treatment with vanillin was not able protect cells against methylglyoxal toxicity. This data is in 
agreement with the results for 1321N1 cells. Similarly, pre-treatment with vanillin could not protect 
cells against acrolein toxicity. The results for acetaldehyde show that the concentration used was not 
sufficient to cause significant loss in viability. Hence the effect of vanillin could not be fully evaluated. 
However it was noted that vanillin itself reduced the viability of cells, and that vanillin is not able to 
protect the cells against the acetaldehyde. The combination of vanillin and acetaldehyde is additive.  
In conclusion vanillin is not able to protect the cells against the toxic aldehydes tested. 
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Resveratrol was the second anti-oxidant to be tested. In the Figure 25 is possible to see the response of 
the cells line 1321N1. 
 
Resveratrol against 
methylglyoxal 
Resveratrol against 
acrolein 
Resveratrol against 
acetaldehyde 
   
Figure 25: protection offer to cell line 1321N1 by resveratrol. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Resveratrol in different concentration let in contact with the cells for 24 
hours. The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the 
antioxidant. 
  
Resveratrol concentrations of 45µM are able to reduce the viability of cells significantly. However, 
resveratrol is not able to protect the cells against methylglyoxal or acrolein toxicity. This is a different 
situation for the cells exposure to acetaldehyde. In this case, lower concentrations of resveratrol show 
a clear capacity to protect the cells from acetaldehyde toxicity. 45µM of resveratrol is able to induce a 
significant difference to the sample treated with acetaldehyde but the effect is not protective but 
increases the toxicity of the acetaldehyde reducing cell viability significantly.  
 
Resveratrol against 
methylglyoxal 
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Figure 26: protection offer to cell line HepG2 by resveratrol. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Resveratrol in different concentration let in contact with the cells for 24 
hours. The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the 
antioxidant. 
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Resveratrol was also tested for its capacity to protect HepG2 cells (Figure 26) against the same 
aldehydes. The higher concentrations of resveratrol tested reduced the cells viability compared to 
control sample. This data are in agreement with previous results Figure 19. It can be seen that 
resveratrol does not protect cells against methylglyoxal. For cells exposed to acrolein however, the 
cells pre-treated with resveratrol did show protection against acrolein at higher concentrations of 
resveratrol. In the cells treated with acetaldehyde, acetaldehyde is not very toxic, and resveratrol is 
not able to protect the cells against the effects of acetaldehyde. The combination of resveratrol and 
acetaldehyde is toxic. The last anti oxidant tried is the gallic acid.  The first cells line used for this 
experiment is the 1321N1. 
 
Gallic acid against 
methylglyoxal 
Gallic acid against acrolein Gallic acid against 
acetaldehyde 
   
Figure 27: protection offer to cell line 1321N1 by gallic acid. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Gallic Acid in different concentration let in contact with the cells for 24 
hours. The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the 
antioxidant. 
Gallic acid was also tested for its ability to protect cells. Treatment with gallic acid alone gave results 
that are in agreement with the curve shown at Figure 20. Pre-treatment with gallic acid did not protect 
cells against methylglyoxal toxicity, and in fact treatment with gallic acid followed by methylglyoxal 
led to significant toxicity. Pretreatment with gallic acid didn’t protect cells against acrolein toxicity. For 
1321N1 the gallic acid is not able to offer protection against acetaldehyde at the concentrations tested. 
In conclusion the gallic acid is not able to offer protection to the brain cells against the toxic aldehydes 
tried. 
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The possible role of the protection offer by gallic acid was also tested in the cell line HepG2 as show in 
the Figure 28 below. 
Gallic acid against 
methylglyoxal 
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 Figure 28: protection offer to cell line 1321N1 by gallic acid. Control is sample untreaded. Toxics used is the 
methylglyoxal, acrolein and acetaldehyde. Van in different concentration let in contact with the cells for 24 hours. 
The sample label with + were expose also to the toxic for 20 hours after the pre-treatment with the antioxidant. 
 
In agreement with previous results, gallic acid treatment lowers cell viability in HepG2 cells. Liver cells 
pre-treated with gallic acid are not able to protect the cells against the methylglyoxal. None of the cells 
pre-treated with gallic acid were protected against acrolein toxicity. In the analysis of acetaldehyde 
toxicity there was no difference between the control sample and the sample only treated with 
acetaldehyde. Gallic acid appears to increase the toxicity of acetaldehyde and is not able to protect the 
cells against the different aldehydes tested. 
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 CONCLUSION 
 
Vanillin, resveratrol and gallic acid are compounds found in many alcoholic drinks. These compounds 
are intensively studied for their properties as antioxidants and for their interaction with the human 
body. In this study it was shown that when the cell lines 1321N1 and HepG2 are supplemented with 
these antioxidants in a range from 100nM to 45µM for 24 hours, resistance to reactive aldehydes 
methylglyoxal, acrolein and acetaldehyde is not improved.  
It is apparent that the concentration of antioxidant in some instances is influencing the toxicity of the 
aldehyde. This could be investigated by using a wider range of concentrations of antioxidant.  Further 
analysis needs to be carried out particularly to evaluate the actual amount of antioxidant present in 
the cells.  
Another important part is to evaluate is the long term effect of the antioxidants and also their capacity 
to over or down regulated some genes.  
In addition the aldehydes are all reactive and it is not clear the actual amount of aldehyde present 
inside the cells and for how long. Another problem to overcoming is the high volatility of the 
acetaldehyde that is incompatible with the incubator temperature (37°C). The cells can’t be closed 
hermetically because they need a exchange of oxygen.  For this reason another way is needed to add 
acetaldehyde to the media. A good solution would be to add the media supplemented with 
acetaldehyde every hour to keep the amount of acetaldehyde in contact with the cells constant.  
With particular reference to alcohol metabolism, the antioxidants were not able to protect the cells 
against acetaldehyde, the first metabolite of the alcohol oxidation. In almost all cases, the cells pre-
treated with antioxidant look less able to deal with aldehydes especially when the concentration of 
antioxidant is high at 45µM. This aspect needs more investigation especially as it has been shown that 
vanillin is able to decrease the alcohol metabolism and slow down the acetaldehyde release in the 
blood (91). 
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THE EFFECT OF VANILLIN ON THE ACTIVITY OF 
ALDEHYDE REDUCTASES 
 
In 2007 two articles focused on vanillin and its interaction with alcohol kinetic metabolism in the 
mouse (91) and in human Hepatocarcinoma cells (109). The first paper showed the ability of vanillin 
to reduce ethanol metabolism in mice, the second showed the capacity of the vanillin to down regulate 
some of the genes related to the cell cycling and apoptosis. These down regulated genes were found in 
carcinoma cells and their down regulation indicates a protective role of vanillin against cancer. The 
data obtained during the MTT assay with the aim of investigating the protection offer by vanillin 
against different toxic aldehydes showed a reduction in viability of the cells pre-treated with this 
antioxidant. These papers and data provide ideas for better investigating the role of vanillin and its 
interference in the metabolism of aldehydes.  
To test the effects of vanillin 1321N1 cells were treated with 45µM of vanillin in the media for 13 
hours and total protein extracted used for enzyme assays. Two different substrates were used p-
nitrobenzaldehyde and acrolein. The activity in mg/nmoli/minutes is expressed in the Table 4 and in 
the figure Figure 29.   
Table 4: aldehyde reductase activity of protein extraction from cell 1321N1 treat with vanillin 45µM. 
Substrate NADPH µM NADH µM [substrate] Control activity Vanillin treated 
pNBA 6.2 / 100 µM 8.97  3.35 5.65  2.45 
pNBA / 6.2 100 µM 1.75  0.64 / 
Acrolein 6.2 / 1mM 1.09  0.51 1.28  0.31 
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Figure 29: aldehyde reductase activity in mg/ml/minute of protein extract 1321N1 with different substrate (pNAB 
and acrolein) different cofactor (NADPH and NADH) and cells treated with vanillin 45µM and not treated used as 
control. 1 ,3 and 5 are the controls sample. 2,4 and 6 are the cells pre-treated with vanillin.  Reactions 1 and 2 the 
substrate is pNAB and the cofactor is NADPH. In the reactions 3 and 4 the substrate is pNAB and the cofactor NADH, 
in the reactions 5 and 6 the substrate is the acrolein and the cofactor is NADPH. Each reaction is made with three 
sample from three different cells line. 
 
Figure 29 shows that the pre-treatment with vanillin is able to lower the aldehyde reductase activity of 
the cell extracts by 37% when using pNBA as substrate. The reduction of activity is statistically 
significant. Changing the cofactor from NADPH to NADH made the activity of the treated samples so 
slow that was impossible to be measured.  When acrolein was used as substrate there was no 
difference in activity. Within the cells it is likely that there are several different types of aldo-keto 
reductase. It’s not possible to establish which of the enzymes has lower activity, but from the data it is 
possible to conclude that pNBA and acrolein are reduced by two different groups of enzymes, the first 
group being influenced by vanillin exposure and the second group is responsible for acrolein 
metabolism, and not influenced by the vanillin treatment.  
It’s possible that vanillin is interacting with a promoter and is down-regulating the expression of 
different enzymes involve in this reaction. A Q-PCR targeting specific mRNAs is needed to establish 
whether there is a change in gene expression at the mRNA level. Western Blots can be used to 
investigate changes in protein levels. Alternatively, the low activity of the vanillin groups could be also 
explained by an interaction of the vanillin with the catalytic site of the enzyme responsible as an 
inhibitor. This theory was also proposed to explain the low amount of acetaldehyde found in the blood 
stream of rats fed with ethanol and vanillin. It was also proposed that vanillin is able to interact with 
the active site of ADH (96). This data totally agrees with the previous analysis in which vanillin was 
not able to protect the cells against the toxic acrolein in the MTT assay.  
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VANILLIN AND EXPRESSION OF THE  AKR7A2 
 
Western Blotting was carried out to evaluate the possible change of expression of the aldo-keto 
reductase AKR7A2. The cells line investigated was 1321N1, because it was the same one used for the 
inhibition experiment previously discussed. Cells were exposure to 45 µM vanillin for 24 and the 
proteins extracted and used for Western Blotting. As a control cells not treated with vanillin were 
used. The samples didn’t show any difference to each other in the expression of the AKR7A2 (data not 
shown). Other trials will be made using a quantitative PCR a technique more adequate for this purpose 
and other AKRs will be investigated. 
 
INHIBITION OF ALDEHYDE REDUCTASE AND ADH BY 
PYRAZOL AND VANILLIN  
 
The aim of this experiment was evaluate the total aldehyde reductase activity of the protein extract 
prepared from 1321N1 and test whether this activity was inhibit able by vanillin. The substrate used 
was pNBA 1mM, chosen because is able to give a good rate of reduction. Acetaldehyde and acrolein are 
not good enough substrates for whole crude cells extract. The cofactor used was NADPH and can be 
followed at 340nm. It is known that some enzymes of the family ADH are able to metabolize aldehydes 
and it is also known that pyrazole is a good inhibitor of this class of enzymes. The reduction of pNBA in 
the presence pyrazole and vanillin was investigated. This showed in Figure 30 that pyrazol at a 
concentration of 45µM is able to inhibit pNBA reductase activity by 24% compared to control, and the 
vanillin at the same concentration inhibited pNBA reductase activity by 50%. This pyrazole data 
suggests that ADH could play a role in the detoxification of aldehydes and has a quarter of the total 
pNBA activity. Vanillin is able to inhibit this activity more strongly than the pyrazole, probably is able 
to interact with enzymes other than ADH.  This evidence is supported to the last experiment where the 
concentration of vanillin was 150µM and the inhibition of activity was the 72%.  At the same 
concentration the pyrazole was not able to cause significant inhibition. The data also shows the power 
of the vanillin to inhibit the activity of the reaction. The vanillin is able to inhibit a wider range of 
enzymes compared to the pyrazole especially for the enzymes involve in aldehyde reduction.   
Unfortunately, the data obtained with the MTT assay in which vanillin and acetaldehyde were involved 
were not able to give more information about the effect of the vanillin on the metabolism of the 
acetaldehyde. However the data collected suggests that the vanillin doesn’t affect the viability of the 
cells treated with acetaldehyde and consequently its metabolism. This data is in contrast with the data 
obtained with the vanillin which is able to inhibit aldehydes metabolism. 
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  A possible explanation could be the low capacity of the acetaldehyde to kill cells in vitro and 
consequently if the vanillin could inhibit acetaldehyde metabolism, this wouldn’t be translated in a 
reduction of viability. 
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Figure 30: activity of protein extract 1321N1 with the presence of different inhibitors. Three samples for each 
measure. The reference value for the control is 9 nmoli/mg minute with a standard deviation +/- 0,26. 
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CONCLUSION 
 
The effect of the vanillin to inhibit the total aldehyde reductase activity was evaluated in the cell line 
1321N1. The vanillin shown can inhibit the reduction of the substrate pNBA by the cell extracts. The 
inhibition caused is able to block the enzymes involved in pNBA reduction, but not the enzymes 
involved in acrolein metabolism. With this evidence is possible to affirm that the enzymes involved in 
the pNBA reduction are not the same as those involved in acrolein reduction.  
The comparison between proteins obtained from cells pre-treated with vanillin and control cells was 
useful to determinate whether the vanillin is able to change the expression of enzymes involved in 
pNBA metabolism. The absence of difference between the two samples suggests that the vanillin is not 
able to interact with the expression of these enzymes, but is able to inhibit their activity. The property 
of vanillin to inhibit pNBA activity was also compared with inhibitory power of pyrazole. Pyrazole is 
known to be selective for the ADH. The vanillin showed a major inhibition compared to the pyrazole in 
reducing the enzymatic activity on the substrate pNBA. Vanillin is able to interact with a wider 
spectrum of enzymes and this is demonstrated in its capacity to increase the inhibition of the enzyme 
assay when its concentration is increased, in contrast to the pyrazole.  
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CHARACTERIZATION OF THE HUMAN AKR7A2 AND 
AKR7A5 
 
The purpose of this part of the thesis is add new data to the data present in literature about the two 
enzymes. This includes an evaluation of the preference for the two cofactors NADH and NADPH, as 
normally the AKR are able to use both substrates. In additional, further substrates of interest will be 
tested including acetaldehyde derived from alcohol metabolism and other aldehydes generated during 
oxidative stress. Oxidative stress is also generated during the ethanol metabolism. The main data 
obtained will be useful for better characterizing the physiological role of these enzymes with 
particularly focus on the human AKR7A2. Other than the role of these enzymes in vitro, particular 
attention will give to AKR7A2 and its physiological role inside the cell. The cell line 1321N1 will be 
used for generating transient cells that over express this enzyme. The transient cells will be used to 
test their resistance against different aldehydes recognized to be dangerous for humans, and the data 
obtained will be compared with a control cell line. The data obtained will be useful to explain the 
physiological role of AKR7A2 in protection against aldehyde and oxidative stress. 
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RECOMBINANT EXPRESSION OF THE ENZYMES AKR7A2 
AND AKR7A5 
 
The two aldo keto reductases were cloned previously (38), (44). The two proteins were cloned inside 
the pET-15b vector (Novagen) and transformed into E.coli BL21 pLysS to allow their expression. The 
proteins were expressed following the normal induction process treating with 0.05 mM IPTG 
(isopropyl-beta-thio galactopyranoside) at OD600 between 0.4-0.6. Using the His-tag the proteins were 
simply purified by automatic FPLC (Fast protein liquid chromatography). In Figure 31 , it is possible 
see the expression of both proteins in E.coli and the high purity of the protein obtained with the HIS-
tag purification method. The AKR7A5 is expressed more strongly than AKR7A2.  
 
Figure 31: M: Marker, NI: not induced, I: induced bacteria, 7A2: purify , 7A5:purify. 
 
 
Figure 32: Western Blotting using rabbit antibody against his tag present in the proteins expressed. 
 
Antibodies against the HIS-tag were used to confirm the correct protein was expressed and the result 
is shown in Figure 32.  Different fractions were eluted during purification by FPLC and analyzed by 
SDS-page to evaluate the purity of the single fraction. All the fractions to be used for other experiments 
were tested using an enzyme assay to evaluate the correct folding of the protein and consequently its 
correct catalytic activity. Normally, not more than three fractions for purification were kept. All the 
experiments were carried out not more than three days after the protein purification.  These enzymes 
need to be used in a very short period of time after their purification because they tend to lose most of 
their activity in less than one week. 
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ACTIVITY OF THE TWO ALDO KETO REDUCTASE 
 
In the first part of the study, the two aldo keto reductases were tested to evaluate the best cofactor for 
them. The test was made under saturated condition of different substrates and cofactors (NADH or 
NADPH). The first substrate tested was SSA known as a good substrate for these enzymes (46). 
Afterwards, other substrates were tested including acrolein and acetaldehyde. Acetaldehyde was of 
particular interest to evaluate the possibility of this enzyme to contribute to global ethanol metabolism 
with a focus on reducing the acetaldehyde to ethanol. All the experiments were carried out in triplicate 
and the values are expressed as the specific activity of the enzyme (nmol/mg/minute). As can be seen 
in Table 5 these enzymes show a preference for the cofactor NADPH regardless of the substrate used.  
For the substrates in which this enzyme (AKR7A2) shows a high Vmax (SSA and p-nitrobenzaldehyde) 
the reaction is possible with both cofactors. When NADH was used as cofactor, the Vmax of the 
reaction is decreased by around four-fold.  
When acrolein and acetaldehyde were used as substrates and NADPH as cofactor, the specific activity 
was too low to be calculated. Particularly when acetaldehyde was used as a substrate, the monitoring 
of the change in absorbance was very difficult, probably due to the high volatility of this chemical or 
because of its reaction with the enzyme and consequently a change in the UV spectra. During the 
reaction with acetaldehyde there were fluctuations in the absorbance at 340nm, which indicates some 
variability within the instrumentation. In a normal reaction, as seen for SSA, the saturated amount of 
co-factor and substrate generated a constant decrease in absorbance. In all the reactions the cofactor 
became oxidized and there was a decrease in absorbance at 340nm.   
When acrolein was used as substrate, a small reduction in absorbance was detected. This reduction 
was very low compared to other substrates such as SSA. Therefore acrolein and acetaldehyde do not 
appear to be good substrates for this enzyme, especially acetaldehyde.  
The results for mouse AKR7A5 showed a lower activity compared to AKR7A2 for the substrates SSA 
and p-nitrobenzaldehyde. Also, for this enzyme with these substrates, the activity was higher with the 
cofactor NADPH but still worked with NADH although at a slower rate. A difference was observed 
however between acrolein and acetaldehyde. With acrolein, AKR7A5 doesn’t show a great preference 
for the co-factor. Acetaldehyde was still metabolized but with a very low rate. For both the enzymes 
studied it seems that acetaldehyde is not a good substrate for these enzymes, not only because of the 
low rate of reaction, but especially because of the high concentrations of substrate that need to be in 
the reaction.   
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Table 5:  human AKR7A2  and mouse AKR7A5 and is activity with selected substrate and cofactor. 
 
 
Substrate 
Human AKR7A2 
NADPH µM NADH µM Substrate  Activity nmol/mg/minute 
SSA 5.6  1 mM 1056  37.4 
SSA / 6.3 1 mM 220  35.5 
p-Nitrobenzaldehyde 5.6 / 100 µM 423.4  2.9 
p-Nitrobenzaldehyde / 19 100 µM 56.4 1.3 
Acrolein   11.2 / 100 mM 56.4  1.3 
Acrolein / 25 100 mM 7.66  2.9 
Acetaldehyde 11.2 / 100 mM 7.6  2.9 
Acetaldehyde / 12.6 100 mM 1  0.4 
 
 
Substrate 
Mouse AKR7A5 
NADPH µM NADH µM Substrate  Activity nmol/mg/minute 
SSA 5.6 / 1mM 865.7  20.9 
SSA / 6.3 1mM 74.5  13.1 
p-Nitrobenzaldehyde 5.6 / 100 µM 338.3  32 
p-Nitrobenzaldehyde / 19 100 µM 42.3   5.6 
Acrolein 11.2 / 100mM 26.9  2.5 
Acrolein / 25 100mM 32.54   9.6 
Acetaldehyde 11.2 / 100mM 13.1  7.5 
Acetaldehyde / 12.6 100mM / 
 
With this experiment is possible to say that both the enzymes expressed show a strong preference for 
NADPH as cofactor, but are also able to utilize NADH, and this could be important inside the cells when 
the ratio between NADPH and NADH can change during metabolism or stress. 
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THE ROLE OF AKR7A2 AND AKR7A5 IN THE PROTECTION 
AGAINST TOXIC ALDEHYDES 
 
Ethanol metabolism is able to produce a stress inside the cell, in particular it is able to cause an 
imbalance in the normal ratio between NAD+/NADH.  The electron flow in the mitochondria is able to 
generate some ROS during the normal metabolism. ROS have the ability to react with different 
macromolecules such as proteins nucleic acids and lipids. In particular, the reaction with the lipids is 
able to generate some highly reactive aldehydes. These dangerous aldehydes can move throughout the 
human body or stay close to their source.  
It is thought that the aging process begins when the human body is not able to detoxify the aldehydes 
present in the human body that have arisen from endogenous or exogenous sources.  The aldo keto 
reductase family has a known ability to metabolize a wide range of aldehydes and ketones.  
To better understand the physiological role of the two AKR7A enzymes, especially the human AKR7A2, 
they were characterized in vitro using different toxic aldehydes, and physiological molecules such as 
SSA. In the Table 6 are shown the Michaelis-Menten curves obtained with different substrates. The 
apparent Km and Vmax values were estimated from the initial velocities measured over a range of 
substrate concentrations. The cofactor NADPH was used at high concentration (0.1 mM) in order to 
consider it saturating during all the reactions, as describe in the Material and Methods. The Michaelis-
Menten curves were also used to the determinate the Km and Vmax. In the study of the kinetic 
parameters it was assumed that these enzymes are dimeric (with two catalytic sites), so the molecular 
weight used is the double of a single subunit of the enzyme. The same considerations were used for the 
experiment involving the human AKR7A2 and for the mouse AKR7A5, and the Michaelis-Menten 
curves are shown in the Table 7. 
 The enzymes used were freshly prepared and kept on ice and they are not more than three days old.  
 
 
 
 
 
 
 
 
82 
 
Table 6: characterization of the human AKR7A2 with different substrate made during the lipid peroxidation or 
present physiology in the human body. 
 AKR7A2 
 
 
 
Vmax  0,99 µM/mg/min Km 654,2 µM Vmax 0,93 µM/mg/min Km 1,948mM 
4p-nitrobenzaldehyde
0 1000 2000 3000 4000 5000
0.00
0.01
0.02
0.03
0.04
0.05
[s] µM
d
A
/m
in
 
Methylglyoxal
0 5000 10000 15000
0.00
0.01
0.02
0.03
0.04
[s] µM
d
A
/m
in
 
Vmax 1,34 µM/mg/min Km 21,38 µM Vmax 0,379 µM/mg/min Km 966 µM 
SSA
0 50 100 150 200 250
0.00
0.05
0.10
0.15
[s] µM
d
A
/m
in
 
Muconaldehyde
0.0 0.5 1.0 1.5 2.0 2.5
0.00
0.01
0.02
0.03
0.04
[s] mM
d
A
/m
in
 
Vmax 0,072 µM/mg/min Km 23,86mM   Vmax 0,237 µM/mg/min Km 59,65 mM 
Acrolein
0 50 100 150 200
0.00
0.01
0.02
0.03
0.04
0.05
[s] mM
d
A
/m
in
 
Crotonaldehyde
0 20 40 60
0.000
0.005
0.010
0.015
[s] mM
d
A
/m
in
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Vmax 0,062 µM/mg/min Km 6,55µM Vmax 0,08 µM/mg/min Km 1,481mM 
5 hydro 1-4napto quinone
0 20 40 60
0.000
0.002
0.004
0.006
0.008
[s] µM
d
A
/m
in
 
menadione
0 200 400 600 800
0.000
0.002
0.004
0.006
0.008
0.010
[s]µM
d
A
/m
in
 
Vmax 0,149 µM/mg/min Km 449,2µM  
2 hydroxy 1,4-quinone
0 50 100 150
0.000
0.001
0.002
0.003
0.004
0.005
[s] µM
d
A
/m
in
 
 
Some of the graphs show ideal Michaelis-Menten curves, for example SSA, 4-nitrobenzaldehyde, 
methylglyoxal and 5 hydro 1-4 napto quinone. The Km calculated for SSA is around 21 µM, and this is 
the only Km with a real low value, providing more supporting evidence for the role of this enzyme 
inside the human body in the metabolism of the succinic semialdehyde.  Some curves show a poor fit 
to Michaelis-Menten, such as like the 2-hydroxy 1,4-quinone. These substrates were very difficult to 
study particularly because is very difficult to get reproducible data. The reduction in absorbance at 
340nm was not constant in all the reactions and sometimes there were fluctuations in the absorbance. 
For this reason, this reactions were carried out several times and only the reproducible data collected 
was used to generate the curves. There is no real explanation for these fluctuations in absorbance, 
which could be made for a chemical reaction between the aldehydes used and the cofactor or the 
enzyme itself. These substrates for this reason were considered poor and the high Km calculated led to 
the assumption that these substrates are not suitable for enzyme study. The same consideration can be 
made for the AKR7A5 enzyme.  
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This kinetic study was also difficult because most of the aldehydes studied are liquid so they change 
the density of the solution inside the reaction tube.  
With some substrates, the enzymes did not work well and is possible see this from the graphs 
presented - crotonaldehyde and acrolein are good examples of this. This is different from the situation 
for SSA, where the Michaelis-Menten curve is very close to the ideal one. 
Table 7: characterization of the mouse AKR7A5 with different substrate made during the lipid peroxidation or 
present physiology in the mouse body. 
 AKR7A5 
 
 
Vmax 3,9 µM/mg/min Km 2,14mM Vmax 1,90 µM/mg/min Km 6.24mM 
p-Nitrobenzaldehyde
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Methylglyoxal
0 5000 10000 15000 20000 25000
0.00
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d
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Vmax 2,7 µM/mg/min Km 15,17 µM Vmax 1,09 µM/mg/min Km 3,04mM 
SSA
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Muconaldehyde
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Vmax 0,736 µM/mg/min Km 280mM Vmax 0,253 µM/mg/min Km 209mM 
Acroline
0 50 100 150 200 250
0.00
0.01
0.02
0.03
0.04
[s] mM
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Crotonaldehyde
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As described earlier, as the sequence identity between the enzymes is 78% with a similarity of 87% 
(40) it is interesting to compare the values obtained for the same substrate. This data can be also 
interpreted and can be helpful to structural biologists to increase the knowledge about the structure 
and function of the active site of the enzymes, that can be combined with data obtained using software 
used to predict the tertiary structure from the amino acid sequence. 
The data obtained from these two different enzymes is summarized in Table 8. The physiological 
substrate succinic semialdehyde appears to be a better substrate for the mouse than for the human 
enzyme. The turnover for this substrate is around twice as high for the mouse, respectively 1.73 and 
0.88; the Km is very low for the enzymes in the range of 20 µM. These data confirm that probably in 
the mouse that SSA is really the native substrate for AKR7A5 but this may not be the case for the 
human enzyme as the turnover is lower. The model substrate for the aldo-keto reductase 4-NBA 
interacts in a different way with these two enzymes. The kcat for the mouse is 2.51 s-1 and the kcat for 
the human is four time less. The mouse enzyme is also more difficult to be saturated by 4-NBA as 
indicated by its higher Km of 2.14 mM. In any event, the global efficiency of the enzyme expressed as 
kcat/ Km is not very different.  
However noticeable differences were observed when other aldehydes were used as substrates. The 
aldehydes tested can be generated inside the human body by the peroxidation of the lipids. Both the 
enzymes show a very low Vmax with the substrates (methylglyoxal, muconaldehyde, acrolein and 
crotonaldehyde), and normally a high Km which suggests that these substrates are not ideal for these 
enzymes. The Km for all these substrates is in the millimolar range, increasing to 205mM for 
crotonaldehyde for the mouse AKR7A5.  
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The corresponding Km for the human enzyme is four times lower at 59mM for crotonaldehyde. These 
values being so high for the Km suggest that these enzymes are not involved in the detoxification of this 
reactive aldehyde under physiological conditions.  
The Km calculated for muconaldehyde is 0.96 mM for the human enzyme, indicating that this enzyme 
could play a role in the detoxification of muconaldehyde during exposure to high levels.  
 Using the efficiency parameter for the enzyme, the kcat/ Km, it is possible to see that this parameter is 
around hundred times less for muconaldehyde and methylglyoxal, compared to succinic semialdehyde. 
Succinic semialdehyde was proposed as physiological substrate for this enzymes (80), and the data 
obtained in this thesis indicate that AKR7A2 could play a key role in the metabolism of this substrate.  
The situation is not the same for two other aldehydes tried, that is acrolein and crotonaldehyde with a 
Km of 23.8 mM and 55.9 mM respectively, and the kcat/ Km is a thousand times less than for succinic 
semialdehyde. For these two last substrates, the mouse enzyme shows a higher Km compared to the 
human enzymes. A comparison of the substrates studied and the values obtained, in particular the 
kcat/ Km shows that AKR7A5 prefers longer chain aldehydes. This looks clear when comparing the 
shorter acrolein with the longer crotonaldehyde, which has two more carbon atoms. Also as has been 
shown previously, the presence of an alpha-beta unsaturated double bound between the carbon atoms 
makes the turnover slower.  
The considerations made for AKR7A5 can also be seen for human AKR7A2. Analyzing the situation for 
the AKR7A2 and comparing it with AKR7A5 it is possible see that the mouse enzyme has a better 
efficiency for the metabolism of SSA and pNBA.   
The other substrates tested are better substrates for the human enzyme compared to the mouse but 
they are still very poor compared to the SSA and 4-NBA.  These data can be used to better understand 
the mechanism of interaction between the enzyme and substrate, and the importance of particular 
amino acid residue differences between the two enzymes utilized. These data can be also utilized to 
predict how other enzymes of the aldo keto reductase family might function. In Table 8 it is possible 
see all the data generated with the different substrates tried and the comparison between the two 
enzymes. 
 
 
 
 
87 
 
 
Table 8: comparison of the main data obtained with AKR7A2 and AKR7A5 with different substrates. 
Substrate Enzyme Vmax 
µmoles/mg 
enzyme/min 
Km 
mM 
Vmax/km 
Min1*mg*ml 
Kcat 
s-1 
Kcat/km 
Min-1/M 
 
Succinic 
semialdehyde 
AKR7A5 2.7 0.015 178 1.73 6.88 X 106 
AKR7A2 1.34 0.021 62 0.88 2.49 X 106 
pNBA 
 
AKR7A5 3.90 2.148 1.81 2.51 7.01 X 104 
AKR7A2 0.99 0.65 1.52 0.65 6.03 X 104 
Methylglyoxal 
 
AKR7A5 1.90 6.23 0.30 1.22 1.18 X 104 
AKR7A2 0.93 1.94 0.47 0.616 1.9 X 104 
Muconaldehyde AKR7A5 1.09 3.04 0.36 0.70 1.39 X104 
AKR7A2 0.379 0.966 0.39 0.25 1.56 X 104 
Acrolein AKR7A5 0.736 280 2.63 X 10
-3
 0.47 1.02 X 102 
AKR7A2 0.072 23.86 3.5 X 10
-3
 0.048 1.21 X 102 
Crotonaldehyde AKR7A5 0.253 209 1.21 X 10
-3
 0.16 4.69 X 101 
AKR7A2 0.237 55.9 3.9 X 10
-3
 0.156 1.57 X 102 
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The values obtained for the enzymes expressed and purify during this thesis were compared with the 
data present in the scientific lecture. In Table 9 is shown the main values obtained for the mouse 
AKR7A5 during this thesis and a comparison with other value present in the science literature.  
 
Table 9: comparison of the main value obtained from the mouse AKR7A5 during this thesis works and the data 
present in the literature.  
Substrate Source Vmax 
µmoles/mg 
enzyme/min 
Km 
mM 
Vmax/km 
Min1*mg*ml 
Kcat 
s-1 
Kcat/km 
Min-1/M 
Reference 
 
Succinic semi 
aldehyde 
Mouse 2,70 0,015 
 
178 
 
1,73 
 
6,88X106 This thesis 
Rat 1.46 0.14 10,43 0,93 4,02X104 (39) 
Rat   Not given 0,184 Not given 1,15 3,8X105 (40) 
Mouse Not given 0,02 Not given 1,33 4,2X106 (45) 
pNBA 
 
Mouse 3,90 2,148 1,81 2,51 7,01X104 This thesis 
Rat  Not given 3,6  4,1 6,9X104 (40) 
Rat 2,58 0.72 3.58 1,40 1,16X105 (39) 
Mouse Not given 0.87 Not given 0,76 5,34X104 (45) 
Methylglyoxal 
 
Mouse 1,90 6,23 0,30 1,22 1,18X104 This thesis 
Rat 1,13 7,22 0,16 0,71 5,9X103 (39) 
Mouse Not given 3,98 Not given 0,78 1,18X104 (45) 
Muconaldehyde Mouse 1,09 3,04 0,36 0,70 1,39X104 This thesis 
Mouse Not given 7,1 
+/- 6 
Not given 1,56 1,31X104 (45) 
Acrolein Mouse 0,736 280 2,63X10-3 0,47 1,02X102 This thesis 
Crotonaldehyde Mouse 0,253 209 1,21X10-3 0,16 4,69X101 This thesis 
 
 
The data obtained in this thesis are close with the data published in the 2002 (45) especially for the 
value of the Kcat/km that is an important indicator of the enzyme efficiency, and is also able to give an 
indication as to which substrate is preferred by an enzyme. The mouse AKR7A5 shows a higher 
preference for the substrate tested than the rat characterized previously (39). This data became 
particularly more evident for the physiological substrate succinic semialdehyde where the mouse 
enzyme showed a preference of a hundred times for this substrate compared to the rat. The reactive 
aldehydes made during lipid peroxidation can also be part of the substrates metabolized by this 
enzyme. Methylglyoxal and muconaldehyde have a good kcat/Km ratio. AKR7A5 may play a secondary 
role in detoxification because for both substrates the Km calculated is very high, in the range of mM. 
Other than comparing the data the mouse AKR7A5 was also characterized with two new substrates, 
acrolein and crotonaldehyde.  
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These two substrates are very poor for this enzyme as shown by the kcat/km value.  The other two 
important parameters are the Vmax and the Km, and together these values reveal how poor these 
substrates are. The Vmax values are very low compared to the succinic semialdehyde, around four 
times for acrolein and ten times for crotonaldehyde with a very high Km for both indicating low 
affinity. This enzyme is very difficult to saturate with these two substrates.  
A similar comparison was also made for the human AKR7A2 to better understand its role in human 
physiology. The data obtained during this thesis were compared with the data present in the literature 
and summarized in Table 10. 
Table 10: comparison of the main value obtained from the mouse AKR7A2 during this thesis works and the data 
present in the literature. 
Substrate Source Vmax 
µmoles/mg 
enzyme/min 
Km 
mM 
Vmax/km 
Min1*mg*ml 
Kcat 
s-1 
Kcat/Km 
Min-1/M 
Reference 
 
Succinic semi 
aldehyde 
Human 1,34 
 
0,021 62 0,88 2,49X106 This thesis 
Human Not given 0,02 Not given 1, 88 5,7X106 (140) 
Human 0,512 0,0154 33,2 1,53 6X106 (40) 
pNBA 
 
 
 
 
 
 
Human 0,99 0,65 1,52 0,65 6,03X104 This thesis 
Human Not given 6,1 Not given 1,56 1,5X104 (40) 
Human 
 
 
 
Not given 2,74 Not given 0,78 2X104 (140) 
Methylglyoxal 
 
Human 0,93 1,94 0,47 0,616 1,9X104 This thesis 
Human 0,096 Not 
given 
Not given 0,063  (40) 
Muconaldehyde 
 
Human  0,379 0,966 0,39 
 
0,25 1,56X104 This thesis 
Human 0,168 Not 
given 
Not given 0,11 Not 
given 
(40) 
Crotonaldehyde 
 
Human  0,237 55.9 3,9X10-3 0,156 1,57X102 This thesis 
Human 0,018 Not 
given 
Not given 0,011 Not 
given 
(40) 
2-OH-1,4-NQ 
 
Human  0,149 0,44 0,33 0,098 1,32X104 This thesis 
Human 0,061 Not 
given 
Not given 0,04 Not 
given 
(40) 
5-CH3-1,4-NQ 
 
Human  0,062 6,56X103 9,45 0,04 3,75X105 This thesis 
Human  0,05 Not 
given 
Not given 0,033 Not 
given 
(40) 
Menadione  
 
Human 0,08 1,48 0,054 0,053 2,15X103 This thesis 
Human  0,018 Not Not given 0.019 Not (40) 
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given given 
Acrolein 
 
Human 0,072 23,86 3,5X10-3 0,048 1,21X102 This thesis 
Human  0,013 Not 
given 
Not given 0,0085 Not 
given 
(40) 
 
The data presented in this work has added significantly to the previous characterization of the enzyme 
AKR7A2. In particularly a good affinity for the substrate succinic seimialdehyde is confirmed, showing 
with a very low Km and high turnover value indicating a great efficiency with this substrate. Its does 
not appear to be particularly involved in the detoxification of other aldehydes generated during the 
lipid peroxidation. The data obtained were also compared with other data present in the science 
literature wherever possible. The data obtained in this experiment especially for the SSA are very close 
to the data presented previously with the Kms reported being almost identical as is the efficiency 
calculated as kcat/Km. A difference is for the ratio Vmax/km, as the value obtained in this experiment is 
around twice the value of earlier data (40) and (140) as well the kcat s-1. When pNBA was used as a 
substrate, the difference in Km was more evident, and the Km calculated in this thesis is four to ten 
times less than others. However, the turnover values are very close to each other in particularly when 
compared to the data obtained from (140).  
When methylglyoxal is used as substrate the enzyme expressed in this study is saturated more readily 
and shows a higher kcat, around ten times more compared to (40). The same situation is seen for 
crotonaldehyde, 2-OH-1,4-NQ and menadione, but the data for the 5-CH3-1,4-NQ are very close to each 
other. The data obtained for acrolein though are quite different to each other, especially for the 
turnover ratio. 
In conclusion it is possible to affirm the role of the AKR7A2 in SSA metabolism especially because of its 
low Km value and the data are in agreement with other authors. The data obtained for other substrates 
and analyzed and compared with other authors also showed similar differences in the Km, and the 
turnover ratios indicate the low affinity of this enzyme for these substrates, and normally the Km value 
is higher than 1 mM.  
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TRANSFECTION OF THE GENE ENCODING AKR7A2 INTO 
HUMAN CELLS 1321N1 
 
Other than the characterization of the purified enzymes with different substrates, their role inside 
human cells was investigated. 1321N1 cells were used to make transient transfectants that were able 
to overexpress the human protein AKR7A2. The enzyme was cloned in the mammalian expression 
vector pCI-Neo (Promega), and the plasmid DNA was transfected into the cells.  Different conditions 
were tested to identify the best ratio of pCI neo vector / lipofectamine that was able to give high 
expression of the enzyme studied. Different ratios of DNA and lipofectamine were evaluated in their 
capacity to generate an efficient expression of the exogenous protein.  The ratios tried were 0.33, 0.25, 
0.2 and 0.16 µg DNA / µl of lipofetamine. The efficiency of the transfection was also evaluated 
quantitatively by making extracts of the cells and analyzing with Western Blotting.  
Using antibodies against AKR7A2 on the Western Blot, it was possible evaluate the efficiency of the 
transfection. 70 µg of protein was loaded for every sample, in order to detect the AKR protein as it is 
only a small fraction of the whole protein extraction. In the Figure 33 the Western Blotting confirmed 
that the cells had been transfected and were expressing AKR7A2.  The AKR7A2 band protein is weak 
and it was confirmed by comparison to markers and a previous Western Blot using the AKR7A2 
purified from bacteria as a marker. The nonspecific band on the blot is due to the use of polyclonal 
antibodies that are able to react with other proteins present in the whole cell extract.  
 
Figure 33: different ratio DNA/lipofectamine for generate transfected cells line 1321N1. C; control, 1; ratio 
DNA/lipofectamine 0.33, 2; ratio DNA/lipofectamine 0.25, 3; ratio DNA/lipofectamine 0.2, 4; DNA/lipofectamine 
0.16.  The red arrow indicates the AKR7A2 used for the transfection. 
The bands present in this Western Blotting are weak. This is because the target protein is present in a 
relatively low amount in the whole extract. It was not possible increase the exposure time to give 
stronger bands, because the nonspecific band would saturate the image and make the protein target 
totally obscured.  The target protein is present in all the samples tested including the control, this is 
not an expected result because the AKR7A2 is  a  physiological protein present in most cells. The target 
band present in the control is weaker compared to the other samples, especially compared to Lane 
four. This data suggests that the transfection protocol worked in the cell line 1321N1.  
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Another experiment was carried out to evaluate the efficiency of the transfection. The second 
experiment was made by transfecting the cells with another gene, the Renilla luciferase.   This gene is 
able to produce a protein that can oxidize the coelenterate-luciferin (coelenterazine) and produce 
light. The presence of the light in the well reaction confirmed the good method used for the 
transfection. Figure 34  shows the result of this experiment with the cells 1321N1.  The amount of 
Renilla luciferase DNA used for transfection is the same amount that was used for the experiment when 
the AKR7A2 DNA was used to transfect the cells. 
 
Figure 34: different ratios of Renilla luciferase /lipofectamine used to transfect 1321N1. C; control, 1; ratio Renilla 
luciferase /lipofectamine 0.33, 2; ratio Renilla luciferase /lipofectamine 0.25, 3; ratio Renilla luciferase 
/lipofectamine 0.2, 4; Renilla luciferase /lipofectamine 0.16.   
This luciferase assay is more specific than the Western Blotting using the AKR7A2 because the Renilla 
luciferase is a exogenous gene and is not normally present in 1321N1 cells. Figure 34 shows very 
clearly that the control sample does not show any light in its well. All the other wells present gave a 
different intensity of light particularly in the third and fourth well.  The result of this experiment made 
it clear that the method used for the cells transfection was efficient and confirmed that it is likely that 
the AKR7A2 gene was also transfected efficiently inside this cell line. After the result of the two 
previous experiments a large number of cells were transfected and used to evaluate the role of the 
AKR7A2 in the protection against toxic aldehydes, namely methylglyoxal, muconaldehyde and 
crotonaldehyde. The DNA / lipofectamine used were 0.2. The cells were kept in contact with the toxic 
aldehyde for 20 hours. The method used to evaluate the role of this enzyme in preventing cell toxicity 
is the MTT assay. The protective role of this enzyme is evaluated by the viability of the transfected 
cells that over-express AKR7A2 compared to control cells in response to exposure of different toxic 
aldehdyes. The first aldehyde tested is methylglyoxal. The enzyme kinetic study gave an apparent Km 
1,948mM for methylglyoxal.  The concentration of methylglyoxal used for this experiment start from 
55µM to 2,75mM which covers the concentration at which the AKR7A2 would be working at half the 
maximum rate. 
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Figure 35: comparison of viability between the cell line 1321N1 (control) and cells 1321N1 transfected with the gene 
AKR7A2. The methylglyoxal used for generate the cells reduction was kept in contact with cells for twenty hours.        
* the data in the transfected cells line significantly different to the control cells line. N=4. 
Treatment of cells with 550 µM methylglyoxal significantly reduced the cells viability. The situation is 
different for the cells transfected with AKR7A2, and the lowest concentration able to reduce the cells 
viability is 55µM. All the concentration tested are able to reduce the cells viability with exclusion of 
100 µM. The standard error associated with the calculated viability for the concentration at 100µM is 
very low in both cells line and the vehicle used to treat the cells is the same for both the cells line.  This 
indicates that AKR7A2 is increasing the sensitivity of the cells to methylglyoxal. 
The data is not easy to explain.  It looks that the enzyme AKR7A2 is involved in the methylglyoxal 
metabolism, because the difference between the control sample and the transfected sample starts to 
be significant after 750µM which is very close to the Km calculated for this substrate. More difficult is 
to understand why there is a significant reduction of viability in the transfect cells compared to the 
control. The explanation could be in the molecules generated from reduction of the methylglyoxal to 
its relative alcohol the 1,2 propanediol which may be more toxic to these cells than methylglyoxal. 
Another possible explanation could be that other metabolic pathways contribute to detoxification of 
methylglyoxal, creating an abundance of NAD(P)+ which leads to increase in the exposure time of high 
levels of methylglyoxal inside the cell. These are only hypothesis because the capacity of this enzyme 
to convert the 1,2 propanediol to methylglyoxal has not been investigated. 
A similar analysis was made to evaluate the protective effect against muconaldehyde, a very reactive 
aldehyde (Figure 36). It dangerous propriety are evident in the low amount that require for reduce cell 
viability compared to the other aldehydes tested in all this dissertation.  
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Figure 36: comparison of vitality between the cell line 1321N1 (control) and cells 1321N1 transfected with the gene 
AKR7A2. The muconaldehyde used for generate the cells reduction was kept in contact with cells for twenty hours.    
* the data in the transfected cells line significantly different to the control cells line. N=3. 
Muconaldehyde is able to induce a significant (50%) reduction in viability in the transfected cells 
1321N1 at concentrations of 10 µM, which is much lower than for the control cells where the 
concentration required is 14 µM  for have a reduction of vitality. The two curves are very close to each 
other up to the concentration of 8 µM. After this concentration the transfected cells reduce their 
viability drastically compared to the control. It seems that 8 to 10 µM is the threshold value indicating 
that the transfected cells have a major tendency to succumb to muconaldehyde exposure.  
It is not clear how the over expression of this enzyme leads to the effects observed, in particularly 
because the apparent Km (966µM) calculated for this substrate is very different to the value used for 
generating the curve. However, similar to the situation seen with methylglyoxal, it is possible that over 
expression of AKR7A2 leads to an imbalance of cofactor levels which could reduce cell viability in the 
presence of aldehyde. 
The last substrate tested was crotonaldehyde. The range of crotonaldehyde tested is in the range 
between 0.59 µM to 118 µM, so this aldehyde is looks less toxic compared to muconaldehyde which an 
IC50 between 100 and 118 µM. In the Figure 37 it is possible see the curve generated when the cells are 
expose to this toxic aldehyde. 
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Figure 37:  comparison of viability between the cell line 1321N1 (control) and cells 1321N1 transfected with the 
gene AKR7A2. The crotonaldehyde used for generate the cells reduction was kept in contact with cells for twenty 
hours.  * the data in the transfected cells line significantly different to the control cells line. A; the full curves 
generated, B; the focusing on the high concentration of crotonaldehyde. N=4. 
 
The analysis of the data shows that only the higher concentrations of crotonaldehyde (118 µM) are 
able to reduce the cells viability in the control sample in a significant manner. The other 
concentrations show no real different compared to untreated cells. The transfected cells show a low 
resistance to crotonaldehyde compared to the control cells. The first concentration able to reduce 
significantly the cells viability is 59µM. Comparing the two curves shows that the transfected cells are 
more sensitive at lower concentrations  of crotonaldehyde but this difference disappears at 
concentrations of 1 µM.  However at the higher concentrations tested the transfected cells show a 
higher vitality compared to the control. This is the only situation found in which the transfected cells 
have more resistance then the control.  
The apparent Km calculated for this substrate is 55.9mM. With this data it is possible hypothesize that 
the aldo-keto reductase AKR7A2 could play role in protecting cells against crotonaldehyde at higher 
concentrations. AKR7A2 is not able to offer protection to 1321N1 cells against muconaldehyde but is 
able to protect the cells against crotonaldehyde. This enzyme shows a higher Km for crotonaldehyde 
than the Km calculated for muconaldehyde. Also the turnover rate calculated for the muconaldehyde is 
hundred times higher that the one calculated for the crotonaldehyde. Hence it appears that a low level 
of activity towards a substrate may allow the enzyme to function more usefully in the cell that a high 
level of activity which appears to to lead to increased toxicity. 
This experimental data show that in cells, AKR7A2 plays a more significant role in the detoxification of 
crotonaldehyde than muconaldehyde which is opposite the data expected from the enzyme 
characterization. 
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TRANSFECTION OF THE GENE ENCODING AKR7A2 INTO 
HUMAN CELLS HEPG2 
 
The cell line HepG2 was also transfected with the human enzyme AKR7A2. The HepG2 cell line being 
derived from liver should be richer in metabolizing enzymes compared to 1321N1 cell line. For the 
transfection of the cell line HepG2 only one ratio of DNA/ lipofectamine was tried because the method 
has already been optimized for this cell line by Invitrogen (141). The ratio DNA / lipofectamine used 
was 0.25. The efficiency of transfection method was evaluated as for the transfection of the cell line 
1321N1, and the level of expression of AKR7A2 evaluated using Western blotting.  
The toxic aldehydes methylglyoxal, muconaldehyde and crotonaldehyde were used to compare the 
different responses of the two cells line. The first toxic aldehydes tested was methylglyoxal and the 
viability curve is show in  Figure 38 below. 
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Figure 38: comparison of viability between the cell line HepG2 (control) and cells HepG2 transfected with the gene 
AKR7A2. The methylglyoxal used for generate the cells reduction was kept in contact with cells for twenty hours.        
* the data in the transfected cells line significantly different to the control cells line. N=4. 
In contrast to the viability curve made with the same aldehyde in the cells line 1321N1 show in Figure 
35,  the HepG2 cells have a greater resistance to MG. In addition, the transfected HepG2 cells appear to 
show higher viability than the control cells after exposure to MG. The first concentration able to 
significantly affect the control cells line is 2.75 mM. The HepG2 transfected cells show their capacity to 
protect the cells against methylglyoxal at concentrations of 5.5mM.  
Control cells show a viability of 45%; transfected cells around the 75%, indicating that the AKR7A2 
has a major role in the metabolism of this aldehyde when it is present at high concentrations. There is 
no evidence that the enzyme offers any protection at concentrations below 5.5 mM.  
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In the 1321N1 transfected cells, a reduction in viability in the transfected cells was observed. As 
discussed this may be due to the inability of the 1321N1 cells to deal with the product of the reaction 
or redox/cofactor imbalance. This is not the case with HepG2 cells, which seem capable of handling the 
product of the reaction or the supply of cofactor.  
The second aldehyde tested was muconaldehyde. This toxic aldehyde was shown to be more 
dangerous for the cells, able to reduce their viability in concentrations in µM range. In Figure 39 it is 
possible see the response of the HepG2 cells.  
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Figure 39: comparison of viability between the cell line HepG2 (control) and cells HepG2 transfected with the gene 
AKR7A2. The muconaldehyde used for generate the cells reduction was kept in contact with cells for twenty hours.     
* the data in the transfected cells line significantly different to the control cells line. N=4. 
8µM of muconaldehyde are able to generate a significant reduction in viability in the control cells 
compared to the untreated cells. The reduction of viability is around the 15%. The transfected cells in 
comparison do not seem to be affected by muconaldehyde treatment at any of the concentrations 
tested. A comparison between the two curves generated shows that above the concentration of 8µM 
exists a real significant difference between the two curves, show that the AKR7A2 is important in 
protect the cells against this aldehyde. This indicates that AKR7A2 enzyme can play a key role in the 
metabolism of muconaldehyde or one of its metabolites and is able to protect the cells against this 
compound.  
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The role of the AKR7A2 was also tested in protect the cells line HepG2 against the toxic aldehyde 
crotonaldehyde.  Figure 40 shows the response of the control and transfected cell lines. 
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Figure 40: comparison of viability between the cell line HepG2 (control) and cells HepG2 transfected with the gene 
AKR7A2. The crotonaldehyde used for generate the cells reduction was kept in contact with cells for twenty hours. * 
the data in the transfected cells line significantly different to the control cells line. A; the full curves generated, B; the 
focusing on the high concentration of crotonaldehyde. N=4. 
In these curves the control HepG2 cells show no decrease in viability when exposed to crontoaldehyde. 
This is in contrast to the 1321N1 cells where high concentrations of crotonaldehyde showed a 
decrease in viability. Surprisingly the transfected HepG2 cells were much less resistant to 
crotonaldehyde that the control cells at all the concentrations tested. This indicates that expression of 
AKR7A2 increases the sensitivity of HepG2 cells to crotonaldehyde suggesting that AKR7A2 is 
metabolizing crotonaldehyde to a more toxic compound or depleting cofactor reserves. It is clear that 
the AKR7A2 is not involved in the protection of the cells line HepG2 against the crotonaldehyde. 
These results are in contrast with those obtained for 1321N1 cells, where the expression of AKR7A2 
was able to offer some protection to the cells at the higher concentrations of crotonaldehyde. 
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CONCLUSION  
  
The evaluation of the favorite substrates for the enzymes AKR7A2 and AKR7A5 was made by 
calculating the Vmax of these two enzymes with different substrates under saturating conditions and 
using different cofactors. The enzymes studied show a strong preference for the cofactor NADPH, but 
they are also able to catalyze same reaction with NADH but with a real slow Vmax compared to the 
same reaction made with NADPH. 
The characterization of the two enzymes was made using different substrates, especially aldehydes 
that are known to be dangerous for the cells, and that are generated in different ways including normal 
eating or smoking. Different aldehydes were tested including the physiological substrate succinic 
semialdehyde, acrolein present in cigarette smoking and acetaldehyde, the first metabolite of alcohol 
metabolism.  
The first enzyme tested was the human AKR7A2. The experiments carried out in vitro showed that 
succinic semialdehyde is the best substrate compared to all the ather substrates tried. This data is 
confirmed by the high Kcat/km 2,49X106 and the relative low value of the Km 21µM. All the other 
reactive aldehydes tested show a higher km value, but more importantly show a slower turnover 
number.  The data obtained were compared with other data present in literature. With some 
substrates the data obtained are very close to other published data especially for substrates that better 
fit this enzyme (SSA and pNBA). The other substrates show value of kcat/Km very close to the value 
obtained in this thesis.  
A similar set of experiments were carried out for the mouse AKR7A5. For this enzyme, the NADPH is 
the favorite cofactor in accordance with previous work (45). For AKK7A5 the SSA is also shown be the 
best substrate and this enzyme was discovered as succinic semialdehyde reductase, the ratio kcat/km 
(6,88X106) is higher than the human enzyme. The data obtained were compared with the data found in 
the literature which showed that the data are very close to each other. In general both enzymes are not 
particularly good at reducing toxic aldehydes tested. In particular, acetaldehyde does not appear to be 
a good substrate for either of the enzymes tested.  
The role of AKR7A2 was also investigated by transiently transfecting the human cells line 1321N1. The 
transfected cells did not show an increase in resistance compared to a control cells when treated with 
different aldehydes, in almost all cases. The transfected cells did show a protection against 
crotonaldehyde when the chemical is used in high concentrations 118µM. In fact the transfected cells 
show a reduction in viability compared to control cells. 
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 This may be because the enzyme leads to the production of toxic metabolites and/or influences the 
NADPH/NADP ratio that causes a loss of viability.  
The cells line HepG2 was also transfected with the enzyme AKR7A2 to evaluate the role of this enzyme 
against the same compounds tested to the cells line 1321N1. In general HepG2 is more resistant to the 
toxic aldehydes compared 1321N. The concentration of muconaldehyde used was increased in an 
attempt to generate a significant reduction of viability. In cells that over express AKR7A2 it is evident 
that the enzyme provides significant protection against methylglyoxal and muconaldehyde indicating 
that this enzyme can play a significant role in the metabolism of these two compounds directly or 
indirectly. However the situation is different with crotonaldehyde. With this aldehyde, AKR7A2 
expression did not offer any protection, compared to the control cells and it appears that the enzyme 
increases the toxicity of crotonaldehyde.  
In the future it will be important to investigate the role of these enzymes using a wider range of toxic 
aldehydes. The data obtained with the transient cells need to be confirmed with data generated using 
stable cells line that overexpress AKR7A2. The full metabolism of the aldehydes needs to be evaluated 
using labeled carbon atoms in order to evaluate which compounds are generated inside the cells and 
obtain more data about the metabolism of these toxic aldehydes.  
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V MATERIALS AND METHODS 
MATERIALS 
 
All chemicals were obtained from Sigma-Aldrich UK unless otherwise stated. 
PLASMIDS 
 
Plasmids were obtained from lab stocks as follows (Table 11): 
 
Table 11: list of the plasmids used in this thesis 
Plasmid Purpose Description Source/Reference 
pAH Bacterial expression of 
AKR7A5 
Based on pET15b. 
AKR7A5 cloned into the 
Nde1-BamHI site 
Hinshelwood et al., 
2002 
pLI16 Bacterial expression of 
AKR7A2 
Based on pET15b. 
AKR7A2 cloned into the 
Nde1-BamHI site 
Ireland et al., 1998 
pCI-neo Vector Mammalian expression 
of AKR7A5 
Based on pCI-Neo  
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CELL LINES 
 
1321N1 human astrocytoma cells were obtained from Dr Eve Lutz, University of Strathclyde (142). 
HepG2 human hepatoma cells were obtained from American Type Culture Collection (143).  
 
CELL CULTURE GROWTH 
 
Cells were grown in flasks and dishes pre-treated for cells culture use. The cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) bought from Sigma-Aldrich. To the media was added: 
1321N1: 10% bovine calf serum, 1% penicillin/streptomycin 
HepG2: 10% bovine calf serum, 1% penicillin/streptomycin1% non essential amino acid 1% 
sodiumpyruvate. 
The cells were kept in CO2 5% incubator at 37°C saturated of humidity. 
 
CELL COUNTING 
 
Cells were washed twice with cold PBS (Sigma) then treated for five minutes with a solution of trypsin 
to lift the cells from. Once released, fresh medium was added to the cells to block the action of the 
trypsin. The cells were harvested in a sterilized tube at 1000rpm for 5 minutes and re-suspended in a 
reasonable amount of media (normally 1ml for a 75cm 2 flask). A mix of 10µl medium and 10µl cell 
suspension was added to the haematocytometer.  The cells deposited on the glass surface were 
counted using a microscope. Only the cells in the four squares present in the haemocytometer were 
counted. Every square present in the haemocytometer has a surface of 1mm2 and deepness of 0.1mm.  
The average value of the cells counted was determined according to the formula:  
    
              
 
                 * 104 
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MTT ASSAY 
 
The MTT assay is a cell viability assay that depends on the ability of metabolically active cells to reduce 
MTT (yellow) to the purple formazan derivate. It can be used to measure loss of viability due to 
treatment with toxic agent, or growth inhibition, as well as proliferative effects and increases in cell 
number. The amount of purple formed will depend on the number of viable cells present and the time 
of incubation with the dye. The assay is linear only within a certain range and it is important that 
various preliminary experiments were included to demonstrate the assays validity. 
Protocol: 
Cells were seeded in triplicate in 96-well plates at a density that gives around 60% confluence within 
24 hours. This needed to be experimentally determined for each cell line used. After 24 hours, cells 
were treated with different concentration of toxic agent or proliferating agent for a specified amount 
of time. A treatment with a known effect on the cells was used a control. For cell death, Triton X-100 
was used. After the required period of time the media was changed.  
20µl of a 4mg/ml MTT solution (made up in PBS and filter sterilized) was added to the media in each 
well and incubated for up to four hours under normal condition. Three control wells that have no cells 
in it were included (just MTT in media).  
The formation of the purple dye was monitored every 30 minutes. Once sufficient purple had formed, 
all the media was carefully removed without disturbing the attached cells. To stop the assay 150µl of 
isopropanol or DMSO was added to each well and pipette up and down to solublize the crystals and 
left at 37°C for 5 minutes.  
The purple colour was read at 540nm using a plate-reader. The background value (no cells) was 
substracted and the % viability was calculated as the absorbance for treated cells / absorbance for 
control cells. 
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PREPARATION OF CELL EXTRACTS: 
 
Media was removed and cells were washed with HBSS. Cells were collected by centrifugation and the 
pellet frozen at -80 °C. The pellet was re-suspended in prewarmed 100 -150 ul TE buffer (250 mM 
Tris-Cl pH 7.5) and kept at 37oC for 5 mins.  Cells were frozen at -80oC and the freeze-thaw cycle 
repeated. The cells suspension was centrifuged at 13000 for 5 minutes and the supernatant store at -
80oC. 
 
TRANSFECTION OF HUMAN CELLS 
 
Transfection is the process used to introduce exogenous DNA inside the mammalian cells. Different 
methods were considered but the most effective uses Lipofectamine reagent (Invitrogen). The cells 
were transfected when the confluence was between the 50-80%. The amount of DNA to be transfected 
into the cells was diluted in Opti-MEM® I Reduced Serum Medium (invitrogen). The Opti-MEM® I 
Reduced Serum Medium is a serum-free media. 
A range of amount of Lipofetamine reagent was added to the diluted DNA and mixed as shown in Table 
12 
Table 12: amount of reagents need for generate transient cells using lipofectamine from invitrogen. 
Culture 
vessel 
Surface 
area 
per 
well 
Volume plating 
medium 
Cells per 
well 
Volume 
dilution 
medium 
DNA Lipofectamine™ 
LTX Reagent 
96-well 0.3 cm2 100µl 8X103 20 µl 100ng 0.35 - 0.55 μl 
48-well 1 cm2 200 µl 2 X104 40 µl 200 
ng 
0.7 - 1.1 μl 
24- well 2 cm2 500 µl 5 X104 100 µl 500 
ng 
1.75 - 2.75  μl 
12- well 4 cm2 1ml 8 X104 200 µl 1µg 3.5 - 5.5 μl 
6- well 10 cm2 2ml 2 X105 500 µl 2.5 µg 8.75 - 13.75 μl 
 
After 25 minutes of incubation time at room temperature the cell growth media was replaced with 
fresh media and the DNA-lipofectamine complex was added drop-wise. The plate was rocked back and 
forth during the drop-wise process. The transfected cells were grown from 12 to 48 hours in a CO2 
incubator at 37°C before being tested for transgene expression.  
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The optimum ratio between lipofectamine and DNA needed to be tested experimentally to identify the 
best conditions to give efficient transfection and a high level of expression. It was important also to 
evaluate the viability of the cells after lipofectamine exposure because lipofectamine is toxic for the 
cells.  
 
DNA MIDI PREP 
 
This method yields about 20-100µg of plasmid DNA, depending on the copy number of the plasmid. 
The method was is based on that of Birnboim and Dolly (144). E. coli NM522 containing the vector pCI-
Neo (Invitrogen) or pCI-Neo with the gene of interested inserted was used. The E.coli was grow 
overnight in LB broth 40ml at 37°C in selective conditions ampicillin. Cells were harvested in a 
benchtop centrifuge at 5000 rpm for 5 minutes. Cells were resuspended in 1 ml TEG and vortexed 
thoroughly. 1 ml 4mg/ml lysozyme was added made up in TEG. Cells were transferred to a 15ml corex 
tube and incubated on ice for 20 minutes. Cells were vortexed, and 4ml lysis solution was added the 
tube inverted several time. The mixture was kept on ice for 5 minutes. 3M NaAcetate pH5, was added, 
and mixed by inversion then left on ice for 45 minutes. The lysed cells were centrifuged at 9000 rpm 
for 30 minutes. The supernatant was carefully removed to a 30ml corex tube, and 16ml of cold ethanol 
was added and the tube incubated for 15 minutes on ice. To collect the DNA, cells were centrifuged at 
9000rpm for 10 minutes. The DNA pellet was dissolved in 2ml of Low Salt Buffer. 2ml of 
phenol/chloroform/isoamylalcohol (50:49:1) was added, mixed and centrifuged for 10 minutes at 
3000 rpm in benchtop centrifuge. The aqueous phase was transferred to a 15ml corex tube. To the 
phenol layer, 2ml Low Salt Buffer mix was added and centrifuged at 3000 rpm for 10 minutes. Both the 
aqueous phases were combined and 15ml of cold ethanol was added. The solution was incubated at -
20°C for 15 minutes, and then centrifuged for 10 minutes at 9000rpm. The pellet was dissolved in 
0.4ml TE and transferred to an eppendorf tube. 20µl 4M NaCl was added along with 1 ml cold ethanol 
and kept at -20°C for 20 mins, then centrifuged at 12000rpm for 5 minutes at 4°C. The pellet was 
dissolved in 0.2ml TE, 20µl pancreatic Ribonuclease A was added and incubated for 1 hour at 37°C. 
20µl 4M NaCl, 0.2ml water and 0.4ml phenol/chloroform/isoamylalcohol (50/49/1) was added, the 
mixture vortexed and centrifuged for 1 minute. The aqueous phase was removed 0.4 ml 
chloroform/isoamylalcohol was added and the solution vortexed and centrifuged. The aqueous phase 
was removed and 0.8 ml cold ethanol was added. The DNA was kept at -20°C for 10 minutes and 
centrifuged for 5 minutes. The pellet was dissolved in 0.3ml TE. 
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Solutions needed: 
TEG: 25mM Tris-HCl, 10mM EDTA 50mM glucose pH 8 
Lysis buffer: 0,2M NaOH, 1% SDS 
Low Salt Buffer: 0,1M Na acetate, 1mM EDTA, 0,1% SDS, 40mM Tris.HCl pH 8 
 
TE: 10mM Tris-HCl, 1mM EDTA pH8 
 
Ribonuclease A solution 1mg/ml: 10mg Bovine Pancreatic Ribonuclease A, made up in 10ml 10mM 
Tris HCl, 15mM NaCl, pH 7.5 Heat to 100°C for 15 minutes to remove DNAse. Store at -20°C in 0.5ml 
aliquots. 
 
EXPRESSION OF RECOMBINANT PROTEIN AND 
PURIFICATION  
 
The expression of AKR7A2 and AKR7A5 was induced for 4 hours at 37 °C by adding 0.5 mM IPTG and 
cells were lysed by sonication. Purification of this enzyme from bacterial cultures was carried out 
using HiTrap affinity column (1 ml) (Amersham pharmacia biotech) with Pharmacia FPLC (Fast 
Protein Liquid Chromatography) system. Enzyme activities of purified protein were measured and the 
most active fractions of protein were combined and frozen at -80 °C until required. Purified protein 
was also separated by SDS–PAGE to confirm purity. 
 
SDS-POLY ACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
 
This technique is able to separate proteins according to their molecular weight. The proteins interact 
with the Sodium dodecyl sulphate present in the loading buffer and in the gel. The proteins have a 
negative charge proportionate to the length of the protein chain. The proteins with their negative 
charge are exposed to a electric field, that causes them move inside the gel. The gel has two 
components; the stacking gel which compacts all the proteins in the sample in a unique band. The 
second part - the resolving gel - separates the protein.  
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The solution and the concentration used are shown briefly in this thesis because the SDS-page is a very 
common technique (145). 
Bottom gel (resolving) 10% acrylamide 
30% acrylamide/bisacrylamide solution 6.6ml 
4X resolving buffer 5ml 
Distilled water 8.2ml 
Ammonium persulfate 100mg/ml 100µl 
TEMED 10µl 
 
Top gel (stacking) 5% acrylamide 
30% acrylamide/bisacrylamide solution 1.64ml 
4X stacking buffer 2.5ml 
Distilled water 5.86ml 
Ammonium persulfate 100mg/ml 60µl 
TEMED 10µl 
 
Resolving buffer: Tris 1.5M, SDS 0,014M pH 8.8 
Stacking buffer: Tris 0.5M, SDS 14mM, pH 6.8 
Runnig buffer: Tris 0.25M, glycine 1.91, SDS 35mM,  
Loading buffer: Tris 66mM, SDS 0.14M, 18% glicerolo, 10% β-mercaptoethanol, 0.001 bromophemo 
blue. 
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WESTERN BLOTTING 
 
Western blots in this thesis works were made on Polyvinyl fluoride (PVF) membrane. The antibodies 
used were bought from Santa Cruz (Caspase-3 H227). Polyclonal antibodies against AKR7 proteins 
were made in the Ellis lab in Strathclyde.  Goat anti-rabbit secondary antibodies were from Biorad. 
Proteins were separated by SDS-Page, the stacking gel discarded and soaked briefly in Transfer Buffer 
along with the Whatman 3MM paper, PVF membrane and sponges  
A sandwich was set up as shown in the scheme, carefully removing all air bubbles between layers.  
------------------- Plastic holder (+) 
>>>>>>>>>>>> Sponge 
============ 2 layers of whatman 
************ PVF 
....................... Gel 
============ 2 layers of whatman 
>>>>>>>>>>>> Sponge 
-------------------- Plastic holder (-) 
 
The sandwich was placed in the Transfer Tank with the black face of the plastic holder next to the 
black terminal, and the clear face next to the red terminal. The transfer was run for 1 hour at 300mA. 
The sandwich was disassembled and the membrane placed into blocking solution for 1-16 hours. 
ANTIBODY DETECTION 
 
The primary antibody was mixed with the blocking solution at a 1:3000 ratio (10µl per 30ml blocking 
solution). The blot was incubated with antibody for 1-16 hours with gentle mixing. The blot was 
washed 4 times, each time for 25 minutes with 100ml of TBST. The secondary antibody was added at 
the same ratio mixed in blocking solution and incubated for 4 hours with gentle agitation. The blot was 
washed 3 times in TBST for 25 minutes and once in TBS for 25 minutes. The blot was developed by 
Enhanced Chemiluminescence (ECL) and visualized using a Fuji Imager.  
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ENHANCED CHEMILUMINESCENCE 
  
Kit ECLtm Prime Western Blotting Detection Reagent (GE healthcare). 
The secondary anty bofy are from Bio RAD: 
Goat Anti Rabbit IgG (H+L)-HRP Conjugate. 
Solutions required: 
 
Transfer Buffer Solution: 0,19M glycine, 25mM Tris, 20% methanol. 
 
TBS: 0.1 M Tris-HCl, 0,137M NaCl, pH 7.6 
 
TBST: TBS solution 0,1 Tween 20. 
 
Blocking solution: 5% skimmed milk in TBST solution. 
 
ISOLATION OF FRAGMENTED DNA 
 
The method used for the isolation of the fragmented DNA was derived from (137) and some 
modifications were added to the protein extraction to make the method more rapid. Briefly, the cells 
were collected from a in a 25cm2  flask and were washed twice in ice cold PBS before collecting by 
centrifugation in an Eppendfor tube. Cells were resuspended in 50 ul lysis buffer and centrifuged for 5 
minutes at 1600 x g. The supernatant was collected and the above step repeated. The two 
supernatants were combined. The supernatant was assumed to contain the fragmented (apoptotic) 
DNA. The pellet was resuspended in 100 ul lysis buffer. The pellet contains the intact (genomic) DNA. 
Both samples were brought up to 1% SDS and  5µg/µl of RNase A, and were incubated at 56oC for 2 
hours. An equal volume of phenol/chloroform was added to the samples and mixed by vortexing. The 
sample was centrifuged for 5 minutes at 5000 rpm. The supernatant was collected and the 
phenol:chloroform extraction repeated. The supernatants for each fraction of DNA were combined and 
the DNA precipitated using a 1/10 volume of NaAcetate 3M pH 5.2 and 3 volumes of ETOH, incubating 
overnight at -80°C. The DNA was collected by centrifugation for 30 minutes at 4°C, and the 
supernatant discarded. The pellet was suspended in appropriate amount of TE buffer. 
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Lysis buffer: 1% NP-40 in 20 mM EDTA, 50 mM Tris-HCl, pH 7.5 
TE buffer: 10 mM Tris-Cl, pH 7.5. 1 mM EDTA. 
 
AGAROSE ELECTROPHORESIS 
 
All gels were made in TBE buffer using high grade agarose (1%). The electrophoresis solution was 
TBE.  
TBE: 0.089M Tris base, 0.089M boric acid, 0.002M EDTA, disodium sale, dihydrate, final pH 8.3. 
 
ALDEHYDE REDUCTASE ASSAYS 
 
All the reactions were carried out in sodium phosphate buffer 0.1M pH 6.6 in 1ml reaction volume. The 
concentration of the cofactors used was 50µM in the cell reaction. Different substrates at different 
concentrations were used to determinate the apparent Km and Vmax values. The reaction was followed by 
monitoring the change in the cofactor concentration by measuring absorbance at 340nm. The reaction time 
was followed from 1 to 5 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
VI BIBLIOGRAPHY 
 
1. Ethanol metabolism, cirrhosis and alcoholism. Lieber, Charles S. 1997, Clinica Chimica Acta 257 
(1997) 59-84. 
2. Ethanol-induced oxidative stress: basic knowledge. Mario Comporti, Cinzia Signorini, Silvia 
Leoncini,Concetta Gardi, Lucia Ciccoli, Anna Giardini. 2010, Genes Nutr (2010) 5:101–109. 
3. Alcohol metabolism in American Indians and whites: Lack of racial differences in metabolic rate and 
liver alcohol dehydrogenase. Bennion, L.J., LI, T.-K. 1976, New England Journal of Medicine 294: 9–13, 
1976. PMID: 1244489. 
4. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the 
genesis of alcohol-related pathology. David W. Crabb, Michinaga Matsumoto, David Chang and Min 
You. 2004, Proceedings of the Nutrition Society (2004), 63, 49–63. 
5. ALCOHOL AND ALDEHYDE DEHYDROGENASE. TORSTEN EHRIG, WILLIAM F. BOSRON and TING-
KAI L. 1990, Alcohol & Alcoholism. Vol. 25. No. 2/3. pp. 105-116.1990. 
6. A New View of Alcohol Metabolism and Alcoholism—Role of the High-Km Class Ⅲ Alcohol 
Dehydrogenase (ADH3). Takeshi Haseba, Youkichi Ohno. 2010, Int. J. Environ. Res. Public Health 
2010, 7, 1076-1092; doi:10.3390/ijerph7031076. 
7. Enzymatic properties of the protein encoded by newly cloned human alcohol dehydrogenase Image 
gene . Cheng-Sheng Chen, Akira Yoshida. 1991, Biochemical and Biophysical Research 
Communications Volume 181, Issue 2, 16 December 1991, Pages 743-747. 
8. The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. 
Lieber, C.S. and DeCarli, L.M. 1972, J. Pharmacol. Exp. Ther. 1972, 181, 279-287. 
9. Overview: How Is Alcohol Metabolized by the Body? Samir Zakhari, Ph.D. 2006, Alcohol Research & 
Health Vol. 29, No. 4, 2006. 
10. Relationships Between Nutrition, Alcohol Use,and Liver Disease. Charles S. Lieber, M.D., M.A.C.P. 
2003, Alcohol Research & Health Vol. 27, No. 3, 2003 221. 
11. Chronic ethanol treatment induces H2O2 production selectively in pericentral regions of the liver 
lobule. MISRA, U.K., et al. 1992, Alcoholism: Clinical and Experimental Research 16:839–842, 1992. 
PMID: 1443417. 
12. Llorente DD, Abrodo PA, de la Fuente ED, Alvarez JG, Alvarez MD, Gomis DB. Experimental 
design applied to the analysis of volatile compounds in apple juice by headspace solid-phase 
microextraction. J Sep Sci. 2011 Jun;34(11):1293-8. doi: 10.1002/jssc.201000881. Epub 2011 Apr 27. 
2011. 
13. Sl´adek, Norman E. Human Aldehyde Dehydrogenases: Potential Pathological, Pharmacological, 
and Toxicological Impact. J BIOCHEM MOLECULAR TOXICOLOGY Volume 17, Number 1, 2003. 2003. 
14. Human aldehyde dehydrogenase gene family. Yoshida A, Rzhetsky A, Hsu LC, Chang C. 1998, Eur 
Biochem 1998;251 :549-57. 
115 
 
15. Satori A Marchitti, Chad Brocker, Dimitrios Stagos, and Vasilis Vasiliou. Non-P450 aldehyde 
oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008 
June ; 4(6): 697–720. 2008. 
16. Structure of mitochondrial aldehyde dehydrogenase: the genetic component of ethanol aversion. 
Curtis G Steinmetz, Peiguang Xie, Henry Weiner and Thomas D Hurley,. 1997, Current Biology Ltd 
ISSN 0969-2126 . 
17. Human Ocular Aldehyde Dehydrogenase Isozymes:Distribution and Properties as Major Soluble 
Proteins in Cornea and Lens. HOLMES, GORDON KING AND ROGER. 1998, KTINHGE AJONUDR RN. 
AHLO OLMF ESXPERIMENTAL ZOOLOGY 282:12–17 (1998). 
18. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and 
retinoic acid. G., Duester. 2000, Eur J Biochem. 2000 Jul;267(14):4315-24. 
19. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Yoshida A, 
Hsu LC, Davé V. 1992, Enzyme. 1992;46(4-5):239-44. 
20. Wang X, Penzes P, Napoli JL. Cloning of a cDNA encoding an aldehyde dehydrogenase and its 
expression in Escherichia coli. Recognition of retinal as substrate. J Biol Chem. 1996 Jul 
5;271(27):16288-93. 1996. 
21. Algar EM, Cheung B, Hayes J, Holmes RS, Beacham IR. Bovine corneal aldehyde 
dehydrogenases: evidence for multiple gene products (ALDH3 and ALDHX). Adv Exp Med Biol. 
1993;328:153-7. 1993. 
22. Daiber A, Wenzel P, Oelze M, Schuhmacher S, Jansen T, Münzel T. Mitochondrial aldehyde 
dehydrogenase (ALDH-2)—Maker of and marker for nitrate tolerance in response to nitroglycerin 
treatment. Chem Biol Interact. 2009 Mar 16;178(1-3):40-7. Epub 2008 Sep 10. 2009. 
23. Marchitti SA, Orlicky DJ, Vasiliou V. Expression and initial characterization of human ALDH3B1. 
Biochem Biophys Res Commun. 2007 May 11;356(3):792-8. Epub 2007 Mar 15. 2007. 
24. Brocker C, Lassen N, Estey T, Pappa A, Cantore M, Orlova VV, Chavakis T, Kavanagh KL, 
Oppermann U, Vasiliou V. Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in 
cellular defense against hyperosmotic stress. J Biol Chem. 2010 Jun 11;285(24):18452-63. Epub 2010 
Mar 5. 2010. 
25. Molecular abnormality in an inactive aldehyde dehydrogenase variant commonly found in Orientals. 
Yoshida, A., Huang, I.-Y. & Ikawa, M. 1984, Proc. Natl. Acad. Sci. USA 81, 258–261. 
26. Evaluation of the self-rating of the effects of alcohol form in Asian Americans with aldehyde 
dehydrogenase polymorphisms. Wall TL, Johnson ML, Horn SM, Carr LG, Smith TL, Schuckit MA. 
1999, J Stud Alcohol. 1999 Nov;60(6):784-9. 
27. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Higuchi S, 
Matsushita S, Murayama M, Takagi S, Hayashida M. 1995, Am J Psychiatry. 1995 Aug;152(8):1219-
21. 
28. Comparative anatomy of the aldo–keto reductase superfamily. Joseph M. JEZ, Melanie J. BENNETT, 
Brian P. SCHLEGE, Mitchell LEWIS and Trevor M. PENNING. 1997, Biochem. J. (1997) 326, 625±636 
(Printed in Great Britain). 
116 
 
29. www.med.upenn.edu/akr. [Online]  
30. The aldo-keto reductase (AKR) superfamily: an update. Joseph M. Jez, Trevor M. Penning. 2001, 
The aldo-keto reductase (AKR) superfamily: an update. 
31. The aldo-keto reductase superfamily homepage. David Hyndman, David R. Bauman, Vladi V. 
Heredia , Trevor. 2003. 
32. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme 
implicated in diabetic complications. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA. 1992, Science. 
1992 Jul 3;257(5066):81-4. 
33. Kinetic mechanism of reduction of testosterone by hepatic 5 beta-reductase of chicken and inhibition 
of the reductase activity by a secosteroid, an azasteroid and glycyrrhetinic acid. Grimshaw CE, Shahbaz 
M, Putney CG. 1990, Biochemistry. 1990 Oct 23;29(42):9947-55. 
34. Structure of 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase complexed with NADP+. Bennett 
MJ, Schlegel BP, Jez JM, Penning TM, Lewis M. 1996, Biochemistry. 1996 Aug 20;35(33):10702-11. 
35. The kinetic mechanism catalysed by homogeneous rat liver 3 alpha-hydroxysteroid dehydrogenase. 
Evidence for binary and ternary dead-end complexes containing non-steroidal anti-inflammatory drugs. 
Askonas LJ, Ricigliano JW, Penning TM. 1991, Biochem J. 1991 Sep 15;278 ( Pt 3):835-41. 
36. [Aflatoxins--health risk factors]. Miliţă NM, Mihăescu G, Chifiriuc C. 2010, Bacteriol Virusol 
Parazitol Epidemiol. 2010 Jan-Mar;55(1):19-24. 
37. A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver 
during carcinogenesis and following the administration of an anti-oxidant. Judah DJ, Hayes JD, Yang JC, 
Lian LY, Roberts GC, Farmer PB, Lamb JH, Neal GE. 1993, Biochem J. 1993 May 15;292 ( Pt 1):13-8. 
38. An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a 
subfamily of aldo-keto reductases. E M Ellis, D J Judah, G E Neal, J D Hayes. 1993, biochemistry. 
39. Substrate specificity of an aflatoxin-metabolizing aldehyde reductase. Ellis EM, Hayes JD. 1995, 
Biochem J. 1995 Dec 1;312 ( Pt 2):535-41. 
40. Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo–keto 
reductase superfamily : evidence that the major 2-carboxybenzaldehyde reductase from human liver is a 
homologue of rat aflatoxin B1-aldehyde reductase. Linda S. IRELAND, David J. HARRISON‹, Gordon E. 
NEALŒ and John D. HAYES. 1998, Biochem. J. (1998) 332, 21±34 (Printed in Great Britain). 
41. Cloning and expression of succinic semialdehyde reductase from human brainIdentity with aflatoxin 
B1 aldehyde reductase. Micheline Schaller, Matteo Schaffhauser, Notker Sans and Bendicht 
Wermuth. 1999, Eur. J. Biochem. 265, 1056±1060 (1999) q FEBS 1999. 
42. Human brain aldehyde reductases: relationship to succinic semialdehyde reductase and aldose 
reductase. Hoffman, P.L., von Wermuth, B. & Wartburg, J.-P. 1980, J. Neurochem. 35, 354±366. 
43. Cloning of the human aflatoxin B1-aldehyde reductase gene at 1p35-1p36.1 in a region frequently 
altered in human tumor cells. Praml C, Savelyeva L, Perri P, Schwab M. 1998, Cancer Res. 1998 Nov 
15;58(22):5014-8. 
117 
 
44. Substrate specificity of mouse aldo keto reductase AKR7A5. Alison Hinshelwood, Gail McGarvie , 
Elizabeth M. Ellis. 2003. 
45. Characterisation of a novel mouse liver aldo-keto reductase AKR7A5. Alison Hinshelwood, Gail 
McGarvie, Elizabeth Ellis. 2002, FEBS Letters 523 (2002) 213^218. 
46. Crystal structure of mouse succinic semialdehyde reductase AKR7A5: structural basis for substrate 
specificity. Zhu X, Lapthorn AJ, Ellis EM. 2006, Biochemistry. 2006 Feb 14;45(6):1562-70. 
47. High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and 
pathogenetic implications. Homann N, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M. 
1997, Carcinogenesis. 1997 Sep;18(9):1739-43. 
48. Acetaldehyde. In: Integrated Risk Information System,. IRIS. 1996. 
49. Alcohol and cancer. Poschl G, Seitz H. K. 2004, Alcohol alcohol 2004; 39 155-165. 
50. In vitro and in vivo inhibitory effect of ethanol and acetaldehyde on O6-methylguanine transferase. 
Espina N, Lima V, Lieber CS, Garro AJ. 1988, Carcinogenesis. 1988 May;9(5):761-6. 
51. Acetaldehyde binds to liver cell membranes without affecting membrane function. R E BARRY, J D 
MCGIVAN, AND M HAYES. 1984, Gut, 1984, 25, 412-416. 
52. Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a 
functional assay, the FASAY (functional analysis of separated alleles in yeast). Paget V, Lechevrel M, 
Sichel F. 2008, Mutat Res. 2008 Mar 29;652(1):12-9. Epub 2007 Dec 23. 
53. Acetaldehyde stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 
phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis. Marietta C, 
Thompson LH, Lamerdin JE, Brooks PJ. 2009, Mutat Res. 2009 May 12;664(1-2):77-83. Epub 2009 
Apr 5. 
54. DNA Adducts with Lipid Peroxidation Products. Blair, Ian A. 2008, J Biol Chem. 2008 June 6; 
283(23): 15545–15549. . 
55. —. Blair, Ian A. 2008, J Biol Chem. 2008 June 6; 283(23): 15545–15549. . 
56. MARNETT, AARON T. JACOBS AND LAWRENCE J. Systems Analysis of Protein Modification and 
Cellular Responses Induced by Electrophile Stress. ACCOUNTS OF CHEMICAL RESEARCH 673-683 May 
2010 Vol. 43, No. 5. 2010. 
57. Lipid peroxidation in relation to ageing and the role of endogenous aldehydes in diabetes and other 
age-related diseases. L.F. Dmitriev, V.N. Titov. 2010, Ageing Research Reviews 9 (2010) 200–210. 
58. Acrolein in Wine: Importance of 3-Hydroxypropionaldehydeand Derivatives in Production and 
Detection. ROLENE BAUER, DONALD A. COWAN and ANDREW CROUCH. 2010, J. Agric. Food Chem. 
2010, 58, 3243–3250. 
59. ACROLEIN:Sources, metabolism, and biomolecular interactions relevant to human health and disease. 
Maier, Jan F. Stevens and Claudia S. 2008, Mol Nutr Food Res. 2008 January ; 52(1): 7–25. 
60. Acrolein health effects. O Faroon, N Roney, J Taylor, A Ashizawa, MH Lumpkin and DJ Plewak. 
2008, Toxicology and Industrial Health 2008; 24: 447–490. 
118 
 
61. Antioxidants and cancer. IV. Initiating activity of malonaldehyde as a carcinogen. Shamberger RJ, 
Andreone TL, Willis CE. 1974, J Natl Cancer Inst. 1974 Dec;53(6):1771-3. 
62. Oxidative stress and aging: Is methylglyoxal the hidden enemy? Kaushik M. Desai, Tuanjie Chang, 
Hui Wang, Ali Banigesh, Arti Dhar, Jianghai Liu Ashley Untereiner, and Lingyun Wu. 2010, Can. J. 
Physiol. Pharmacol. Vol. 88, 2010. 
63. Characteristic effects of methylglyoxal and its degraded product formate on viability of human 
histiocytes: A possible detoxification pathway of methylglyoxal. Kenji Koizumi, Masaaki Nakayama, 
Wan-Jun Zhu, Sadayoshi Ito. 2011, Biochemical and Biophysical Research Communications 407 
(2011) 426–431. 
64. Systems analysis of protein modification and cellular responses induced by electrophile stress. Jacobs 
AT, Marnett LJ. 2010, Acc Chem Res. 2010 May 18;43(5):673-83. 
65. Transduction of Redox Signaling by Electrophile-Protein Reactions. Freeman, Tanja K. Rudolphand 
Bruce A. 2009, Science. Signal., 29 September 2009. 
66. DNA adducts with lipid peroxidation products. IA., Blair. 2008, J Biol Chem. 2008 Jun 
6;283(23):15545-9. Epub 2008 Feb 19. 
67. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. 
Zuhal Yildirim, Nil Irem Ucgun, Filiz Yildirim. 2011, CLINICS 2011;66(5):743-746. 
68. The simple and sensitive measurement of malondialdehyde in selected The simple and sensitive 
measurement of malondialdehyde in selected performance liquid chromatography. Marian Czaudernaa, 
Jan Kowalczyk, Milan Marounek. 2011, Journal of Chromatography B, 879 (2011) 2251– 2258. 
69. Insights into the Formation and Isomerization of the Benzene Metabolite Muconaldehyde and Related 
Molecules: Comparison of Computational and Experimental Studies of Simple, Benzo-Annelated, and 
Bridged 2,3-Epoxyoxepins. Greenberg, Jessica Morgan and Arthur. 2010, J. Org. Chem. Vol. 75, No. 14, 
2010. 
70. The benzene metabolite trans,trans-muconaldehyde blocks gap junction intercellular communication 
by cross-linking connexin43. Rivedal E, Leithe E. 2008, Toxicol Appl Pharmacol. 2008 Nov 
1;232(3):463-8. Epub 2008 Aug 6. 
71. Metabolism of trans, trans-muconaldehyde, a microsomal hematotoxic metabolite of benzene, by 
purified yeast aldehyde dehydrogenase and a mouse liver soluble fraction. Kirley TA, Goldstein BD, 
Maniara WM, Witz G. 1989, Toxicol Appl Pharmacol. 1989 Sep 1;100(2):360-7. 
72. METABOLISM AND CYTOTOXICITY OF trans,trans-MUCONALDEHYDE AND ITS DERIVATIVES: 
POTENTIAL MARKERS OF BENZENE RING CLEAVAGE REACTIONS. DANIEL GOON, JAMES MATSUURA 
and DAVID ROSS. 1993, Chem.-Biol. Interactions, 88 (1993) 37-53. 
73. Metabolism of trans, trans-muconaldehyde, a cytotoxic metabolite of benzene, in mouse liver by 
alcohol dehydrogenase Adh1 and aldehyde reductase AKR1A4. Duncan M. Short, Robert Lyon , David 
G. Watson , Oleg A. Barski , Gail McGarvie , Elizabeth M. Ellis. 2006, Toxicology and Applied 
Pharmacology 210 (2006) 163 – 170. 
119 
 
74. cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the 
aldo-keto reductase superfamily, AKR7A3. Laundette P.Knight, Thomad Primiano, Johon D 
Groopman. 1999, carcinogenesis vol.20 no.7 pp1215-1223, 1999. 
75. Controlled Drugs and Substances Act. 1996. Act, The Canadian Controlled Drug and Substances. 
2007, http://laws.justice.gc.ca/en/ShowFullDoc/cs/C-38.8///en. 
76. Withdrawal from gamma-hydroxybutyrate,1,4-butanediol and gamma-butyrolactone: a case report 
and systematic review. Jeremy M. Wojtowicz, MD, Mark C. Yarema, MD and Paul M. Wax, MD. 2008, 
CJEM 2008;10(1):69-74. 
77. A case of prolonged withdrawal from use of 1,4-butanediol complicated by seizure and 
rhabdomyolysis [abstract]. Wojtowicz JM, Yarema MC, Wax PM. 2006, CJEM 2006;8:195. 
78. Behavioral Analyses of GHB: Receptor Mechanisms. Lawrence P. Carter, Wouter Koek, and 
Charles P. France. 2009, Pharmacol Ther. 2009 January ; 121(1): 100–114. 
79. The Impact of Gamma Hydroxybutyrate (GHB) Legal Restrictions on Patterns of Use: Results from an 
International Survey. Anderson I, Kim-Katz S, Dyer J, Blanc P. 2010, Drugs (Abingdon Engl). 2010 
Oct;17(5):455-469. 
80. Synthesis and Catabolism of -Hydroxybutyrate in SH-SY5Y Human Neuroblastoma Cells. Robert C. 
Lyon1, Stuart M. Johnston, David G. Watson, Gail McGarvie, and Elizabeth M. Ellis. 2007, THE 
JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 36, pp. 25986–25992, September 7, 2007. 
81. Vitamins D and K as pleiotropic nutrients: clinical importance to the skeletal and cardiovascular 
systems and preliminary evidence for synergy. PM., Kidd. 2010, Altern Med Rev. 2010 Sep;15(3):199-
222. 
82. Synergy Effect of Vitamin K3 on Cytotoxicity of Campthotecin in HCT116 Cells. Nobuhiro Yoshimoto, 
Yuji Takebayashi, Seichi Takenosita. 2007, Ann. Cancer Res. Therap. Vol. 15, No. 2, pp. 54-60, 2007. 
83. The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell 
death. Basis for their potential use as coadjuvants in anticancer therapy. Verrax J, Cadrobbi J, Delvaux 
M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc Calderon P. 2003, Eur J Med Chem. 2003 
May;38(5):451-7. 
84. 5-Hydroxy-1,4-naphthoquinone (juglone) and 2-hydroxy-1,4-naphthoquinone (lawsone) influence on 
jack bean urease activity: Elucidation of the difference in inhibition activity. Mirosława Kot, Waldemar 
Karcz, Wiesława Zaborska. 2010, Bioorganic Chemistry, Volume 38, Issue 3, June 2010, Pages 132-
137 . 
85. Cytotoxic properties of iron-hydroxynaphthoquinone complexes in rat hepatocytes. Kumbhar A, 
Padhye S, Ross D. 1996, Biometals. 1996 Jul;9(3):235-40. 
86. Quantification of p-phenylenediamine and 2-hydroxy-1,4-naphthoquinone in henna tattoos. Almeida 
PJ, Borrego L, Pulido-Melián E, González-Díaz O. 2012, Contact Dermatitis. 2012 Jan;66(1):33-37. 
doi: 10.1111/j.1600-0536.2011.01992.x. Epub 2011 Oct 5. 
87. Biological effects of resveratrol. L., Frémont. 2000, Life Sci. 2000 Jan 14;66(8):663-73. 
120 
 
88. Moderate Ethanol Preconditioning of Rat Brain Cultures Engenders Neuroprotection Against 
Dementia-Inducing Neuroinflammatory Proteins: Possible Signaling Mechanisms. Mitchell, Michael A. 
Collins & Edward J. Neafsey & Kewei Wang Nicholas J. Achille & Robert M. 2010, Mol Neurobiol 
(2010) 41:420–425. 
89. [Alcohol consumption and coronary heart disease in Eastern Asian men: a meta-analysis of 
prospective cohort studies]. Liu PM, Dosieah S, Zheng HS, Huang ZB, Lin YQ, Wang JF. 2010, 
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Nov;38(11):1038-44. 
90. Chemistry of Secondary Polyphenols Produced during Processing of Tea and Selected Foods. Takashi 
Tanaka, Yosuke Matsuo and Isao Kouno. 2010, Int. J. Mol. Sci. 2010, 11, 14-40; 
doi:10.3390/ijms11010014. 
91. Maturation of Whisky Changes Ethanol Elimination Kinetics and Neural Effects by Increasing 
Nonvolatile Congeners. Takeshi Haseba, Keiko Mashimo, Junichi Sugimoto, Shigeo Sato, and 
Youkichi Ohno. 2007, ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH Vol. 31, No. S1 2007. 
92. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of 
plasma from healthy volunteers. Duthie GG, Pedersen MW, Gardner PT, Morrice PC, Jenkinson AM, 
McPhail DB, Steele GM. 1998, Eur J Clin Nutr. 1998 Oct;52(10):733-6. 
93. Phenolic constituents, furans, and total antioxidant status of distilled spirits. Goldberg DM, Hoffman 
B, Yang J, Soleas GJ. 1999, J Agric Food Chem. 1999 Oct;47(10):3978-85. 
94. The effect of cask charring on Scotch whisky maturation. JANICE CLYNE, ALISTAIR PATERSON,. 
1993, International Journal of Food Science & Technology Volume 28, Issue 1, pages 69–81, February 
1993. 
95. Assessment of the Antioxidant Potential of Scotch Whiskeys by Electron Spin Resonance Spectroscopy: 
Relationship to Hydroxyl-Containing Aromatic Components. Donald B. McPhail, Peter T. Gardner, 
Garry G. Duthie,Gordon M. Steele. 1999, J. Agric. Food Chem. 1999, 47, 1937-1941. 
96. Phytophenols in whisky lower blood acetaldehyde level by depressing alcohol metabolism through 
inhibition of alcohol dehydrogenase 1(class I) in mice. Takeshi Haseba, Junichi Sugimoto, Shigeo 
Sato, Yuko Abe, Youkichi Ohno. 2008, Metabolism Clinical and Experimental 57 (2008) 1753–1759. 
97. Effects of ultraviolet irradiation on resveratrol and changes in resveratrol and various of its 
derivatives in the skins of ripening grapes. Roggero JP, Garciaparrilla C. 1995, Sci Aliments 1995; 
15:411e22. 
98. Resveratrol in cardiovascular health and disease. Petrovski G, Gurusamy N, Das DK. 2011, Ann N Y 
Acad Sci. 2011 Jan;1215:22-33. doi: 10.1111/j.1749-6632.2010.05843.x. 
99. Bioavailability of resveratrol. T., Walle. 2011, Ann N Y Acad Sci. 2011 Jan;1215:9-15. doi: 
10.1111/j.1749-6632.2010.05842.x. 
100. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, 
pharmacokinetics, and effect on the insulin-like growth factor axis. Brown VA, Patel KR, Viskaduraki 
M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward 
WP, Gescher AJ, Brenner DE. 2010, Cancer Res. 2010 Nov 15;70(22):9003-11. Epub 2010 Oct 8. 
121 
 
101. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and 
duodenum. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000, Xenobiotica. 2000 
Jun;30(6):609-17. 
102. Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism 
of lifespan prolongation and cancer protection. Zhou R, Fukui M, Choi HJ, Zhu BT. 2009, Br J 
Pharmacol. 2009 Sep;158(2):462-74. Epub 2009 Jun 25. 
103. Anti-Inflammatory Activity of Gallic Acid. Kroes, B. H., et al. 1992, Planta Med 1992; 58: 499-504. 
104. Nicholas J. Walton, Melinda J. Mayer, Arjan Narbad. Vanillin. Phytochemistry 63 (2003) 505–
515 507. 2003. 
105. Keshava, C., Keshava, N., Whong, W.-Z., Nath, J., Ong, T.M. Inhibition of methotrexate-induced 
chromosomal damage by vanillin and chlorophyllin in V79 cells. Teratogenesis, Carcinogenesis,and 
Mutagenesis 17, 313–326. 1998. 
106. Suppression of 6-TG-resistant mutations in V79 cells and recessive spot formations in mice by 
vanillin. Imanishi H, Sasaki YF, Matsumoto K, Watanabe M, Ohta T, Shirasu Y, et al. 1990, Mutat 
Res 1990; 243:151–8. 
107. Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. 
Lirdprapamongkol K, Sakurai H, Kawasaki N, Choo MK, Saitoh Y, Aozuka Y,. 2005, Pharmaceut Sci 
2005; 25:57–65. 
108. Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin. Ho K, 
Yazan LS, Ismail N, Ismail M. 2009, Cancer Epidemiol. 2009 Aug;33(2):155-60. Epub 2009 Jul 3. 
109. Microarray analysis of vanillin-regulated gene expression profile in human hepatocarcinoma cells. 
Cheng WY, Hsiang CY, Bau DT, Chen JC, Shen WS, Li CC, Lo HY, Wu SL, Chiang SY, Ho TY. 2007, 
Pharmacol Res. 2007 Dec;56(6):474-82. Epub 2007 Sep 12. 
110. Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. 
Shahrzad S, Aoyagi K, Winter A, Koyama A, Bitsch I. 2001, J Nutr 131:1207–1210. 
111. Gallic acid provokes DNA damage and suppresses DNA repair gene expression in human prostate 
cancer PC-3 cells. Liu KC, Ho HC, Huang AC, Ji BC, Lin HY, Chueh FS, Yang JS, Lu CC, Chiang JH, Meng 
M, Chung JG. 2011, Environ Toxicol. 2011 Sep 2. doi: 10.1002/tox.20752. [Epub ahead of print]. 
112. Gallic acid-induced lung cancer cell death is accompanied by ROS increase and glutathione 
depletion. Kim, Bo Ra You Sung Zoo Kim Suhn Hee. 2011, Mol Cell Biochem (2011) 357:295–303. 
113. Gallic Acid Suppresses Lipopolysaccharide-Induced Nuclear Factor- kB Signaling by Preventing RelA 
Acetylation in A549 Lung Cancer Cells. Kyung-Chul Choi, Yoo-Hyun Lee, Myung Gu Jung, et al. 2009, 
Mol Cancer Res 2009;7:2011-2021. 
114. Effect of Micronutrients on Methylglyoxal-Mediated In Vitro Glycation of Albumin. Agte, Kirtan V. 
Tarwadi & Vaishali V. 2011, Biol Trace Elem Res (2011) 143:717–725. 
115. Potent protection of gallic acid against DNA oxidation: Results of human and animal experiments. 
Franziska Ferk, Asima Chakraborty, Walter Jäger, Michael Kundi, Julia Bichler. 2011, Mutation 
Research 715 (2011) 61– 71. 
122 
 
116. Genotoxic effects of dietary and lifestyle related carcinogens in human derived hepatoma (HepG2, 
Hep3B) cells. Bernhard J Majera, Volker Mersch-Sundermannb, Firouz Darroudic, Brenda Lakya, 
Kristal de Witc, Siegfried Knasmüllera. 2004, Mutation Research 551 (2004) 153–166. 
117. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms 
that determine lower expression in cultured cells. Rodriguez-Antona, C., Donato, M.T., Boobis, A., 
Edwards,R.J., Watts, P.S., Castell, J.V., Gomez-Lechon, M.J., 2002. 2002, Xenobiotica 32 (6), 505–
520. 
118. Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; 
current state of knowledge. Knasmüller S, Mersch-Sundermann V, Kevekordes S, Darroudi F, 
Huber WW, Hoelzl C, Bichler J, Majer BJ. 2004, Toxicology. 2004 May 20;198(1-3):315-28. 
119. Establishment of a recombinant hepatic cell line stably expressing alcohol dehydrogenase. Clemens 
DL, Halgard CM, Miles RR, Sorrell MF, Tuma DJ. 1995, Arch Biochem Biophys. 1995 Aug 
20;321(2):311-8. 
120. Optimizing culture system of mouse marrow mesenchymal stem cells in vitro and investigating effect 
of alcohol and acetaldehyde on the cells. Li H, Qu W, Wu D. 2006, Zhongguo Xiu Fu Chong Jian Wai Ke 
Za Zhi. 2006 Apr;20(4):471-4. 
121. Comparative study of the damage produced by acute ethanol and acetaldehyde treatment in a 
human fetal hepatic cell line. Olivares IP, Bucio L, Souza V, Cárabez A, Gutiérrez-Ruiz MC. 1997, 
Toxicology. 1997 Jun 27;120(2):133-44. 
122. Astrocytes as the site for bioactivation of neurotoxins. Di Monte DA, Royland JE, Irwin I, 
Langston JW. 1996, Neurotoxicology. 1996 Fall-Winter;17(3-4):697-703. 
123. Role of acetaldehyde in the actions of ethanol on the brain--a review. WA., Hunt. 1996, Alcohol. 
1996 Mar-Apr;13(2):147-51. 
124. Putative role of brain acetaldehyde in ethanol addiction. Deitrich, Xin-sheng Deng and Richard 
A. 2008, Curr Drug Abuse Rev. 2008 January ; 1(1): 3–8. 
125. Ethanol and acetaldehyde action on central dopamine systems: mechanisms, modulation, and 
relationship to stress. Melis M, Diana M, Enrico P, Marinelli M, Brodie MS. 2009, Alcohol. 2009 
Nov;43(7):531-9. 
126. Chronic consumption of ethanol leads to substantial cell damage in cultured rat astrocytes in 
conditions promoting acetaldehyde accumulation. Signorini-Allibe N, Gonthier B, Lamarche F, 
Eysseric H, Barret L. 2005, Alcohol Alcohol. 2005 May-Jun;40(3):163-71. Epub 2005 Mar 14. 
127. Comparison of ethanol and acetaldehyde toxicity in rat astrocytes in primary culture. Sarc L, 
Lipnik-Stangelj M. 2009, Arh Hig Rada Toksikol. 2009 Sep;60(3):297-305. 
128. Impaired acetaldehyde oxidation in alcoholics. JENKINS, K R PALMER and W J. 1982, Gut, 1982, 
23, 729-733. 
129. Ethanol metabolism in the brain. SERGEY M. ZIMATKIN, RICHARD A.DEITRICH. addiction 
biology 9 JUN 2006. 
123 
 
130. Toxicity of beta-carotene and its exacerbation by acetaldehyde in HepG2 cells. Ni R, Leo MA, Zhao J, 
Lieber CS. 2001, Alcohol Alcohol. 2001 Jul-Aug;36(4):281-5. 
131. Apoptosis: mechanisms and clinical implications. Ferch, P. C. A. Kam and N. I. 2000, Anaesthesia, 
2000, 55, pages 1081±1093. 
132. Interventional Strategies to Prevent beta-Cell Apoptosis in Islet Transplantation. Shapiro, Juliet A. 
Emamaullee and A.M. James. 2006, DIABETES, VOL. 55, JULY 2006. 
133. Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism 
of lifespan prolongation and cancer protection. Zhou R, Fukui M, Choi HJ, Zhu BT. 2009, Br J 
Pharmacol. 2009 Sep;158(2):462-74. Epub 2009 Jun 25. 
134. —. Zhou R, Fukui M, Choi HJ, Zhu BT. 2009, Br J Pharmacol. 2009 Sep;158(2):462-74. Epub 
2009 Jun 25. 
135. Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with 
Apoptosis. Reiner U. Ja¨ nicke, Michael L. Sprengart, Mas R. Wati, and Alan G. Porter. 1998, THE 
JOURNAL OF BIOLOGICAL CHEMISTRY. 
136. Regulation of DNA fragmentation: the role of caspases and phosphorylation. Kitazumi I, 
Tsukahara M. 2011, FEBS J. 2011 Feb;278(3):427-41. doi: 10.1111/j.1742-4658.2010.07975.x. Epub 
2010 Dec 23. 
137. A rapid and simple method for the isolation of apoptotic DNA fragments. M.Herrmann, H.-
M.Lorenz, R.Voll, M.Griinke, W.Woith and J.R.Kalden. 1994, Nucleic Acids Research, 1994, Vol. 22, 
No. 24. 
138. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. 
Claudine Manach, Gary Williamson, Christine Morand, Augustin Scalbert, and Christian Rémésy. 
2005, Am J Clin Nutr 2005;81(suppl):230S– 42S. Printed in USA. 
139. Dietary polyphenols: Focus on resveratrol, promising agent in the prevention of cardiovascular 
diseases and control of glucose homeostasis. A. Borriello, V. Cucciolla, F. Della Ragione, P. Galletti. 
2010, Nutrition, Metabolism & Cardiovascular Diseases (2010) 20, 618e625. 
140. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde 
reductase and the principal human aldo-keto reductase AKR1 family members. O'connor T, Ireland LS, 
Harrison DJ, Hayes JD. 1999, Biochem J. 1999 Oct 15;343 Pt 2:487-504. 
141. invitrogen. www.invitrogen.com. [Online] 12 25, 2011.  
142. University, strathclyde. staff detail2. Strathclyde Institute of Pharmacy and Biomedical Sciences . 
[Online] 2012. http://spider.science.strath.ac.uk/sipbs/staffDetails2.php?u=eve.lutz. 
143. Center, ATCC: The Global Bioresource. www.atcc.org/. ATCC: The Global Bioresource Center. 
[Online] 1 2012.  
144. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Birnboim HC, Doly 
J. 1979, Nucleic Acids Res. 1979 Nov 24;7(6):1513-23. 
124 
 
145. One-dimensional SDS gel electrophoresis of proteins. SR., Gallagher. 2007, Curr Protoc Cell Biol. 
2007 Dec;Chapter 6:Unit 6.1. 
146. Reactive oxygen species and intracellular Ca2+, common signals for apoptosis induced by gallic acid. 
Sakaguchi N, Inoue M, Ogihara Y. 1998, Biochem Pharmacol. 1998 Jun 15;55(12):1973-81. 
147. Enzimatic detection of Gamma Hydroxybutyrate using Aldo-Keto Reductase 7A2. Bendinskas, 
Kestutis, et al. 2011, j foresinc May 2011. 
148. Antioxidants and Cancer. IV. Initiating Activity of Malonaldehyde as a Carcinogen. Raymond J. 
Shamberger, Ph.D., Theresa L. Andreone, and Charles E. Willis, M.D. 1974, JOURNAL OF THE 
NATIONAL CANCER INSTITUTE, VOL. 53, NO. 6, DECEMBER 1974. 
149. —. Raymond J. Shamberger, Ph.D., Theresa L. Andreone, and Charles E. Willis, M.D. 1974, 
JOURNAL OF THE NATIONAL CANCER INSTITUTE, VOL. 53, NO. 6, DECEMBER 1974. 
150. Systems Analysis of Protein Modification and Cellular Responses Induced by Electrophile Stress. 
MARNETT, AARON T. JACOBS AND LAWRENCE J. 2010, ACCOUNTS OF CHEMICAL RESEARCH Vol. 
43, No. 5 May 2010 673-683. 
151.  
152. Role of human aldehyde dehydrigenase in endobiotic and xenobiotic metabolism. Vasiliou V, Pappa 
A, Estey T,. 1994, Drug Met Rev 1994;36:279-99. 
153. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase S-methyl N,N-
diethylthiolcarbamate sufloxide, a new metabolite of disulfiram. Hart, B.W. & Faiman, M.D. 1992, 
Biochem. Pharmacol. 43,403–406. 
154. The cellular basis of corneal transparency: evidence for ‘corneal crystallins’. Jester JV, Moller-
Pedersen T, Huang J, Sax CM, Kays WT, Cavangh HD, Petroll WM, Piatigorsky J. 1999, J Cell Sci. 
1999 Mar;112 ( Pt 5):613-22. 
155. Distinct functions for Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid 
signaling pathways. Haselbeck RJ, Hoffmann I, Duester G. 1999, Dev Genet. 1999;25(4):353-64. 
156. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Kim 
H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, Brooks JD, Pollack JR. 2005, Cancer Res. 
2005 Sep 15;65(18):8118-24. 
157. Molecular Cloning, Genomic Organization, and Chromosomal Localization of an Additional Human 
Aldehyde Dehydrogenase Gene, ALDH6. Lily C. Hsu, Wen-Chung Chang, Lea Hiraoka and Chih-Lin 
Hsieh. 1994, Genomics Volume 24, Issue 2, 15 November 1994, Pages 333-341 . 
158. Cloning and characterization of a new functional human aldehyde dehydrogenase gene. Hsu LC, 
Chang WC. 1991, J Biol Chem. 1991 Jul 5;266(19):12257-65. 
159. 10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in 
tumor tissues and possesses suppressor effects on cancer cells. Krupenko SA, Oleinik NV. 2002, Cell 
Growth Differ. 2002 May;13(5):227-36. 
125 
 
160. The regulation of folate and methionine metabolism. Krebs HA, Hems R, Tyler B. 1976, Biochem J. 
1976 Aug 15;158(2):341-53. 
161. Partial purification of a 10-formyl-tetrahydrofolate: NADP oxidoreductase from mammalian liver. 
Kutzbach C, Stokstad EL. 1968, Biochem Biophys Res Commun. 1968 Jan 25;30(2):111-7. 
162. Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. 
Anguera MC, Field MS, Perry C, Ghandour H, Chiang EP, Selhub J, Shane B, Stover PJ. 2006, J Biol 
Chem. 2006 Jul 7;281(27):18335-42. Epub 2006 Apr 2. 
163. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Chen Z, Stamler JS. 
2006, Trends Cardiovasc Med. 2006 Nov;16(8):259-65. 
164. Chromosome assignment, biochemical and immunological studies on a human aldehyde 
dehydrogenase, ALDH3. Santisteban I, Povey S, West LF, Parrington JM, Hopkinson DA. 1985, Ann 
Hum Genet. 1985 May;49(Pt 2):87-100. 
165. Human ocular aldehyde dehydrogenase isozymes: distribution and properties as major soluble 
proteins in cornea and lens. King G, Holmes R. 1998, J Exp Zool. 1998 Sep-Oct 1;282(1-2):12-7. 
166. Ultraviolet radiation decreases expression and induces aggregation of corneal ALDH3A1. Manzer R, 
Pappa A, Estey T, Sladek N, Carpenter JF, Vasiliou V. 2003, Chem Biol Interact. 2003 Feb 1;143-
144:45-53. 
167. Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical 
characterization. Kelson TL, Secor McVoy JR, Rizzo WB. 1997, Biochim Biophys Acta. 1997 Apr 
17;1335(1-2):99-110. 
168. Cloning of a cDNA encoding human ALDH7, a new member of the aldehyde dehydrogenase family. 
Hsu LC, Chang WC, Yoshida A. 1994, Gene. 1994 Dec 30;151(1-2):285-9. 
169. Acrolein-induced cell death in PC12 cells: Role of mitochondria-mediated oxidative stress. Jian Luo 
a, J. Paul Robinson b, Riyi Shi a,. 2005, Neurochemistry International 47 (2005) 449–457. 
170. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. 
Mukherjee S, Ray D, Lekli I, Bak I, Tosaki A, Das DK. 2010, Can J Physiol Pharmacol. 2010 
Nov;88(11):1017-25. 
171. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Vidavalur 
R, Otani H, Singal PK, Maulik N. 2006, Exp Clin Cardiol. 2006 Fall;11(3):217-25. 
172. The crystal structure of rat liver AKR7A1. A dimeric member of the aldo-keto reductase superfamily. 
Kozma E, Brown E, Ellis EM, Lapthorn AJ. 2002, J Biol Chem. 2002 May 3;277(18):16285-93. Epub 
2002 Feb 11. 
173. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic 
activities and production of reactive oxygen intermediates. Dai Y, Rashba-Step J, Cederbaum AI. 1993, 
Biochemistry. 1993 Jul 13;32(27):6928-37. 
174. Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism 
of lifespan prolongation and cancer protection. Zhou R, Fukui M, Choi HJ, Zhu BT. 2009, Br J 
Pharmacol. 2009 Sep;158(2):462-74. Epub 2009 Jun 25. 
126 
 
 
 
 
 
 
 
 
 
 
 
 
Human aldo–keto reductase AKR7A2 protects against the cytotoxicity and
mutagenicity of reactive aldehydes and lowers intracellular reactive oxygen
species in hamster V79-4 cells
Dan Li a,b, Michele Ferrari a, Elizabeth M. Ellis a,⇑
a Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom
bDepartment of Biopharmaceuticals, School of Pharmaceutical Science, China Medical University, Heping District, Shenyang 110001, China
a r t i c l e i n f o
Article history:
Received 1 June 2011
Received in revised form 26 September 2011
Accepted 27 September 2011
Available online 5 October 2011
Keywords:
Aldo–keto reductase
Oxidative stress
Aldehydes
Menadione
a b s t r a c t
Aldo–keto reductase (AKR) enzymes are critical for the detoxication of endogenous and exogenous alde-
hydes. Previous studies have shown that the AKR7A2 enzyme is catalytically active toward aldehydes
arising from lipid peroxidation, suggesting a potential role against the consequences of oxidative stress,
and representing an important detoxication route in mammalian cells. The aim of this study was to deter-
mine the ability of AKR7A2 to protect cells against aldehyde cytotoxicity and genotoxicity and elucidate
its potential role in providing resistance to oxidative stress. A transgenic mammalian cell model was
developed in which AKR7A2 was overexpressed in V79-4 cells and used to evaluate the ability of AKR7A2
to provide resistance against toxic aldehydes. Results show that AKR7A2 provides increased resistance to
the cytotoxicity of 4-hydroxynonenal (HNE) and modest resistance to the cytotoxicity of trans, trans-
muconaldehyde (MUC) and methyglyoxal, but provided no protection against crotonaldehyde and acro-
lein. Cells expressing AKR7A2 were also found to be less susceptible to DNA damage, showing a decrease
in mutation rate cause by 4-HNE compared to control cells. Furthermore, the role of the AKR7A2 enzyme
on the cellular capability to cope with oxidative stress was assessed. V79 cells expressing AKR7A2 were
more resistant to the redox-cycler menadione and were able to lower menadione-induced ROS levels in
both a time and dose dependent manner. In addition, AKR7A2 was able to maintain intracellular GSH lev-
els in the presence of menadione. Together these findings indicate that AKR7A2 is involved in cellular
detoxication pathways and may play a defensive role against oxidative stress in vivo.
 2011 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Aldehydes and ketones are found in a range of compounds
including drugs, food and environmental pollutants, and are also
produced endogenously. Some aldehyde and ketones such as acro-
lein and 4-hydroxy trans 2-nonenal (4-HNE) are extremely reac-
tive, and can cause damages to protein, DNA and lipids, leading
to pathophysiological consequences [1]. For example, 4-HNE has
been reported to cause cytotoxicity in several cell lines, and is
the most toxic aldehyde produced during the peroxidation of
x-6-polyunsaturated fatty acids [2]. In addition, several reactive
aldehydes have been confirmed as mutagenic through their inter-
actions with DNA [3], and have been reported to induce mutations
in mammalian cell lines in a dose-dependent manner [4]. These
damaging events may play a significant role in the progression of
diseases where elevation of oxidants is known to be high [5].
Other reactive aldehydes such as the benzene metabolite trans,
trans-muconaldehyde (MUC) can cause DNA strand breaks leading
to induce bone marrow depression and inhibition of erythropoiesis
in mice [6]. Another reactive aldehyde, methyl glyoxal, is an active
intermediate in the Maillard reaction, cross-linking with proteins.
It is elevated in uncontrolled diabetes, and is associated with dia-
betic complications [7].
In order to counter the potentially lethal effects of toxic alde-
hydes and ketones, several metabolizing enzyme systems exist
that can render aldehydes either more readily excreted or less bio-
logically active. Aldo–keto reductases (AKR) are a superfamily of
NADP(H)-dependent enzymes that reduce aldehydes and ketones
to alcohols [8]. The AKR superfamily includes enzymes from
bacteria, yeast, plants and mammals that are capable of reducing
0009-2797/$ - see front matter  2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.cbi.2011.09.007
Abbreviations: AKR, aldo–keto reductase; SSA, succinic semialdehyde; CBA,
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carbonyls present in a diverse range of natural and synthetic com-
pounds [8]. Several human AKR enzymes have been identified as
capable of reducing reactive aldehydes such as 4-HNE, acrolein
and methyl glyoxal. These include aldose reductase (AKR1B1)
[9,10]; 20a(3a-hydroxysteroid dehydrogenase (AKR1C1) [11];
aldehyde reductase (AKR1A1) [12]; and the aflatoxin B1 aldehyde
reductases (AFAR/AKR7A2 and AKR7A3) [13,14]. Of these, the hu-
man AKR7A subfamily members are of interest, because they are
related to a rat enzyme (AKR7A1) that is inducible by dietary anti-
oxidants [15]. This inducibility has the potential to lead to valuable
therapeutic approaches for diseases in which reactive carbonyls
have been implicated [5,15].
We have shown previously that mammalian cells expressing rat
AKR7A1 are protected from the mutagenicity of acrolein [16]. Rat
AKR7A1 has also been shown to be associated with protection
against aflatoxin toxicity in vitro [15,17], and more recently, using
transgenic rats, AKR7A1 has been shown to protect animals against
aflatoxin toxicity but not mutagenicity [18,19]. In the mouse, there
appears to be only one AKR7A enzyme, AKR7A5, and we have
shown previously that V79 cells transfected with mouse AKR7A5
are relatively more resistant to 4-HNE-induced apoptosis [20,21].
Taken together this information suggests that the AKR7A subfam-
ily of enzymes generally serves a cytoprotective function. However
little is known of the function of the humanmembers of the AKR7A
subfamily. Two human AKR7A enzymes have been isolated, human
AKR7A2 and human AKR7A3 [13,14]. Whether the human AKR7A
enzymes are similarly involved in detoxication pathways has not
been explored previously.
The human AKR7A2 was identified in brain as a succinic semi-
aldehyde reductase [22], and we have shown previously that it is
the main enzyme responsible for the reduction of succinic semial-
dehyde (SSA) to c-hydroxybutyrate (GHB) in human neuroblas-
toma cells [23]. AKR7A2 is known to be present in a range of
tissues, including liver, kidney as well as brain [12]. However, it ap-
pears to accumulate in specific regions of the brain in Alzheimer’s
Disease [24].
The aim of this study was to test whether the human enzyme
AKR7A2 also plays a role in detoxication, as is the case with rat
AKR7A1 and mouse AKR7A5. In order to investigate this, we have
stably expressed AKR7A2 in V79-4 Chinese hamster lung cells,
and have tested the ability of expressed AKR7A2 to protect against
the cytotoxicity and mutagenicity of several toxic aldehydes. Fur-
thermore, the role of the AKR7A2 enzyme in enhancing the cell’s
ability to cope with elevated ROS is also assessed.
2. Methods
2.1. Chemicals
All chemicals were obtained from Sigma except for 4-hydroxy-
nonenal, purchased from Alexis Caymen Corporation – Europe
(Nottingham, UK).
2.2. Cell culture
V79-4 Chinese hamster fibroblasts cells were obtained from the
American Type Culture Collection (ATCC) and maintained in
Dulbecco’s Modified Eagle’s Media (DMEM) with L-glutamate, 1%
(v/v) penicillin and streptomycin, and 5% (v/v) fetal bovine serum.
2.3. Generation V79-4 cell lines stably transfected with AKR7A2
The full length human AKR7A2 cDNA was amplified from an
AKR7A2 expression construct [13], a gift from Professor John D.
Hayes, and subcloned into the pCI-Neo expression plasmid to give
plasmid pCI-Neo-AKR7A2. V79-4 cells were seeded in 24 well
plates and pCI-Neo-AKR7A2 was transfected into V79-4 cells using
Fugene 6 reagent. Several stable clones were selected as geneticin
(G418) resistant. AKR7A2 expression levels in each clone were ana-
lyzed by Western blotting. One clone demonstrating strong
AKR7A2 expression was maintained for further study.
2.4. Preparation of cell extracts from cell lines
For detection of AKR7A2 expression, whole cell extracts from
V79 cells were prepared from 75 cm2 flasks using a ‘‘Freeze–thaw’’
protocol that does not affect enzyme activity [23]. Briefly, after
cells were washed three times in ice-old PBS, 3 ml ice-cold TEN
(40 mM Tris–Cl, PH 7.5, 1 mM EDTA, PH 8.0, 150 mM NaCl) solu-
tion was added to each flask. Cells were harvested and resus-
pended in 0.2 M phosphate buffer pH 7.5. The cell suspension
was frozen in dry ice for 5 min and then transferred to 37 C for
5 min. The freeze–thaw procedure was repeated twice. The cell
lysate was centrifuged at 12,000g for 5 min at 4 C, and the super-
natant was ready for further analysis. Protein concentrations were
determined using the method of Bradford against bovine serum
albumen standards [25].
2.5. Protein gels and Western blots
Portions of cell extract were separated by SDS–PAGE gel (12%)
[26] and transferred onto nitrocellulose membrane (Bio-Rad Inc.).
Antisera to AKR7A2 was raised in this lab as previously described
[20] and used at a dilution of 1:2000 and goat anti-rabbit IgG-
Horse radish peroxidase conjugate secondary antibody (1:10000
dilution). Western blots were developed with enhanced chemilu-
minescence. (ECL; Amersham) and images were analyzed by LAS-
3000 luminescent image analyzer (Fuji). Quantification of band
intensities was performed using Kodak one-dimensional image
analysis software. A standard curve allowing quantitation of
AKR7A5 was achieved by using serial dilutions of purified AKR7A2
recombinant enzyme and plotting concentration versus pixel den-
sity of each band determined using NIH Image.
2.6. Expression and purification of recombinant human AKR7A2
Bacterial expression vector pLI19 containing an N-terminal
polyhistidine tagged AKR7A2 was a gift from Professor John D.
Hayes, University of Dundee [13]. Purification of this enzyme from
bacterial cultures was carried out using HiTrap affinity column
(5 ml) (Amersham pharmacia biotech) with Pharmacia FPLC (Fast
Protein Liquid Chromatography) system. Enzyme activities of puri-
fied protein were measured and the most active fractions of pro-
tein were combined and frozen at 80 C until required. Purified
protein was also separated by SDS–PAGE to confirm purity.
2.7. Aldo–keto reductase (AKR) assays
Aldehyde- and ketone-reducing activity was determined using
an enzyme assay described previously [27], and routinely mea-
sured with a Beckman DU650 UV single-beam recording spectro-
photometer by following the initial rate of oxidation of NADPH at
340 nm (e340 = 6270 M1 cm1). The assays were performed at
25 C in reaction mixtures of 1 ml containing 100 mM sodium
phosphate buffer, pH 6.8, and 0.05 mM NADPH. The concentration
of the substrate in the reaction mixture was between 10 lM and
10 mM (depending on solubility) with a maximum concentration
of 2% (v/v) methanol or 4% (v/v) acetonitrile as carrier; neither
methanol nor acetonitrile was found to interfere with the assay
or enzyme activity under these conditions. Approximately 1 lg of
enzyme or 100 lg cell extract was added to the cuvette to initiate
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the reaction and the reaction rate was measured against an identi-
cal blank with no enzyme added. Activity was measured for 5 min.
Any background rate of decrease in NADPH arising in the absence
of substrate was subtracted from the rate determined in the pres-
ence of substrate. Km and Vmax values for purified AKR7A2 were
determined by altering the substrate concentration while main-
taining NAPDH at 0.05 mM. Fitting to the Michelis–Menten equa-
tion was carried out using Graph-Pad Prism software. The kcat
was calculated assuming the molecular weight of the AKR7A2 di-
mer as 79,198 Da, and 2 active sites per molecule of dimer.
2.8. Cytotoxicity assay (MTT assay)
Cell viability assays were performed using a modified method
that uses 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) [28]. Briefly, cells were seeded in a 24 well plate
and incubated until a confluent monolayer formed. On the day of
assay, media was aspirated and fresh media (1 ml) containing a
range of various concentrations of aldehydes was added. Cells were
exposed with chemicals for certain time. Media containing 0.2 mg/
ml MTT solution was added to each well and plates were incubated
at 37 C for 4 h. The medium was discarded and the reaction was
stopped by the addition of 200 ll acidified DMSO (0.04 M HCl/
DMSO). With 2 h incubation at 37 C, the solubilized formazan
solution was transferred to a 96-well plate. The absorbance was
read at 540 nm using a 96-well Labsystems iEMS plate-reader
and plotted as % of untreated control. The half maximal inhibitory
concentration (IC50) values were determined as the concentration
which reduced the viability to 50%.
2.9. Mutagenicity (HGPRT) assay
Mutagenicity assays were performed essentially using the mod-
ified hypoxanthine guanine phosphoribosyl transferase (HGPRT)
method [29]. Briefly, cells were seeded at 5  105 in 75 cm2 flasks
and incubated for 24 h before the treatment. Aldehydes were dis-
solved in DMSO and added to the flasks. After 4 or 8 h exposure,
fresh media was added. After a further 72 h incubation, cells were
harvested and re-seeded at 106 cells/100 mm dish for the detection
of 6-thioguanine-resistant colonies (5 dishes/per cell line). For
cloning efficiency 200 cells/60 mm dishes were seeded (5 dishes/
per cell line or treatment). 5 ml media containing 7 lg/ml
(30 lM) 6-thioguanine was added to 100 mm dishes and media
only was added to 60 mm dishes for cloning efficiency. The cloning
efficiency was obtained by counting the number of colonies after
incubation for 7–8 days. The cloning efficiency of both treated
and untreated cells was comparable and considered as 100% in
the determination of the survivors. The selection of 6-thioguanine
resistant mutants required about 13 or 14 days incubation. For col-
ony counting, 1 ml methanol was added and left for 5 min to fix the
cells, and 0.4% Giemsa (dissolved in methanol) was used to stain
the colonies.
2.10. Measurement of cellular ROS level
Intracellular ROS level was determined by measuring the fluo-
rescence of the oxidized form of the probe 2070-dichlorodihydroflu-
orescein diacetate (DCFH/DA) using a modified method of [30].
Cells were seeded in 100  20 mm dishes and incubated in 2 ml
serum-free DMEM containing 100 lM DCFH/DA (48.7 g/ml media)
at 37 C for 1 h. Cells were then washed with PBS and pretreated
with menadione for required conditions in a serum-free media.
Cells treated with DCFH/DA only were used as a control and dupli-
cate dishes were measured for each sample. After treatment, cells
were washed with ice-old PBS and 2% TritonX-100/PBS was added
to the cells and incubated for 5 min. Lysate cells were sonicated for
5 s twice and centrifuged for 10 min at 3000g. DCF fluorescence in
the supernatant was measured using a Bio-Tek FL600™ fluorescent
plate-reader (Bio-Tek Instruments, Inc.). Ninety-six-well black so-
lid plates were used and sensitivity of the photomultiplier was
set up to 75. KC4 System software was used to create the protocol
and analyze the data.
2.11. Measurement of intracellular glutathione levels
Intracellular glutathione (GSH) levels were determined using a
fluorimetric method described previously [31]. Cells were seeded
in 100  20 mm dishes and treated with menadione at the speci-
fied conditions in 5 ml media. DMSO (0.1%) was used as a solvent
control. Following treatment, media was aspirated and cells were
washed twice with 1 PBS. 1 ml of 15% trichloroacetic acid was
added to cells at room temperature for 15 min. The supernatant
was collected and centrifuged at 16,000g for 10 min and was kept
at 80 C until GSH measurements were carried out. The precipi-
tated protein remaining in the dish was dissolved in 1 ml 0.5 M
NaOH and 10 ll of this solution was used to measure the protein
content by standard Bradford reagent. For GSH measurement,
50 ll of GSH standard solution or the acidified supernatant was
added to 2.3 ml phosphate–EDTA buffer (0.1 M sodium phosphate,
5 mM EDTA, pH 8.0) and 100 ll of 1 mg/ml o-phthalaldehyde. The
mixture was mixed well and kept at room temperature in the dark
for 15 min and fluorescence was measured in 4.5 ml polymethyl
methacrylates cuvette at room temperature at 350 nm excitation
and 420 nm emission using a RF-5301PC fluorimeter (Shimadzu),
with excitation and emission slit widths both set at 1.5 nm. Exper-
iments were set up in duplicate dishes for each condition (n = 2),
and two parallel determinations per dish were carried out for each
GSH assay. All GSH values were normalized and calculated as nmol
GSH/mg total cell protein.
2.12. Caspase-3 activity assay and subunit detection
Caspase-3 activity was determined using the CaspACETM assay-
kit (Promega) as described previously [20]. Briefly, cells were
seeded in 75 cm2 flasks and treated with various concentrations
of menadione for 4 h. Cells were then collected and resuspended
in Caspase Lysis Buffer. After centrifugation, the supernatant was
used to determine caspase 3 activity according to the manufac-
turer’s instruction. In the assay system, specific cleavage of the
substrate (Ac-DEVD-pNA) by caspase-3 releases free p-nitroanilide
(pNA) producing a yellow color that can be monitored spectropho-
tometrically at 405 nm. Data was normalized to protein content of
each sample.
3. Results and discussion
3.1. Identification of new AKR7A2 substrates
AKR7A2 has been characterized previously with regards to its
ability to reduce a range of toxic aldehydes and ketones [12,13].
To gain a clearer view of the function of AKR7A2, we tested addi-
tional aldehyde substrates that have not been previously investi-
gated. The results in Table 1 show that purified recombinant
AKR7A2 displays modest activity towards the benzene metabolite
MUC, and has reductase activity towards benzaldehyde, hexanal
and trans-2-nonenal. AKR7A2 appears to have no activity towards
1,4-naphthoquinone (NQ), but was able to reduce 1,4-NQ deriva-
tives, including menadione, with a substituted group on either
benzene ring (Table 1). The apparent Km and kcat values were
determined for some of these substrates, and the turnover number
calculated. The data in Table 2 reveals that of the substrates tested,
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Table 1
Enzymatic activity of recombinant human AKR7A2 with aldehydes and dicarbonyls.
Substrate Structure Concentration (mM) Specific activity (nmol min1 mg1)
Succinic semialdehyde 1 512 ± 21
2-Carboxybenzaldehyde 1 726 ± 5
9,10-PQ 0.05 1061 ± 5
Benzaldehyde 1 65 ± 3
Methylgloxal 1 96 ± 11
Hexanal 1 14 ± 2.5
t,t-Muconaldehyde 0.1 168 ± 20
4-Hydroxynonenal 1 18 ± 1.8
trans-2-Nonenal 1 9.5 ± 1.2
Acrolein 1 13 ± 1.9
Crotonaldehyde 1 18 ± 2.2
1,4-NQ 0.1 <5.0
5-OH-1,4-NQ 0.1 50 ± 9.1
5-CH3-1,4-NQ (Menadione) 0.1 18 ± 2.8
2-OH-1,4-NQ 0.1 61 ± 11
Enzyme assays were performed at 25 C in reaction mixtures of 1 ml containing 100 mM sodium phosphate buffer, pH 6.8 and 0.05 mM NADPH.
Substrate concentrations were measured as presented in the table (bold highlights substrates not tested in previous studies with human
AKR7A2). Data is presented as mean ± S.E.M. (n = 3) from triplicate independent experiments.
Table 2
Apparent catalytic constants for human AKR7A2 with selected aldehydes and dicarbonyls.
Substrate Km (lM) kcat (min1) kcat/Km (min1 M1)
Succinic semialdehyde 21 ± 1.4 54.59 ± 1.05 2.55  106
Methyl glyoxal 1948 ± 302 37.03 ± 3.74 1.90  104
2-OH-1,4-NQ 449 ± 39.8 7.47 ± 0.553 1.66  104
t,t-Muconaldehyde 966 ± 177 15.03 ± 1.27 1.56  104
4-Hydroxynonenal 1940 ± 320 13.85 ± 2.77 7.14  103
5-CH3-1,4-NQ (Menadione) 1481 ± 207 6.12 ± 3.06 2.06  103
Acrolein 136,000 ± 23,000 29.83 ± 2.9 2.18  102
Crotonaldehyde 59,650 ± 4500 9.39 ± 4.2 1.66  102
Km and kcat values for recombinant AKR7A2 determined by altering the substrate concentration while maintaining NAPDH at 0.05 mM
(saturating). Fitting to the Michaelis–Menten equation was carried out using Graph-Pad Prism software. The kcat was calculated
assuming the molecular weight of the AKR7A2 dimer as 79,198 Da, and 2 active sites per molecule of dimer.
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recombinant AKR7A2 has very high affinity towards SSA as previ-
ously demonstrated, with a Km of 21 lM [12,13]. The kcat for SSA,
calculated per active site of the dimer, is also similar to that previ-
ously reported [12,13]. The results also show that AKR7A2 has rel-
atively high affinity for MUC and modest affinity for the NQ
derivatives, including menadione. AKR7A2 displayed lowest affin-
ity towards acrolein and crotonaldehyde. However, despite this,
the enzyme was able to catalyze the reduction of acrolein reason-
ably efficiently. This indicates that at higher concentrations of
these aldehydes, AKR7A2 may play a useful role in their
detoxication.
3.2. Characterization of V79 cells stably expressing human AKR7A2
V79-4 Chinese hamster lung fibroblast cells were used for this
study as we have previously shown that they are a useful model
for studying toxicity and do not appear to express AKR7A2 protein
[20]. V79-4 cells were transfected with the pCI-Neo-AKR7A2
construct in which AKR7A2 has been placed under the control of
the human cytomegalovirus (CMV) immediate-early enhancer/
promoter, and stable clones were selected in the presence of
G418. The expression of AKR7A2 in stably-transfected V79-4 cells
was confirmed by Western blots (Fig. 1). A novel band of approxi-
mately 38 kDa was detected in cells transfected with AKR7A2
corresponding to the size of purified recombinant AKR7A2, but
was not detected in control cells transfected with the empty plas-
mid pCI-Neo only (V79-pCINeo). The expression levels of AKR7A2
in V79-AKR7A2 cells was quantified using a standard curve derived
from purified recombinant AKR7A2 and calculated as approxi-
mately 20.1 lg per mg of cell extract. One transfectant (V79-
AKR7A2) that expressed AKR7A2 at levels comparable to human
kidney and liver tissues (approximately 3 lg per mg cell extract,
[13]) was selected for further study (Fig. 1).
In order to establish that the human AKR7A2 enzyme expressed
in V79-AKR7A2 cells was functionally active, cell extracts were
prepared from V79-AKR7A2 cells and V79-pCI-Neo (vector only
control) cells. Aldo–keto reductase activity was measured in total
cell extracts using the model substrates 2-carboxybenzaldehyde
(2-CBA), SSA and a selection of toxic aldehyde or ketone substrates,
including MUC, 4-HNE, menadione, acrolein and crotonaldehyde.
V79-AKR7A2 cells showed a significant increase in 2-CBA and
MUC reductase activity (Fig. 2A and B) and a small but significant
increase in crotonaldehyde, 4-HNE and acrolein reductase activity
compared to control V79-pCINeo (Fig. 2C, F and G). There was no
significant increase in reductase activity towards menadione
which is not unexpected, given the low activity of AKR7A2 towards
this substrate (Fig. 2D). Surprisingly, though there was no signifi-
cant increase in SSA reductase activity (Fig. 2E), which would be
expected as SSA is such a good substrate for AKR7A2. It is possible
however that the presence of competing enzymes in the cell ex-
tract (for example SSA dehydrogenase) are contributing to the
reduction of any NADP formed. Together, these results demon-
strate that stably-expressed AKR7A2 enzyme in V79-AKR7A2 cells
Fig. 1. Western blotting analysis of overexpressing human AKR7A2 in V79 cells.
V79 cells were stably transfected with a construct containing human AKR7A2 or
transfected with empty vector pCI-Neo as control. 10 lg protein extract was
separated by SDS–PAGE and analyzed by Western blots using AKR7A2 antibodies.
Purified recombinant AKR7A2 protein was serially-diluted and 1 ll loaded as
standards to quantify the level of overexpressed AKR7A2, and analysis carried out
by comparing pixel densities using ImageJ software. 10 lg protein extract from rat
liver was also included to compare expression with rat AKR7A1 expression in vivo.
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Fig. 2. Aldo–keto reductase activity in V79 cells overexpressing AKR7A2. Enzyme
assays were carried out on cell extracts prepared from control and AKR7A2
transfected V79 cells using substrates A, 2-CBA; B, MUC; C, 4-HNE; D, SSA; E,
Menadione; F, Crotonaldehyde; G, acrolein at a standard concentration of 1 mM
(except for MUC and menadione, 0.1 mM). AKR activity was calculated as nmol/
min/mg protein. Values were from three independent experiments (n = 3) and
presented as mean ± S.E.M. (⁄⁄p < 0.01 indicating statistically significant difference,
ns; no significant difference.)
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is active and contributes to the reduction of aldehydes and ketones
in a cell environment.
3.3. Protective role of AKR7A2 against aldehyde cytotoxicity
To study the ability of AKR7A2 to detoxify aldehydes in cells,
the sensitivity of cells lines to the cytotoxicity of some of the reac-
tive aldehydes was measured using a modified MTT cytotoxicity
assay. The results in Fig. 3 show that expressing AKR7A2 confers
significant protection against 4-HNE, a major product of lipid
peroxidation (Fig. 3B). With a 4 h exposure to 4-HNE, only 20% of
V79-pCINeo survived at 40 lM 4-HNE; in contrast, 60% of V79-
AKR7A2 cells survived (Fig. 3B), and the IC50 increased significantly
from 28.5 ± 2.7 lM in vector-only transfected cells to over 40 lM
in cells expressing AKR7A2.
Similarly, AKR7A2 was also able to protect against another
reactive aldehyde, MUC, Only 50% of V79 control cells survived
after treatment with 20 lM MUC for 24 h, but cells expressing
AKR7A2 showed significantly increased resistance to 20 lM MUC,
with 80% surviving (Fig. 3A), giving rise to an increase in IC50. Cells
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Fig. 3. Effect of overexpressing AKR7A2 on the resistance of V79 cells to aldehyde and ketone cytotoxicity. V79 cells transfected with AKR7A2 or pCI-Neo control were treated
with various concentrations of aldehydes for 24 h or menadione for 4 h and cell viability was measured using the MTT assay. A, MUC; B, 4-HNE; C, methylglyoxal; D,
menadione; E, crotonaldehyde; F, acrolein. Values represent the mean of four experiments (n = 4) ± S.E.M. Statistically significant differences relative to control were
determined using two-way ANOVA: ⁄⁄p < 0.01, statistically significant difference between V79 pCI-Neo control and V79-AKR7A2 cells.
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expressing AKR7A2 also showed a modest increase in resistance to
methylglyoxal (Fig. 3C), with IC50 values increasing approximately
2-fold compared with control cells.
Interestingly, expression of AKR7A2 was able to increase resis-
tance against the cytotoxic effects of menadione (Fig. 3D), a com-
pound that is known to give rise to increased ROS within the cell
through redox-cycling, but which does not appear to be a particu-
larly good substrate for AKR7A2 (Table 2).
Overexpression of AKR7A2 did not appear to provide any signif-
icant increase in resistance against the cytotoxicity of crotonalde-
hyde or acrolein (Fig. 3E and F) at tested concentrations, despite
the increase in crotonaldehyde and acrolein reductase activity ob-
served earlier (Fig. 2). This could be due to several factors including
the low efficiency of the enzyme for these substrates (Table 2), and
the fact that the concentrations used in the cytotoxicity assays
were lower than the Km and also lower than the concentrations
used for the enzyme assays. In addition, other metabolizing en-
zymes are known to contribute to the detoxification of these two
aldehydes [32,33], and their presence at high levels in V79-4 cells
would considerably influence the relative contribution of AKR7A2
towards their metabolism.
Overall, however, the resistance to toxicity conferred by
AKR7A2 is reasonably well correlated with the activity measured
towards these aldehydes indicated in Table 1, with the notable
exception of menadione, which does not appear to be a good sub-
strate of AKR7A2.
To investigate the mechanism by which aldehydes and ketones
cause cell death, the activity of the executioner caspase 3 was
investigated following exposure to HNE or menadione. The results
in Fig. 4 show that treatment of cells with reactive carbonyls leads
to an increase in caspase 3 activity at low concentrations, indicat-
ing that cells are undergoing apoptosis. At higher concentrations,
caspase 3 activation is lower indicating that cells are undergoing
necrosis. In cells that are expressing AKR7A2, there is significantly
less activation of caspase 3, indicating that this enzyme protects
cells from apoptosis at the lower concentrations of both 4-HNE
and menadione.
3.4. Effect of AKR7A2 on 4-HNE – induced mutagenicity
Given the ability of ARK7A2 to protect cells from the cytotoxic
effects of 4-HNE, an aldehyde that is known to damage DNA, the
ability of AKR7A2 to protect against the mutagenicity of 4-HNE
was evaluated. The HGPRT assay was used to identify mutations
generated by 4-HNE [34]. Cells expressing AKR7A2 or vector-only
transfected control cells were treated with 4-HNE or DMSO for
4 h prior to sub-culturing and reseeding with the selection agent
(7 lg/ml 6-thioguanine). A subtoxic concentration of 4-HNE
(10 lM) was utilized to avoid the overlapping of cytotoxic and
mutagenic concentrations; this concentration is in agreement with
that previously used by others [35]. There was no significant differ-
ence in mutation rate between V79 control cells and V79-AKR7A2
cells. Exposure to 4-HNE (10 lM) significantly increased the muta-
tion frequency in V79 control cells by approximately 1.5-fold com-
pared to untreated cells (Table 3). However, the mutation
frequency in HNE-treated V79 cells expressing AKR7A2 was signif-
icantly lower than HNE-treated control cells. The genotoxic effect
of 4-HNE has been explained previously through it forming DNA
adducts with the guanine group of DNA or by the oxidation of 4-
HNE to its epoxide which then forms an adduct with the guanine
group of DNA. The resulting etheno adducts have been detected
in human lung tissue [36]. It appears that the expression of
AKR7A2 contributes to the removal of 4-HNE that effectively pre-
vents the formation of adducts in the cell, leading to the observed
decrease in mutation rate.
We also tested the ability of AKR7A2 to protect against the
mutagenicity of crotonaldehyde. At low sub-lethal concentrations
of crotonaldehyde, cells expressing AKR7A2 were significantly
protected against crotonaldehyde mutagenicity, despite the previ-
ously observed inability to protect against crotonaldehyde cytotox-
icity at higher concentrations. It is likely that AKR7A2 has some
protective effect at lower sub-lethal, yet genotoxic concentrations
of crotonaldehyde, but little effect at higher concentrations of this
aldehyde.
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Fig. 4. Effect of AKR7A2 on protection of V79 cells against aldehyde and ketone-
induced apoptosis. V79 pCI-Neo cells (light shading) or V79-AKR7A2 cells (dark
shading) were treated with various concentrations of A, HNE or B, menadione for
4 h and caspase-3 activity was evaluated in cell extracts using DEVD-pNA as
substrate, calculated using a pNA standard calibration curve. Results are presented
as mean ± S.E.M. from three independent experiments. Statistically significant
differences relative to control were determined using two-way ANOVA, ⁄p < 0.01,
statistically significant difference between V79 control and V79-AKR7A2 cells.
Table 3
Effect of overexpressing AKR7A2 on resistance against aldehyde mutagenicity.
Relative mutation rate
V79-control V79-AKR7A2
Control (DMSO) 1.5 ± 0.1 1.0 ± 0.2
4-HNE (10 lM) 2.3 ± 0.3* 1.5 ± 0.2a
Crotonaldehyde (10 lM) 3.2 ± 0.6* 2.1 ± 0.2a
Cells expressing AKR7A2 or empty vector were exposed to 10 lM 4-hydroxynon-
enal or 10 lM crotonaldehyde for 4 h prior to sub-culturing and reseeding into
medium containing 7 lg/ml 6-thioguanine. DMSO was used as a control. Data are
presented as mutation frequency relative to cloning efficiency and values represent
means ± S.E.M. (n = 5). The mutation frequency represents the number of mutant
colonies per 106 survivors. The cloning efficiencies were comparable for untreated
and treated cells. Values were compared using one-way ANOVA followed by Dun-
nett’s Multiple Comparison post test.
* p < 0.01, treated cells are significantly different from V79 control cells.
a p < 0.01, treated V79-AKR7A2 cells are significantly different from treated V79
control cells.
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3.5. Protective role of AKR7A2 against menadione toxicity
It was surprising that V79-4 cells that expressed AKR7A2 were
protected from the cytotoxic and apoptotic effects of menadione
(Figs. 3 and 4), given that purified recombinant AKR7A2 exhibited
low menadione reductase activity (Tables 1 and 2), and also that
the overexpression of AKR7A2 did not significantly increase the to-
tal menadione reductase activity of V79 cells (Fig. 2E). This indi-
cated that the observed protection against menadione is likely to
be due to a mechanism other than the direct metabolism of men-
adione by AKR7A2.
Menadione is a quinone-containing chemotherapeutic drug that
can generate ROS, and has been extensively used as a model com-
pound for the study of cellular oxidative stress [37]. Most of the
menadione-induced cytotoxicity is thought to be a consequence
of the oxidative damage induced by ROS [38]. We hypothesized
that AKR7A2 is able to defend against menadione toxicity by pre-
venting an increase in intracellular ROS levels. To examine this
hypothesis, ROS levels were measured in control and AKR7A2-
expressing cells following exposure to menadione.
Following 4 h treatment with 5 lM menadione, ROS levels in
control cells transfected with vector only were significantly in-
creased, up to 1.5-fold relative to untreated control (Fig. 5A). In
contrast, in cells expressing AKR7A2, ROS levels were not signifi-
cantly increased 4 h after menadione treatment. This difference
was also seen 6 and 8 h after treatment with 5 lM menadione. In
the dose response curve, cells expressing AKR7A2 had significantly
lower ROS levels than vector-only transfected cells when exposed
to between 5 and 20 lMmenadione for 4 h, but not at 30 lMmen-
adione, a dose that is highly cytotoxic (Fig. 5B). The capability of
the cells to deal with menadione-induced ROS appeared to be ex-
ceeded at this higher concentration of the redox cycler.
How might AKR7A2 contribute to the lowering of menadione-
dependent intracellular ROS? It is known that menadione exposure
leads to increased ROS production, which in turns gives rise to the
depletion of GSH levels. To test the effect of AKR7A2, we measured
GSH levels in menadione-treated V79 cells. The results in Fig. 6
show that menadione treatment leads to GSH depletion, indicating
a significant alteration in redox balance. It is also apparent that
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Fig. 5. Effect of AKR7A2 in preventing menadione-induced oxidative stress. V79
pCI-Neo cells (light shading) or V79-AKR7A2 cells (dark shading) were seeded on
100 mm dishes and incubated until 80% confluent. Cells were preincubated with
100 lM DCFH/DA for 1 h and exposed to (A) 5 lMmenadione for increasing time or
(B) increased concentrations of menadione for 4 h. Duplicate dishes were used for
each condition and each sample was measured in triplicate. Protein content was
measured using the standard Bio-Rad Bradford reagent. Cellular ROS level was
calculated as fluorescence units/mg protein. Values represent mean ± S.E.M. from
two independent experiments and calculated as percentage of untreated cells.
Statistically significant differences relative to control were determined using two-
way ANOVA. ⁄p < 0.01 indicating statistically significant difference.
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Fig. 6. Effect of AKR7A2 in preventing menadione-dependent GSH depletion. V79
pCI-Neo cells (light shading) or V79-AKR7A2 cells (dark shading) were seeded in
100 mm dishes and pretreated with (A) 15 lMmenadione for increasing time or (B)
increased concentrations of menadione for 4 h. DMSO was used as a solvent control.
Each condition was performed in duplicate dishes and two parallel determinations
per dish were measured for GSH assay. GSH values was normalized to mg protein
and calculated as nmol GSH/mg protein. Results are presented as mean ± S.E.M.
from three independent experiments. Statistically significant differences relative to
control were determined using two-way ANOVA. ⁄⁄p < 0.01 or ⁄p < 0.05 indicating
statistically significant difference.
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AKR7A2 expression is able to restore GSH levels within 4 h of expo-
sure. We propose that AKR7A2 is able to prevent GSH depletion
caused by menadione and thereby maintain redox status, prevent-
ing further ROS production and contributing to the resistance
observed. This indicates AKR7A2 may serve an important physio-
logical role in preventing the further production of ROS in oxidant
exposed cells.
In terms of defining a role for human AKR7A2, this enzyme is
known to be expressed in a range of tissues including liver, kidney
as well as brain [12]. In human brain, immunohistochemistry has
revealed that in the cortex and hippocampus, AKR7A2 is localized
to glial cells, astrocytes and microglia [24]. Subcellularly, AKR7A2
localization appears to be perinuclear and cytoplasmic in neurons
and astrocytes. If the only role of AKR7A2 was the synthesis of
GHB, it is unclear why it would be located in perinuclear regions,
given that it is likely that SSA is synthesized from GABA in the
mitochondria. Elevated levels of AKR7A2 are also observed in the
brains of patients with Alzheimer’s Disease (AD) [24]. In AD, a
range of biochemical changes are known to occur, including an
association with elevated ROS and production of reactive alde-
hydes such as 4-HNE, and 4-HNE and acrolein protein-adducts
are elevated in these same regions of brains from AD patients
[39,40]. Given its ability to protect cells from the products of lipid
peroxidation as well as contributing to lowering ROS levels,
AKR7A2 may therefore play a significant role in protecting the
brain from oxidative stress.
4. Conclusions
In this study, we have shown that human AKR7A2 can protect
cells from the cytotoxicity of reactive aldehydes, and also against
DNA damage caused by two of these aldehydes. In addition, we
have shown that the level of menadione-induced ROS in V79-4
cells expressing AKR7A2 is significantly reduced compared with
vector-transfected cells in both a time and dose dependent man-
ner, and that this correlates with enhanced GSH levels. This is
the first demonstration of the role of AKR7A2 in detoxication in a
cell environment. Overall, the results presented in this study sup-
port the role of AKR7A2 as a detoxifying enzyme and indicate that
it has a potential role in the defense against ROS, an important fac-
tor in disease states that have an oxidative stress component.
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